

424 Rec'd PCT/PTO 20 JUL 2000

09/600661
1103326-0631

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED OFFICE (DO/US)

<u>PCT/SE00/00834</u>	<u>03 May 2000</u>	<u>03 May 1999</u>
International Application Number	International Filing Date	Priority Date(s) Claimed

NEW COMPOUNDS
Title of Invention

LINSCHOTEN, Marcel; POLLA, Magnus; and SVENSSON, Peder

Applicant(s) for DO/US

<p>"Express Mail" Label No. <u>EL367957026US</u></p> <p>Date of Deposit <u>JULY 20, 2000</u></p> <p>I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231</p> <p><u>Leslie Boone</u> (Type or print name of person mailing paper or fee)</p> <p><u>Leslie Boone</u> (Signature of person mailing paper or fee)</p>

BOX PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

To the United States Designated Office (DO/US):

- I. Accompanying this transmittal letter are certain items which are required under 35 U.S.C. 371 in order that United States National processing of the above identified International application may commence:
- (X) at the expiration of the applicable time limit under PCT Articles 22 and 39(1) according to the provisions of 35 U.S.C. 371(b).
 - () as soon as possible upon receipt of this express request under 35 U.S.C. 371(f).

1. The U.S. National fee [35 U.S.C. 371(c)(1)]

a. () was previously transmitted by applicant on (date)_____.

b. (X) is submitted herewith as follows:

<u>FOR</u>	<u>NO. FILED</u>	<u>NO. EXTRA</u>	<u>SMALL ENTITY</u>			<u>OTHER THAN</u>	
			<u>RATE</u>	<u>FEE</u>	<u>or</u>	<u>RATE</u>	<u>FEE</u>
Basic Fee	(USPTO NOT ISA OR IPEA)		////	\$485	<u>or</u>	////	\$970
Total Claims	-20 =	--	x 9 =		<u>or</u>	x18 =	\$
Ind. Claims	4 - 3	1	x 39 =		<u>or</u>	x78 =	\$ 78
(X) Multiple Dependent Claim Presented			+130 =		<u>or</u>	+260 =	\$260
<u>TOTAL</u>							
<u>NATIONAL FEE</u>				\$_____	<u>or</u>		\$1308

i. () A check in the amount of \$_____ is enclosed.

ii. (X) Please charge the filing fee, multiple dependent claim fee (if applicable), excess independent claims fee (if applicable), and excess total claims fee (if applicable) to **Deposit Account No. 23-1703**.

iii. (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to **Deposit Account No. 23-1703**. A duplicate copy of this sheet is enclosed.

(iv) () The filing fee is not enclosed.

2. A copy of the International application as filed [35 U.S.C. 371(c)(2)]:

a. (X) is transmitted herewith.

b. () is not required as the application was filed with the United States Receiving Office.

c. () has been transmitted

- i. () by the International Bureau. Date of mailing of the application (from form PCT/IB/308): _____ A copy of form PCT/IB/308 is enclosed.
- ii. () by applicant on (date) _____.
3. A translation of the International application into the English language [35 U.S.C. 371(c)(2)]:
- a. () is transmitted herewith.
- b. (X) is not required as the application was filed in English.
- c. () was previously transmitted by applicant on (date) _____.
4. Amendments to the claims of the International application under PCT Article 19 [35 U.S.C. 371(c)(3)]:
- a. () are transmitted herewith.
- b. () have been transmitted
- i. () by the International Bureau. Date of mailing of the amendments (from form PCT/IB/308): _____.
- ii. () by applicant on (date) _____.
- c. (X) have not been transmitted as
- i. () no notification has been received that the International Searching Authority has received the Search Copy.
- ii. () the Search Copy was received by the International Searching Authority but the Search Report has not yet issued. Date of receipt of Search Copy (from form PCT/ISA/202): _____.
- iii. () applicant chose not to make amendments under PCT Article 19. Date of mailing of Search Report (from form PCT/ISA/210): _____.

- iv. ☒ the time limit for the submission of amendments has not yet expired. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.
- 5. A Translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]:
 - a. ☐ is transmitted herewith.
 - b. ☐ is not required as the amendments were made in the English language.
 - c. ☒ has not been transmitted for reasons indicated at point I.4.b. or c. above.
- 6. An executed declaration for patent application of the inventor [35 U.S.C. 371(c)(4)] complying with 35 U.S.C. 115:
 - a. ☐ was previously submitted by applicant on (date) _____
 - b. ☒ is submitted herewith; and such oath or declaration
 - i. ☒ is attached to the application.
 - ii. ☒ identifies the application and any amendments under PCT Article 19 which were transmitted as stated in points 1.2.b. or c. and 1.4. and states that they were reviewed by the inventor as required by 37 CFR 1.70.
 - c. ☐ will be submitted subsequently.

II. Concerning other documents:

- 1. An International Search Report or Declaration under PCT Article 17(2)(a):
 - a. ☐ has been transmitted by the International Bureau. Date of mailing (from form PCT/IB/308): _____ A copy of form PCT/IB/308 is enclosed
 - b. ☐ is not required as the application was searched by the United States International Searching Authority.
 - c. ☐ A copy of the International Search Report is transmitted herewith.

534 Rec'd PCT/PTC 20 JUL 2000

d. () has been submitted by applicant on (date) _____.

2. A Statement of prior art under 37 CFR 1.97 and 1.98:

- a. (X) is transmitted herewith including copies of the references cited on the attached form PTO-1449. Also enclosed is a copy of the International-Type Search Report (PCT/ISA/201/SE), issued in the Swedish priority application.
- b. () will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).
- c. () was previously submitted by applicant on _____, in application serial no. _____.

3. (X) An Assignment is transmitted herewith for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.


- a. (X) Please charge the \$40.00 assignment recordation fee to Deposit Account No. 23-1703.
- b. () Enclosed is a check in the amount of \$40.

4. Other document(s) or information included:

- Copy of PCT/RO/101 - The PCT Request Form; and
- Return postcard.

Respectfully submitted,

20 July 2000
DATE


John M. Genova
Reg. No. 32,224

White & Case LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787
(212) 819-8200

enclosures

#4
1103326-0631
a**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Linschoten et al.
Serial No. : 09/600,661
Filed : July 20, 2000
For : NEW COMPOUNDS
Examiner : To be assigned
Group Art Unit : To be assigned

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8	
I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on November 5, 2001 at the facsimile number <u>703-305-3230</u>	
Andrew Fessak	48,528
Agent Name	PTO Reg. No.
Andrew Fessak	11/5/2001
Signature	Date of Signature

Box PCT

Assistant Commissioner for Patents
Washington, D.C. 20231

FACSIMILE NO: 703-305-3230
DATE: November 5, 2001
PAGES: 19 pages

PRELIMINARY AMENDMENT

Sir:

Preliminary to examination on the merits, please amend the referenced application as
follows:


11/25/2002 BCAMPBEL 00000001 231703 09600661

01 FC:1615

1090.00 CH

IN THE CLAIMS:**Replace claims 1-9 and 12-17 as originally filed with amended claims 1-9 and 12-17.****Cancel claims 10 and 11.**

1. (Amended) A compound of general Formula I



or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,
wherein:

R₁ is selected from the group consisting of:

- C₁-C₆ alkyl, substituted with one or more basic groups;
- cycloalkyl, substituted with one or more basic groups;
- heterocyclyl, comprising at least one nitrogen atom;
- heterocyclyl, comprising at least one hetero atom selected from S or O, and substituted with one or more basic groups; and
- aryl, substituted with one or more basic groups;

R₂ is selected from the group consisting of H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, a Z₂N-CO-O- group, a ZO-CO-NZ- group, and a Z₂N-CO-NZ- group;

R₃ is selected from the group consisting of COOR₅, SO(OR₅), SO₃R₅, P=O(OR₅)₂, B(OR₅)₂, P=OR₅(OR₅), tetrazole, and a carboxylic acid isostere;

R₄ is SH, S-CO-C₁-C₆ alkyl, or S-CO-aryl;

R₅ is H, C₁-C₆ alkyl, or aryl;

R₆ is H or C₁-C₆ alkyl;

X is selected from the group consisting of O, S, SO, SO₂, C(Z)₂, N(Z), NR₆SO₂, SO₂NR₆, NR₆CO, and CONR₆;

Y is C(Z)₂; and

Z is independently selected from the group consisting of H, C₁-C₆ alkyl, aryl, cycloalkyl, and heterocyclyl.

2. (Amended) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R₁ is selected from the group consisting of:

- cycloalkyl, substituted with one or more basic groups;
- heterocyclyl, comprising at least one nitrogen atom;
- heterocyclyl, comprising at least one hetero atom selected from S or O, and substituted with one or more basic groups; and
- aryl, substituted with one or more basic groups;

R₂ is selected from the group consisting of H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, Z₂N-CO-O-, ZO-CO-NZ-, and Z₂N-CO-NZ-;

R₃ is COOR₅;

R₄ is SH, S-CO-C₁-C₆ alkyl, or S-CO-aryl;

R₅ is H, C₁-C₆ alkyl, or aryl;

R₆ is H or C₁-C₆ alkyl;

X is selected from the group consisting of O, S, SO, SO₂, C(Z)₂, N(Z), NR₆SO₂, SO₂NR₆, and CONR₆;

Y is C(Z)₂; and

Z is independently selected from the group consisting of H, C₁-C₆ alkyl, aryl, cycloalkyl and heterocyclyl.

3. (Amended) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R₁ is selected from the group consisting of:

cycloalkyl, substituted with one or more basic groups;
heterocyclyl, comprising at least one nitrogen atom; and
heterocyclyl, comprising at least one hetero atom selected from S or O, and substituted with one or more basic groups;

R₂ is selected from the group consisting of H, C₁-C₃ alkyl, amino, halogen, and hydroxy;

R₃ is COOR₅;

R₄ is SH, S-CO-C₁-C₆ alkyl, or S-CO-aryl;

R₅ is H, C₁-C₆ alkyl, or aryl;

X is C(Z)₂,

Y is C(Z)₂; and

Z is independently H or C₁-C₆ alkyl.

4. (Amended) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein

R₁ is selected from the group consisting of:

cycloalkyl, substituted with one or more basic groups; and
heterocyclyl, comprising at least one nitrogen atom;

R₂ is H, F, or C₁ alkyl;

R₃ is COOR₅,

R₄ is SH, S-CO-C₁-C₆ alkyl, or S-CO-aryl;

R₅ is H, C₁-C₆ alkyl, or aryl;

X is C(Z)₂;

Y is C(Z)₂; and

Z is independently H or C₁-C₆ alkyl.

5. (Amended) The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R₁ is selected from the group consisting of cyclopentyl, pyridyl, pyrimidinyl, piperidinyl, and thiazolyl;

R_2 is H, F, or C_1 alkyl;

R_3 is $COOR_5$;

R_4 is SH;

R_5 is H,


X is CHZ;

Y is CHZ; and


Z is independently H or C_1 - C_6 alkyl.

6. (Amended) A process for the preparation of a compound according to any one of claims 1-5, wherein R_1 , R_3 , R_4 , and Y are as defined in claim 1, X is $C(Z)_2$, and R_2 is H, comprising the step of:

reacting a compound of Formula VI,




wherein R_1 , R_3 and Y are as defined in claim 1 and X is $C(Z)_2$, with a compound of Formula IX,



wherein R_5 is a protecting group, optionally in the presence of a base or a free-radical initiator.

7. (Amended) A process for the preparation of a compound according to any one of claims 1-5, wherein R_1 , R_2 , R_3 , and R_4 are as defined in claim 1, Y is CH_2 , and X is O, S, $C(Z)_2$, or $N(Z)$, comprising the step of:

reacting a compound of Formula XIV,




wherein R_1 , R_2 , and R_3 are as defined in claim 1, and X is O , S , $\text{C}(\text{Z})_2$, or $\text{N}(\text{Z})$, with a compound of general Formula IX,



wherein R_5 is a protecting group, in the presence of a reagent, under standard conditions.

8. (Amended) A process for the preparation of a compound according to any one of claims 1-5, wherein R_1 , R_2 , R_3 , R_4 , and Y are as defined in claim 1, and X is NR_6CO or NR_6SO_2 , comprising the step of:

reacting a compound of general Formula XV,



wherein R_2 , R_3 , R_6 and Y are as defined in claim 1 and R_5 is a protecting group, with a compound of general Formula XVI,



wherein R_1 is as defined in claim 1 and X is COOH or SO_2Cl , in the presence of a coupling reagent, under standard conditions.

9. (Amended) A pharmaceutical formulation comprising a compound according to any one of claims 1 to 5 as active ingredient in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. (Amended) A method for treatment or prophylaxis of conditions associated with inhibition of carboxypeptidase U, comprising administering to a patient in need of such treatment an effective amount of a compound according to any one of claims 1-5.

13. (Amended) A pharmaceutical formulation for the treatment or prophylaxis of conditions associated with inhibition of carboxypeptidase U, comprising a compound according to any one of claims 1-5 in combination with a pharmaceutically acceptable adjuvant, diluent, or carrier.

14. (Amended) A pharmaceutical formulation, comprising:

- (i) a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; and
 - (ii) one or more antithrombotic agents with a different mechanism of action from that of component (i),
- in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

15. (Amended) A kit of parts comprising:

- (i) a pharmaceutical formulation comprising a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier; and
 - (ii) a pharmaceutical formulation comprising one or more antithrombotic agents with a different mechanism of action from that of component (i),
- in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, wherein compound (i) and agent (ii) are each formulated for administration in conjunction with the other.

16. (Amended) A method for treatment of a patient suffering from, or susceptible to, a condition in which inhibition of carboxypeptidase U and a different antithrombotic mechanism are required or desired, which method comprises administering to the patient a therapeutically effective total amount of:

- (i) a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, and
 - (ii) one or more antithrombotic agents with a different mechanism of action from that of component (i),
- in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

17. (Amended) A method for the treatment of a patient suffering from, or susceptible to, a condition in which inhibition of carboxypeptidase U and a different antithrombotic mechanism are required or desired, which method comprises administering to the patient the formulation according to claim 14.

Add new claims 18-28.

- 18. (New) The compound according to any one of claims 1-4, wherein the basic group is selected from the group consisting of amino, amidino, and guanidino.
- 19. (New) The process according to claim 6, wherein the protecting group is selected from the group consisting of acetate (Ac), benzoyl (Bz), benzyl (Bn), and 4-methoxybenzyl (PMB)
- 20. (New) The process according to claim 6, wherein the base is selected from the group consisting of NaOMe, NaH, and triethylamine .
- 21. (New) The process according to claim 6, wherein the free-radical initiator is α, α' -azoisobutyronitrile (AIBN).
- 22. (New) The process according to claim 7, wherein the protecting group is acetate (Ac) or benzoyl (Bz).
- 23. (New) The process according to claim 7, wherein the reagent is PPh_3 /diisopropyl azodicarboxylate (DIAD).
- 24. (New) The process according to claim 8, wherein the protecting group is selected from the group consisting of acetate (Ac), benzoyl (Bz), benzyl (Bn), and 4-methoxybenzyl (PMB).

25. (New) The process according to claim 8, wherein the coupling reagent is selected from the group consisting of:
- (i) (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP)/diisopropylethylamine (DIPEA);
 - (ii) dicyclohexylcarbodiimide (DCC)/1-hydroxybenzotriazol (HOBt);
 - (iii) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC)/triethylamine (TEA)/N,N-dimethyl amino pyridine (DMAP); and
 - (iv) pyridine.
26. (New) The formulation according to claim 14, wherein the antithrombotic agent with a different mechanism of action is selected from the group consisting of an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor, and an ADP-receptor (P_2T) antagonist.
27. (New) The kit according to claim 15, wherein the antithrombotic agent with a different mechanism of action is selected from the group consisting of an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor, and an ADP-receptor (P_2T) antagonist.
28. (New) The method according to claim 16, wherein the antithrombotic agent with a different mechanism of action is selected from the group consisting of an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor, and an ADP-receptor (P_2T) antagonist.

REMARKS**Amendments**

Claims 1-9 and 12-17 have been amended to place the claims in accordance with U.S. patent practice. Claims 2-5 have been amended to remove the dependency of a multiple dependent claim on another multiple dependent claim. Additionally, exemplary embodiments have been deleted from claims 1-4, 6-8, and 14-16 and presented as new claims 18-28 as shown in the following table:

New Claim	Supported by exemplary embodiment(s) deleted from amended claim(s)	Support for new claim in specification
18	1-4	p. 2- p. 5
19-21	6	p. 10, l. 20 - p. 11, l. 5
22-23	7	p. 12, lines 11-17
24-25	8	p. 13, lines 1-15
26	14	p. 18, lines 7-11
27	15	p. 18, lines 7-11
28	16	p. 18, lines 7-11


Additionally, claims 19 and 21-25 recite the complete names of the compounds or chemical groups whose acronyms were used in original claims 6-8. A list of acronyms used in the application is found on pages 93-94 of the disclosure. Claims 10 and 11 have been canceled.

No new matter is introduced by any of the amendments herein.

SCANNED, # 12

Claims 1-9 and 12-17 -Version With Markings to Show Changes Made:

1. A compound of general Formula I



or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R₁ is selected from the group consisting of: [represents,]

C₁-C₆ alkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

cycloalkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

heterocyclyl, comprising [containing] at least one nitrogen atom;

heterocyclyl, comprising [containing] at least one hetero atom selected from S or O, and substituted with one or more basic groups [such as amino, amidino and/or guanidino]; and

[or] aryl, substituted with one or more basic groups; [such as amino, amidino and/or guanidino,]

R₂ is selected from the group consisting of [represents] H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, Z₂N-CO-O-, ZO-CO-NZ-, and [or] Z₂N-CO-NZ-, [group,]

R₃ is selected from the group consisting of [represents] COOR_s, SO(OR_s), SO₃R_s, P=O(OR_s)₂, B(OR_s)₂, P=OR_s(OR_s), [or] tetrazole, and a [or any] carboxylic acid isostere; [.]

R₄ is [represents] SH, S-CO-C₁-C₆ alkyl, or S-CO-aryl; [.]

R₅ is [represents] H, C₁-C₆ alkyl, or aryl; [.]

R₆ is [represents] H or C₁-C₆ alkyl; [.]

X is selected from the group consisting of [represents] O, S, SO, SO₂, C(Z)₂, N(Z), NR₆SO₂, SO₂NR₆, NR₆CO, and [or] CONR₆; [.]

Y is [represents] C(Z)₂; and [.]

Z is [represents] independently selected from the group consisting of H, C₁-C₆ alkyl, aryl, cycloalkyl, and [or] heterocyclyl.

2. The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R₁ is selected from the group consisting of: [represents,]

cycloalkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

heterocyclyl, comprising [containing] at least one nitrogen atom;

heterocyclyl, comprising [containing] at least one hetero atom selected from S or O, and substituted with one or more basic groups [such as amino, amidino and/or guanidino]; and [or] aryl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

R₂ is selected from the group consisting of [represents] H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, Z₂N-CO-O-, ZO-CO-NZ-, and [or] Z₂N-CO-NZ-, [group,]

R₃ is [represents] COOR₅; [.]

R₄ is [represents] SH, S-CO-C₁-C₆ alkyl, or S-CO-aryl; [.]

R₅ is [represents] H, C₁-C₆ alkyl, or aryl; [.]

R_6 is [represents] H or C_1-C_6 alkyl; [.]

X is selected from the group consisting of [represents] O, S, SO, SO_2 , $C(Z)_2$, $N(Z)$, NR_6SO_2 , SO_2NR_6 , and [or] $CONR_6$; [.]

Y is [represents] $C(Z)_2$; and [.]

Z is [represents] independently selected from the group consisting of H, C_1-C_6 alkyl, aryl, cycloalkyl and [or] heterocycl.

3. The compound according to claim 1 [or 2], or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R_1 is selected from the group consisting of: [represents,]

cycloalkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

heterocycl, comprising [containing] at least one nitrogen atom; and

heterocycl, comprising [containing] at least one hetero atom selected from S or O, and substituted with one or more basic groups [such as amino, amidino and/or guanidino];

R_2 is selected from the group consisting of [represents] H, C_1-C_3 alkyl, amino, halogen, and hydroxy; [.]

R_3 is [represents] $COOR_5$; [.]

R_4 is [represents] SH, S-CO- C_1-C_6 alkyl, or S-CO-aryl; [.]

R_5 is [represents] H, C_1-C_6 alkyl, or aryl; [.]

X is [represents] $C(Z)_2$; [.]

Y is [represents] $C(Z)_2$; and [.]

Z is [represents] independently H or C_1-C_6 alkyl.

4. The compound according to claim 1 [any previous claim], or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R₁ is selected from the group consisting of [represents,]

cycloalkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino]; and

heterocyclyl, comprising [containing] at least one nitrogen atom;

R₂ is [represents] H, F, or C₁ alkyl; [.]

R₃ is [represents] COOR₅; [.]

R₄ is [represents] SH, S-CO-C₁-C₆ alkyl, or S-CO-aryl; [.]

R₅ is [represents] H, C₁-C₆ alkyl, or aryl; [.]

X is [represents] C(Z)₂; [.]

Y is [represents] C(Z)₂; and [.]

Z is [represents] independently H or C₁-C₆ alkyl.

5. The compound according to claim 1 [any previous claim], or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R₁ is selected from the group consisting of [represents] cyclopentyl, pyridyl, pyrimidinyl, piperidinyl, and [or] thiazolyl; [.]

R₂ is [represents] H, F, or C₁ alkyl; [.]

R₃ is [represents] COOR₅; [.]

R₄ is [represents] SH; [.]


R₅ is [represents] H; [.]

X is [represents] CHZ; [.]


Y is [represents] CHZ; and [.]

Z is [represents] independently H or C₁-C₆ alkyl.

6. A process for the preparation of a compound according to any one of claims 1-5, wherein R_1 , R_3 , R_4 , and Y are as defined in claim 1, [and] X is $C(Z)_2$ and R_2 is H , comprising the step of: [.] reacting a compound of Formula VI,




wherein R_1 , R_3 and Y are as defined in claim 1 and X is $C(Z)_2$, with a compound of Formula IX,




wherein R_5 is a [suitable] protecting group, optionally [such as Ac, Bz, PMB or Bn, alone or] in the presence of a [suitable] base [such as NaOMe, NaH or triethylamine] or [alternatively in the presence of] a free-radical initiator [such as AIBN under standard conditions].

7. A process for the preparation of a compound according to any one of claims 1-5, wherein R_1 , R_2 , R_3 , and R_4 are as defined in claim 1, [and] Y is CH_2 and X is O , S , $C(Z)_2$, or $N(Z)$, comprising the step of: reacting a compound of Formula XIV,




wherein R_1 , R_2 , and R_3 are as defined in claim 1, and X is O , S , $C(Z)_2$, or $N(Z)$, with a compound of general Formula IX,



wherein R_5 is a [suitable] protecting group, [such as Ac or Bz,] in the presence of a [suitable] reagent, [such as PPh_3 /DIAD,] under standard conditions.

8. A process for the preparation of a compound according to any one of claims 1-5, wherein R_1 , R_2 , R_3 , R_4 , and Y are as defined in claim 1, and X is NR_6CO [] or NR_6SO_2 , comprising the step of:

reacting a compound of [the] general Formula XV,



wherein R_2 , R_3 , R_6 and Y are as defined in claim 1 and R_5 is a [suitable] protecting group, [such as Ac, Bz, PMB or Bn,] with a compound of [the] general Formula XVI,



wherein R_1 is as defined [for] in claim 1 and X is $COOH$ or SO_2Cl , in the presence of a [suitable] coupling reagent [s, such as PyBOP/DIPEA, DCC/HOBt, EDC/TEA/DMAP or pyridine], under standard conditions

9. A pharmaceutical formulation comprising [containing] a compound according to any one of claims 1 to 5 as active ingredient in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. A method for treatment or prophylaxis of conditions associated with inhibition of carboxypeptidase U, comprising administering to a patient [mammal, including man,] in need of such treatment an effective amount of a compound according to [as defined in] any one of claims 1-5.

13. A pharmaceutical formulation for [use in] the treatment or prophylaxis of conditions associated with inhibition of carboxypeptidase U, comprising a compound according to [as

defined in] any one of claims 1-5 in combination with a pharmaceutically acceptable adjuvant, diluent, or carrier.

14. A pharmaceutical formulation, comprising:

- (i) a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; [.] and
- (ii) one or more antithrombotic agents with a different mechanism of action from that of component (i), [such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P₂T) antagonist,]

in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

15. A kit of parts comprising:

- (i) a pharmaceutical formulation comprising [containing] a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier; and
- (ii) a pharmaceutical formulation comprising [containing] one or more antithrombotic agents with a different mechanism of action from that of component (i), [such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P₂T) antagonist,]

in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, [.]

wherein [which] compound (i) and agent (ii) are each formulated [provided in a form that is suitable] for administration in conjunction with the other.

16. A method for treatment of a patient suffering from, or susceptible to, a condition in which inhibition of carboxypeptidase U and a different antithrombotic mechanism are required or desired, which method comprises administering to the patient a therapeutically effective total amount of:

- (i) a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier; and **[in conjunction with]**
- (ii) one or more antithrombotic agents with a different mechanism of action from that of component (i), **[such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P₂T) antagonist,]**
- in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

17. A method for the treatment of a patient suffering from, or susceptible to, a condition in which inhibition of carboxypeptidase U and a different antithrombotic mechanism are required or desired, which method comprises administering to the patient the [a] formulation according to **[as defined in]** claim 14.

CONCLUSION

Upon entry of this Preliminary Amendment, claims 1-9 and 12-28 are pending. Applicants respectfully submit that claims 1-9 and 12-28 are directed to patentable subject matter.

Accordingly, Applicant requests allowance of the claims

Authorization is hereby given to charge any fee in connection with this communication to Deposit Account No. 23-1703.

Dated: Nov. 5, 2001

Respectfully submitted,

Andrew Fessak

Andrew Fessak
Reg. No. 48,528

Customer No. 07470
Direct Line: (212) 819-8437

ASTRA

09/600661

534 Rec'd PCT/PTC 20 JUL 2000

Applicant: **AstraZeneca AB**
S-151 85 Södertälje
Sweden

Title: **NEW COMPOUNDS**

Reference: **H 2156-1 PCT**

Inventors: **LINSCHOTEN, Marcel**
POLLA, Magnus
SVENSSON, Peder

NEW COMPOUNDS

FIELD OF THE INVENTION

5 The present invention relates to novel compounds, and pharmaceutically acceptable salts thereof, which inhibit basic carboxypeptidases, more specifically carboxypeptidase U, and thus can be used in the prevention and treatment of diseases wherein inhibition of carboxypeptidase U is beneficial. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to
10 pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

BACKGROUND OF THE INVENTION

15

Fibrinolysis is the result of a series of enzymatic reactions resulting in the degradation of fibrin by plasmin. The activation of plasminogen is the central process in fibrinolysis. The cleavage of plasminogen to produce plasmin is accomplished by the plasminogen activators, tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen
20 activator (u-PA). Initial plasmin degradation of fibrin generates carboxy-terminal lysine residues that serves as high affinity binding sites for plasminogen. Since plasminogen bound to fibrin is much more readily activated to plasmin than free plasminogen this mechanism provides a positive feedback regulation of fibrinolysis.

25 One of the endogenous inhibitors to fibrinolysis is carboxypeptidase U (CPU). CPU is also known as plasma carboxypeptidase B, active thrombin activatable fibrinolysis inhibitor (TAFIa), carboxypeptidase R and inducible carboxypeptidase activity. CPU is formed during coagulation and fibrinolysis from its precursor proCPU by the action of proteolytic enzymes *e.g.* thrombin, thrombin-thrombomodulin complex or plasmin. CPU cleaves basic
30 amino acids at the carboxy-terminal of fibrin fragments. The loss of carboxy-terminal lysines and thereby of lysine binding sites for plasminogen then serves to inhibit fibrinolysis.

By inhibiting the loss of lysine binding sites for plasminogen and thus increase the rate of plasmin formation, effective inhibitors of carboxypeptidase U would be expected to facilitate fibrinolysis.


2-mercaptomethyl-3-guanidinoethylthiopropionic acid is reported as a carboxypeptidase N inhibitor. More recently, this compound has been shown to inhibit CPU, Hendriks, D. *et al.*, Biochimica et Biophysica Acta, 1034 (1990) 86-92.

Guanidinoethylmercaptosuccinic acid is reported as a carboxypeptidase N inhibitor. More recently, this compound has been shown to inhibit CPU, Eaton, D. L., *et al.*, The Journal of Biological Chemistry, 266 (1991) 21833-21838.

DISCLOSURE OF THE INVENTION

It has surprisingly been found that compounds of the Formula I are particularly effective as inhibitors of carboxypeptidase U and thereby useful as medicaments for the treatment or prophylaxis of conditions wherein inhibition of carboxypeptidase U is beneficial.

In one aspect, the invention thus relates to compounds of the general Formula I,



or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein

R₁ represents,

C₁-C₆ alkyl, substituted with one or more basic groups such as amino, amidino and/or guanidino;

cycloalkyl, substituted with one or more basic groups such as amino, amidino and/or guanidino;

heterocyclyl, containing at least one nitrogen atom;

heterocyclyl, containing at least one hetero atom selected from S or O,

and substituted with one or more basic groups such as amino, amidino and/or
guanidino;

5 or aryl, substituted with one or more basic groups such as amino, amidino and/or
guanidino,

R_2 represents H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl,
aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano,
cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, Z_2N -
10 CO-O-, ZO-CO-NZ- or Z_2N -CO-NZ- group,

R_3 represents COOR₅, SO(OR₅), SO₃R₅, P=O(OR₅)₂, B(OR₅)₂, P=OR₅(OR₅), or tetrazole,
or any carboxylic acid isostere,

R_4 represents SH, S-CO-C₁-C₆ alkyl or S-CO-aryl,

R_5 represents H, C₁-C₆ alkyl or aryl,

15 R_6 represents H or C₁-C₆ alkyl,

X represents O, S, SO, SO₂, C(Z)₂, N(Z), NR₆SO₂, SO₂NR₆, NR₆CO or CONR₆,

Y represents C(Z)₂,

Z represents independently H, C₁-C₆ alkyl, aryl, cycloalkyl or heterocyclyl.

20 Preferred compounds according to the present invention are those of Formula I, or a
pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,
wherein

R_1 represents,

cycloalkyl, substituted with one or more basic groups such as amino, amidino and/or
25 guanidino;

heterocyclyl, containing at least one nitrogen atom;

heterocyclyl, containing at least one hetero atom selected from S or O, and substituted
with one or more basic groups such as amino, amidino and/or guanidino;

30 or aryl, substituted with one or more basic groups such as amino, amidino and/or
guanidino;

R_2 represents H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl,

arylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, Z_2N -CO-O-, ZO-CO-NZ- or Z_2N -CO-NZ- group,

R_3 represents COOR₅,

5 R_4 represents SH, S-CO-C₁-C₆ alkyl or S-CO-aryl,

R_5 represents H, C₁-C₆ alkyl or aryl,

R_6 represents H or C₁-C₆ alkyl,

X represents O, S, SO, SO₂, C(Z)₂, N(Z), NR₆SO₂, SO₂NR₆ or CONR₆,

Y represents C(Z)₂,

10 Z represents independently H, C₁-C₆ alkyl, aryl, cycloalkyl or heterocyclyl.

More preferred compounds according to the present invention are those of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein

15 R_1 represents,

cycloalkyl, substituted with one or more basic groups such as amino, amidino and/or guanidino;

heterocyclyl, containing at least one nitrogen atom;

20 heterocyclyl, containing at least one hetero atom selected from S or O, and substituted with one or more basic groups such as amino, amidino and/or guanidino;

R_2 represents H, C₁-C₃ alkyl, amino, halogen or hydroxy,

R_3 represents COOR₅,

R_4 represents SH, S-CO-C₁-C₆ alkyl or S-CO-aryl,

R_5 represents H, C₁-C₆ alkyl or aryl,

25 X represents C(Z)₂,

Y represents C(Z)₂,

Z represents independently H or C₁-C₆ alkyl.

Even more preferred compounds according to the present invention are those of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein

30 R_1 represents,

cycloalkyl, substituted with one or more basic groups such as amino, amidino and/or guanidino;

heterocyclyl, containing at least one nitrogen atom;

R₂ represents H, F, or C₁ alkyl,

5 R₃ represents COOR₅,

R₄ represents SH, S-CO-C₁-C₆ alkyl or S-CO-aryl,

R₅ represents H, C₁-C₆ alkyl or aryl,

X represents C(Z)₂,

Y represents C(Z)₂,

10 Z represents independently H or C₁-C₆ alkyl.

Most preferred compounds according to the present invention are those of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein

R₁ represents cyclopentyl, pyridyl, pyrimidinyl, piperidinyl or thiazolyl,

15 R₂ represents H, F, or C₁ alkyl,

R₃ represents COOR₅,

R₄ represents SH,

R₅ represents H,

X represents CHZ,

20 Y represents CHZ,

Z represents independently H or C₁-C₆ alkyl.

The following definitions shall apply throughout the specification and the appended claims:

25

The term "basic group" denotes a basic group, wherein the conjugate acid of said basic group has a pK_a of from about -5 to about 25, preferably of from 1 to 15.

The term "carboxylic acid isostere" denotes an acidic group having a pK_a of from about -5
30 to about 25, preferably of from 1 to 15.

The term "C₁-C₆ alkyl" denotes a straight or branched, saturated or unsaturated, substituted or unsubstituted alkyl group having 1 to 6 carbon atoms in the chain wherein the alkyl group may optionally be interrupted by one or more heteroatoms selected from O, N or S. Examples of said alkyl include, but is not limited to, methyl, ethyl, ethenyl, ethynyl, n-propyl, iso-propyl, propenyl, iso-propenyl, propynyl, n-butyl, iso-butyl, sec-butyl, t-butyl, butenyl, iso-butenyl, butynyl and straight- and branched-chain pentyl and hexyl.

The term "C₁-C₃ alkyl" denotes a straight or branched, saturated or unsaturated, substituted or unsubstituted alkyl group having 1 to 3 carbon atoms in the chain wherein the alkyl group may optionally be interrupted by one or more heteroatoms selected from O, N or S. Examples of said alkyl include, but is not limited to, methyl, ethyl, ethenyl, ethynyl, n-propyl, iso-propyl, propenyl, iso-propenyl, propynyl.

The term "C₁ alkyl" denotes a substituted or unsubstituted alkyl group having 1 carbon atom. An example of said alkyl include, but is not limited to, methyl,

The term "C₁-C₆ alkoxy" denotes an alkyl-O-group, wherein C₁-C₆ alkyl is as defined above.

The term "C₁-C₃ alkoxy" denotes an alkyl-O-group, wherein C₁-C₃ alkyl is as defined above.

The term "heterocyclyl" denotes a substituted or unsubstituted, 4- to 10- membered monocyclic or multicyclic ring system in which one or more of the atoms in the ring or rings is an element other than carbon, for example nitrogen, oxygen or sulfur, especially 4-, 5- or 6-membered aromatic or alifatic heterocyclic groups, and includes, but is not limited to azetidine, furan, thiophene, pyrrole, pyrroline, pyrrolidine, dioxolane, oxathiolane, oxazolane, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, oxadiazole, furazan, triazole, thiadiazole, pyran, pyridine, piperidine, dioxane, morpholine, dithiane, oxathiane, thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, thiadiazine, dithiazine, azaindole, azaindoline,

indole, indoline, naphthyridine groups, and shall be understood to include all isomers of the above identified groups. The term "azetidiny" shall for example be understood to include the 2-, and 3-isomers and the terms "pyridyl" and "piperidiny" shall for example be understood to include the 2-, 3-, and 4-isomers.

5

The term "cycloalkyl" denotes a saturated or unsaturated, substituted or unsubstituted, non-aromatic ring composed of 3, 4, 5, 6 or 7 carbon atoms, and includes, but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclopentadienyl, cyclohexadienyl and cyclo-

10

heptadienyl groups.

The term "halogen" includes fluoro, chloro, bromo and iodo groups.

The term "aryl" denotes a substituted or unsubstituted C₆-C₁₄ aromatic hydrocarbon and includes, but is not limited to, phenyl, naphthyl, indenyl, anthracenyl, fenantrenyl, and fluorenyl.

15

The term "aryloxy" denotes an aryl-O-group, wherein aryl is as defined above.

20

The term "acyl" denotes an alkyl-CO-group, wherein alkyl is as defined above.

The term "aroyl" denotes an aryl-CO-group, wherein aryl is as defined above.

The term "alkylthio" denotes an alkyl-S-group, wherein alkyl is as defined above.

25

The term "arylthio" denotes an aryl-S-group, wherein aryl is as defined above.

The term "aroylamino" denotes an aroyl-N(Z)-group, wherein aroyl and Z is as defined above.

30

The term "acylamino" denotes an acyl-N(Z)-group, wherein acyl and Z is as defined above.

The term "carbamoyl" denotes a $\text{H}_2\text{N-CO-}$ group.

The term "alkylcarbamoyl" denotes a $\text{Z}_2\text{N-CO-}$ group wherein Z is as defined above.

5

The term "substituted" denotes an " C_1 alkyl", " $\text{C}_1\text{-C}_3$ alkyl", " $\text{C}_1\text{-C}_6$ alkyl", "cycloalkyl", "heterocyclyl" or a "aryl" group as defined above which is substituted by one or more acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, thio, $\text{Z}_2\text{N-CO-O-}$, ZO-CO-NZ- , or $\text{Z}_2\text{N-CO-NZ-}$ groups.

10

Moreover, the compounds of Formula I wherein R_4 is mercapto may be present in the form of a dimer which is bonded via -S-S- bond, which is also included in this invention.

15

Both the pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers are within the scope of the present invention. It should also be understood that all the diastereomeric forms possible are within the scope of the invention. Also included in the invention are derivatives of the compounds of the Formula I which have the biological function of the compounds of Formula I, such as prodrugs.

20

Depending on the process conditions the compounds of Formula I are obtained either in neutral or salt form or as a solvate, e.g. a hydrate, and are all within the scope of the present invention.

25

Preparation


The present invention also provides the process A-C for the manufacture of compounds with the general Formula I.

30

Process A

Process A for manufacture of compounds with the general Formula I, wherein R_1 , R_3 , R_4 , and Y are as defined above and R_2 is H, and X is $C(Z)_2$, comprises the following steps:

a) Compounds of the general Formula II,




wherein R_1 , is as defined for Formula I and X is $C(Z)_2$, which are either commercially available or are available using known techniques, can be converted into a compound of the general Formula III,




wherein L is a suitable leaving group, such as chloro, bromo, iodo, triflate or tosyl, under standard conditions using a suitable reagent, such as PPh_3/CBr_4 , $TosCl/pyridine$ or $(CF_3SO_2)_2O/TEA$.

b) Compounds of the general Formula III can thereafter be reacted with compounds of the general Formula IV,




wherein R_2 and R_3 are as defined for Formula I, which are either commercially available, or are available using known techniques, in the presence of a suitable base, such as K_2CO_3 or NaH , under standard conditions to give compounds of the general Formula V.




c) Compounds of the general Formula V wherein R_1 and R_3 are as defined for Formula I and X is $C(Z)_2$ and R_2 is H can thereafter be converted to compounds of the general Formula VI,

10




by treatment with formaldehyd in the presence of a suitable base, such as Et_2NH , under
5 standard conditions.

d) Compounds of the general Formula VI can also be prepared by treating compounds of the general Formula VII,




10 wherein R_3 and R_5 are as defined for Formula I, with an alkylating agent of the general Formula III in the presence of a suitable base, such as LDA or NaH, under standard conditions to give compounds of the general Formula VIII,




15

e) Compounds of the general Formula VIII can thereafter be reacted with an appropriate aldehyde or ketone $\text{OC}(\text{Z})_2$, in the presence of a suitable base, such as KOtBu , LDA or NaH, under standard conditions to give a compound of the general Formula VI.



20 f) Compounds of the general Formula VI can be further reacted with compounds of the general Formula IX,




wherein R_5 is a suitable protecting group, such as Ac, Bz, PMB or Bn, alone or in the presence of a suitable base, such as NaOMe, NaH or triethylamine or alternatively in the presence of a free-radical initiator, such as AIBN under standard conditions to give compounds of the general Formula I, wherein R_1 , R_3 , R_4 , and Y are as defined for Formula I and R_2 is H and X is $C(Z)_2$.

Process B

Process B for manufacture of compounds with the general Formula I, wherein R_1 , R_2 , R_3 , and R_4 , are as defined in Formula I and Y is CH_2 , and X is O, S, SO, SO_2 , $C(Z)_2$, or $N(Z)$, comprises the following steps:


a) Reacting a compound of the general Formula X,




wherein R_1 is as defined for Formula I and X is O, S, or $N(Z)$, with an alkylating agent of the general Formula XI,




wherein R_2 and R_3 are as defined for Formula I and L is a suitable leaving group, such as a chloro, bromo, iodo, triflate or tosylate group, under standard conditions using suitable reagents, such as NaH, Ag_2CO_3 , or $Bu_4NHSO_4/NaOH$, to give compounds of the general Formula XII,




b) Compounds of the general Formula XII can thereafter be reacted with carbon dioxide in the presence of a suitable base, such as LDA or KHMDS under standard conditions to give a compound of the general Formula XIII,



(c) Compounds of the general Formula XIII can thereafter be reacted with an alkyl chloroformate, such as ClCOOMe in the presence of a base, such as triethylamine, and thereafter reducing the formed mixed anhydride with a suitable reducing agent, such as NaBH₄, under standard conditions, to give a compound of the general Formula XIV



(d) Compounds of the general Formula XIV may thereafter be reacted with a compound of the general Formula IX




wherein R₅ is a suitable protecting group, such as Ac or Bz, in the presence of a suitable reagent, such as PPh₃/DIAD, under standard conditions to give compounds of the general Formula I, wherein R₁, R₂, R₃, and R₄ are as defined above and Y is CH₂ and X is O, S, C(Z)₂, or N(Z).

e) Compounds of the general Formula I, wherein R₁, R₂, R₃, R₄ and Y are as defined above and X is S may thereafter be reacted with a suitable oxidizing reagent, such as MCPBA under standard conditions to give compounds of the general Formula I, wherein R₁, R₂, R₃, R₄ and Y are as defined above and X is SO or SO₂.

Process C

Process C for manufacture of compounds with the general Formula I, wherein R_1 , R_2 , R_3 , R_4 , and Y , are as defined above and X is NR_6CO , $CONR_6$, SO_2NR_6 or NR_6SO_2 comprises the following steps:

a) Reacting a compound of the general Formula XV,



wherein R_2 , R_3 , R_6 and Y are as defined for Formula I and R_5 is a suitable protecting group, such as Ac, Bz, PMB or Bn, with a compound of the general Formula XVI,



wherein R_1 is as defined for Formula I and X is $COOH$ or SO_2Cl in the presence of suitable coupling reagents, such as PyBOP/DIPEA, DCC/HOBt, EDC/TEA/DMAP or pyridine under standard conditions to give compounds of the general Formula I, wherein R_1 , R_2 , R_3 , R_4 , and Y , are as defined above and X is NR_6CO or NR_6SO_2 .

b) Reacting a compound of the general Formula XVII,



wherein R_2 , R_3 , and Y are as defined for Formula I and X is $COOH$ or SO_2Cl and R_5 is a suitable protecting group, such as Ac, Bz, PMB or Bn, with a compound of the general Formula XVIII,



wherein R_6 is as defined for Formula I in the presence of suitable coupling reagents, such as PyBOP/DIPEA, DCC/HOBt, EDC/TEA/DMAP or pyridine under standard conditions to give compounds of the general Formula I, wherein R_1 , R_2 , R_3 , R_4 and Y are as defined above and X is $CONR_6$ or SO_2NR_6 .

5

It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be protected by suitable protecting groups.

10 Functional groups, which it is desirable to protect, include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (e.g. t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl and benzyl. Suitable protecting groups for amino, amidino and guanidino include t-butyloxycarbonyl and benzyloxy-carbonyl. Suitable protecting groups for mercapto
15 include $CO-C_{1-6}$ alkyl, p-methoxybenzyl and trityl. Suitable protecting groups for carboxylic acid include C_{1-6} alkyl and benzyl esters.

Protecting groups may be removed in accordance with techniques, which are well known to those skilled in the art and as described hereinafter.

20

Certain protected derivatives of compounds of Formula I, which may be made prior to a final deprotection stage to form compounds of Formula I, are novel.

25

The use of protecting groups is described in 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene & P.G.M. Wutz, Wiley-Interscience (1991). The protective group may also be a polymer resin such as Wang resin or a 2-chlorotrityl chloride resin.

30

It will also be appreciated by those skilled in the art, although such protected derivatives of compounds of Formula I may not possess pharmacological activity as such, they may be administered parenterally or orally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may

therefore be described as "prodrugs". All prodrugs of compounds of Formula I are included within the scope of the invention.

It should also be understood that all polymorphs, amorphous forms, anhydrides, hydrates, solvates of the compounds of the present invention are within the scope of the invention.

Pharmaceutical formulations

In yet a further aspect, the invention relates to pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt thereof, as active ingredient.

For clinical use, the compounds of the invention are formulated into pharmaceutical formulations for oral, intravenous, subcutaneous, tracheal, bronchial, intranasal, pulmonary, transdermal, buccal, rectal, parenteral or other mode of administration. The pharmaceutical formulation contains a compound of the invention in combination with one or more pharmaceutically acceptable ingredients. The carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compounds is between 0.1–95% by weight of the preparation.

In the preparation of pharmaceutical formulations containing a compound of the present invention the compound selected may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture may then be processed into granules or pressed into tablets.

Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain granules of the active compound. Hard gelatine capsules may also contain the active compound in combination

with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, cornstarch, amylopectin, cellulose derivatives or gelatine.

Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.

Liquid preparations may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions containing the active ingredient and the remainder consisting, for example, of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, preservatives, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.

Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients, preservatives and/or buffering ingredients. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent before use.

The typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 0.1 to 1000 mg per day of active substance.

Medical and pharmaceutical use

The compounds of the invention are inhibitors of carboxypeptidase U either as such or, in the case of prodrugs, after administration. The compounds of the invention are thus
5 expected to be useful in those conditions where inhibition of carboxypeptidase U is beneficial, such as in the treatment or prophylaxis of thrombosis and hypercoagulability in blood and tissues of mammals, including man.

It is known that hypercoagulability may lead to thrombo-embolic diseases. Conditions
10 associated with hypercoagulability and thrombo-embolic diseases which may be mentioned include protein C resistance and inherited or acquired deficiencies in antithrombin III, protein C, protein S and heparin cofactor II. Other conditions known to be associated with hyper-coagulability and thrombo-embolic disease include circulatory and septic shock, circulating antiphospholipid antibodies, homocysteinemia, heparin induced
15 thrombocytopenia and defects in fibrinolysis. The compounds of the invention are thus indicated both in the therapeutic and/or prophylactic treatment of these conditions. The compounds of the invention are further indicated in the treatment of conditions where there is an undesirable excess of proCPU/CPU.

20 Particular disease states which may be mentioned include the therapeutic and /or prophylactic treatment of venous thrombosis and pulmonary embolism, arterial thrombosis (e.g. in myocardial infarction, unstable angina, thrombosis-based stroke and peripheral arterial thrombosis) and systemic embolism usually from the atrium during arterial fibrillation or from the left ventricle after transmural myocardial infarction.

25 Moreover, the compounds of the invention are expected to have utility in prophylaxis of re-occlusion and restenosis (*i.e.* thrombosis) after thrombolysis, percutaneous trans-luminal angioplasty (PTA) and coronary bypass operations; the prevention of re-thrombosis after microsurgery and vascular surgery in general.

30 Further indications include the therapeutic and/or prophylactic treatment of disseminated intravascular coagulation caused by bacteria, multiple trauma, intoxication or any other

mechanism, fibrinolytic treatment when blood is in contact with foreign surfaces in the body, such as vascular grafts, vascular stents, vascular catheters, mechanical and biological prosthetic valves or any other medical device, and fibrinolytic treatment when blood is in contact with medical devices outside the body, such as during cardiovascular surgery using a heart-lung machine or in haemodialysis.

The compounds of the invention may also be combined and/or coadministered with any antithrombotic agent with a different mechanism of action, such as the antiplatelet agents acetylsalicylic acid ticlopidine, clopidogrel, thromboxane receptor and/or synthetase inhibitors, fibrinogen receptor antagonists, prostacyclin mimetics and phosphodiesterase inhibitors and ADP-receptor (P_2T) antagonists and thrombin inhibitors.

The compounds of the invention may further be combined and/or coadministered with thrombolytics such as tissue plasminogen activator (natural, recombinant or modified), streptokinase, urokinase, prourokinase, anisoylated plasminogen-streptokinase activator complex (APSAC), animal salivary gland plasminogen activators, and the like, in the treatment of thrombotic diseases, in particular myocardial infarction and stroke.

In vitro experiments

The inhibiting effect of the compounds of the present invention was estimated using the assay described in: Dirk Hendriks, Simon Scharpé and Marc van Sande, Clinical Chemistry, 31, 1936-1939 (1985); and Wei Wang, Dirk F. Hendriks, Simon S. Scharpé, The Journal of Biological Chemistry, 269, 15937-15944 (1994).

EXAMPLES

General Experimental Procedures

Mass spectra were recorded on a Finnigan MAT TSQ 700 triple quadrupole mass spectrometer equipped with an electrospray interface (FAB-MS) and VG Platform II mass spectrometer equipped with an electrospray interface (LC-MS). 1H NMR and ^{13}C NMR measurements were performed on Varian UNITY plus 400, 500 and 600 spectrometers, operating at 1H frequencies of 400, 500 and 600 MHz respectively. Chemical shifts are

given in ppm with the solvent as internal standard. Organic extracts were dried using MgSO_4 or Na_2SO_4 as the drying agent. Chromatography separations were performed using Merck Silica gel 60 (0.063-0.200 mm). HPLC separations were performed on a HIGHCROM KR100-10C8 column.

5

Example 1

2-Mercaptomethyl-3-piperidin-4-yl-propionic acid

(a) 3-Piperidin-4-yl-propionic acid

10 A solution of 3-pyridin-4-yl-acrylic acid (4.20 g, 28.0 mmol) in water (50 mL) and ammonia (aq, 25 %, 4 mL) was hydrogenated at 60 bar in a high pressure steel autoclave in presence of ruthenium (5 % on alumina, 439 mg). When hydrogen pressure remained constant (3 days) the catalyst was removed from the reaction mixture by filtration. The catalyst was washed with ethanol and water, and the ethanol was removed from the
15 solution on a rotavapor and the aqueous solution was freeze dried to give 3-piperidin-4-yl-propionic acid (4.30 g, 100 %).

(b) 4-(2-carboxy-ethyl)-piperidine-1-carboxylic acid *tert*-butyl ester

A solution of 3-piperidin-4-yl-propionic acid (4.79 g, 30.5 mmol), di-*tert*-butyl-dicarbonate (6.98 g, 32.0 mmol) and NaHCO_3 (2.69 g, 32.0 mmol) in THF/water (1:1, 50
20 mL) were stirred at room temperature for 22 h. Another portion of di-*tert*-butyl-dicarbonate (2.00 g, 9.10 mmol) was added together with a catalytic amount of DMAP, the resulting mixture was stirred for another four days. THF was removed under reduced pressure and the aqueous phase was extracted with CH_2Cl_2 . The aqueous was then acidified
25 to pH 2 with 1M HCl and the acid extracted with CH_2Cl_2 . The combined organic extracts were washed with brine, dried and concentrated *in vacuo* to yield 4-(2-carboxy-ethyl)-piperidine-1-carboxylic acid *tert*-butyl ester as a white solid (6.36 g, 81 %).

(c) 4-(3-Benzylsulfanyl-2-carboxy-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester

30 BuLi (1.6 M, 15.3 mL, 24.4 mmol) was added to a solution of diisopropylamine (3.43 mL, 24.4 mmol) in THF (3 mL) at -78°C under argon. After a few min the solution was allowed to warm up to room temperature over a period of 15 min. The resulting LDA

solution was slowly added to a solution of 4-(2-carboxy-ethyl)-piperidine-1-carboxylic acid *tert*-butyl ester (3.07 g, 11.9 mmol) in THF (7 mL) at -78°C . The resulting solution was stirred at -78°C for 10 min., THF (20 mL) was added during that time in order to dissolve the anion which had solidified. The dianion was cooled to -78°C and
5 bromomethyl thiobenzylether (2.72 g, 12.5 mmol) was added as a solution in THF (3 mL), the solution was stirred at -78°C for 30 min, at 0°C for 30 min and then allowed to warm up to room temperature and stirred overnight. The reaction mixture was acidified with 1 M HCl, diluted with EtOAc and the organic phase was washed with water and dried. The crude product was purified by flash chromatography (MeOH/ CHCl_3 , 1:9) to yield 4-(3-
10 Benzylsulfanyl-2-carboxy-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester as a pale yellow oil (3.12 g, 66 %).

(d) 4-(2-Carboxy-3-mercapto-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester

Sodium metal (513 mg, 22.5 mmol) was added in portions during 5 min. to a solution of 4-
15 (3-Benzylsulfanyl-2-carboxy-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.9 g, 2.29 mmol) in THF (45 mL) and liquid ammonia (50 mL) at -60°C under argon. After stirring for 15 min. ammonium chloride (1.7 g, 31.5 mmol) was added in portions. The cooling bath was removed and the ammonia was evaporated using a stream of argon. 0.5 M NaOH was added and the mixture was washed with heptane. The aqueous phase was
20 acidified with 2 M HCl and extracted with methylene chloride. The organic phase was washed with brine, dried and concentrated under reduced pressure to give 4-(2-Carboxy-3-mercapto-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.7 g, 100 %).

(e) 2-Mercaptomethyl-3-piperidin-4-yl-propionic acid

25 To a solution of 4-(2-Carboxy-3-mercapto-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.7 g, 2.29 mmol) in methylene chloride (8 mL) under argon was added triethylsilane (731 μL , 4.58 mmol) followed by TFA (4 mL). The reaction mixture was stirred for 60 min. and then concentrated under reduced pressure. Purification by HPLC (10 \rightarrow 30 % acetonitrile, 0.1 % TFA in water) gave the title compound as the TFA salt (447 mg, 61 %).
30 ^1H NMR (400 MHz, D_2O): δ 1.34-1.50 (m, 2H), 1.54-1.76 (m, 3H), 1.90-1.99 (m, 1H), 2.0-2.1 (m, 1H), 2.9-3.05 (m, 5H), 3.38-3.48 (m, 2H).
MS (+) 204 (M+1).

Example 23-(1-Acetyl-piperidin-4-yl)-2-mercaptomethyl-propionic acid

A solution of 2-Mercaptomethyl-3-piperidin-4-yl-propionic acid TFA salt (0.1 g, 0.32 mmol) in acetic anhydride (2 mL) was stirred over night under argon and then concentrated under reduced pressure. Purification by HPLC (10 → 50 % acetonitrile, 0.1 % TFA in water) gave the title compound (63 mg, 80 %).

¹H NMR (500 MHz, CD₃OD): δ 1.0-1.22 (m, 2H), 1.46-1.55 (m, 1H), 1.55-1.66 (m, 2H), 1.67-1.79 (m, 1H), 1.81-1.92 (m, 1H), 2.08 (s, 3H), 2.55-2.73 (m, 4H), 3.03-3.12 (m, 1H), 3.85-3.94 (m, 1H), 4.45-4.53 (m, 1H).

MS (+) 246 (M+1).

Example 33-Mercapto-5-methyl-2-piperidin-4-ylmethyl-hexanoic acid(a) 4-Hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester

To a solution of , 4-(hydroxymethyl)piperidine (5.00 g, 43.41 mmol THF/ H₂O (1:1, 120 mL) was added di-*t*-butyl dicarbonate (9.47 g, 43.41 mmol). The reaction mixture was stirred for 16 h at room temperature. The reaction mixture was then poured into H₂O (500 mL) and extracted with ethyl acetate (3 x 250 mL). The organic layers were combined and washed with water. The organic layer was dried over sodium sulfate, filtered, and then concentrated under reduced pressure to give 4-hydroxymethyl-piperidine-1-carboxylic acid *tert*-butyl ester (9.01 g, 96%).

(b) 4-Bromomethyl-piperidine-1-carboxylic acid tert-butyl ester

To a solution 4-hydroxymethyl-piperidine-1-carboxylic acid *tert*-butyl ester (8.75 g, 40.64 mmol) in diethyl ether (200 mL) at 0°C under nitrogen. were added triphenyl phosphine (21.32 g, 81.28 mmol) and carbon tetrabromide (26.96 g, 81.28 mmol). The mixture was allowed to warm to room temperature and stirred under nitrogen for 48 h. The reaction mixture was filtered through a pad of Celite and the organic filtrate was washed with 5 % Na₂S₂O₃, water, brine, and dried. The mixture was filtered and concentrated under reduced

pressure. The crude product was purified by column chromatography (ethyl acetate/hexane, 1:9) to give 4-bromomethyl-piperidine-1-carboxylic acid *tert*-butyl ester (8.26 g, 73 %).

5. (c) 4-[2-*tert*-Butoxycarbonyl-2-(diethoxy-phosphoryl)-ethyl]-piperidine-1-carboxylic acid
tert-butyl ester

tert-Butyl diethylphosphonoacetate (75.0 g, 297.32 mmol) was added dropwise to a suspension of sodium hydride (8.03 g, 334.58 mmol) in DMF (450 mL) at 0°C under nitrogen. The mixture was stirred at 0°C for 0.5 h and at room temperature for 0.5 h. 4-bromomethyl-piperidine-1-carboxylic acid *tert*-butyl ester (20.68 g, 74.34 mmol) in DMF (50 mL) was added dropwise to the reaction mixture and the reaction was heated to 60°C and stirred for 16 h. The reaction was cooled to room temperature, poured into H₂O and extracted with ethyl acetate. The organic layers were combined and washed with water. The organic layer was dried, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (ethyl acetate/hexane, 3:7) to give 4-[2-*tert*-Butoxycarbonyl-2-(diethoxy-phosphoryl)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester and unreacted *t*-butyl diethylphosphonoacetate. The product was 47 % pure by HPLC. The product was further purified by vacuum distillation to give 77 % purity. This mixture was taken on to the next reaction.

(d) 4-(2-*tert*-Butoxycarbonyl-5-methyl-hex-2-enyl)-piperidine-1-carboxylic acid *tert*-butyl ester

4-[2-*tert*-Butoxycarbonyl-2-(diethoxy-phosphoryl)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester (8.1 g) in 20 mL DME was added dropwise to a suspension of sodium hydride (1.04 g, 43.13 mmol) in DME (20 mL) at 0°C under nitrogen. The mixture was stirred for 0.75 h and isovaleraldehyde (7.76 g, 90.1 mmol) was added dropwise to the mixture. The mixture was allowed to warm to room temperature and stirred for 48 h. The mixture was diluted with ether and washed with water. The organic layer was dried, filtered, and concentrated under reduced pressure to give 9.4 g of a yellow oil. The crude product was purified by column chromatography (ethyl acetate/hexane, 1:50) to give 4-(2-*tert*-butoxycarbonyl-5-methyl-hex-2-enyl)-piperidine-1-carboxylic acid *tert*-butyl ester (1.53 g, 24 %) for two reactions.

(e) 4-[2-*tert*-Butoxycarbonyl-3-(4-methoxy-benzylsulfanyl)-5-methyl-hexyl]-piperidine-1-carboxylic acid *tert*-butyl ester

A solution of 4-(2-*tert*-butoxycarbonyl-5-methyl-hex-2-enyl)-piperidine-1-carboxylic acid *tert*-butyl ester (2.0 g, 5.24 mmol) in DMF (5 mL) was added to a mixture of potassium carbonate (0.54 g, 3.93 mmol) and 4-methoxy- α -toluenethiol (1.17 g, 10.48 mmol) in DMF (50 mL) under nitrogen. The mixture was refluxed for 5 h and allowed to cool to room temperature. The reaction mixture was then poured into H₂O and extracted with ethyl acetate. The organic layers were combined and washed with water. The organic layer was dried, filtered and concentrated under reduced pressure to give 3.76 g of crude material. The crude product was purified by column chromatography (ethyl acetate/hexane, 1:10) to give 4-[2-*tert*-butoxycarbonyl-3-(4-methoxy-benzylsulfanyl)-5-methyl-hexyl]-piperidine-1-carboxylic acid *tert*-butyl ester (1.77 g, 63 %).

(f) 3-Mercapto-5-methyl-2-piperidin-4-ylmethyl-hexanoic acid

A mixture of H₂O (2.6 mL) and TFA (26 mL) was frozen and then allowed to warm to room temperature under nitrogen. 4-[2-*tert*-butoxycarbonyl-3-(4-methoxy-benzylsulfanyl)-5-methyl-hexyl]-piperidine-1-carboxylic acid *tert*-butyl ester (2.62 g, 4.89 mmol) was added and the mixture was refluxed for 16 h. The mixture was allowed to cool to room temperature and concentrated under reduced pressure. The crude product was purified by reverse-phase column chromatography (MeOH/H₂O, 3:2) to give the title compound as the TFA salt (0.40 g, 22 %).

¹H NMR (300 MHz) (CD₃OD) δ 0.88 (d), 0.94 (d), 1.43 (m), 1.70 (br),

1.94 (m), 2.48 (m), 2.90 (m), 2.99 (br), 3.34 (m).

MS (+) 260.2 (M-TFA).

Example 4

3-Mercapto-4-phenyl-2-piperidin-4-ylmethyl-butyric acid

(a) 4-(2-*tert*-Butoxycarbonyl-4-phenyl-but-2-enyl)-piperidine-1-carboxylic acid *tert*-butyl ester

A solution of 4-[2-*tert*-butoxycarbonyl-2-(diethoxy-phosphoryl)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester (3.0 g) in DME (8 mL) was added dropwise to a suspension of sodium hydride (0.26 g, 10.51 mmol) in DME (8 mL) at 0°C under nitrogen. The mixture was stirred for 0.75 h. Phenyl acetaldehyde (5.26 g, 43.81 mmol) was added dropwise to the mixture at 0°C. The mixture was allowed to warm to room temperature and stirred for 16 h. The mixture was diluted with ether and washed with water. The organic layer was dried, filtered, and concentrated under reduced pressure to give 8.6 g of a yellow oil. The crude product was purified by column chromatography (ethyl acetate/hexane, 1:50 → 1:10) to give 4-(2-*tert*-butoxycarbonyl-4-phenyl-but-2-enyl)-piperidine-1-carboxylic acid *tert*-butyl ester (1.32 g, 62 % yield) for two reactions.

(b) 4-[2-*tert*-Butoxycarbonyl-3-(4-methoxy-benzylsulfanyl)-4-phenyl-butyl]-piperidine-1-carboxylic acid *tert*-butyl ester.

4-(2-*tert*-Butoxycarbonyl-4-phenyl-but-2-enyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.8 g, 1.93 mmol) in DMF (10 mL) was added to a suspension of potassium carbonate (0.20 g, 1.44 mmol) and 4-methoxy- α -toluenethiol (0.54 mL, 3.85 mmol) in DMF (10 mL) under nitrogen. The mixture was heated to 75°C for 24 h and allowed to cool to room temperature. The reaction mixture was then poured into H₂O and extracted with ethyl acetate. The organic layers were combined and washed with water. The organic layer was dried, filtered, and concentrated under reduced pressure to give 1.8 g crude material. The crude product was purified by column chromatography (ethyl acetate/hexane, 1:10) to give 4-[2-*tert*-butoxycarbonyl-3-(4-methoxy-benzylsulfanyl)-4-phenyl-butyl]-piperidine-1-carboxylic acid *tert*-butyl ester (0.55 g, 50 %).

(c) 3-Mercapto-4-phenyl-2-piperidin-4-ylmethyl-butyric acid

A mixture of H₂O (0.65 mL) and TFA (6.5 mL) was frozen and then allowed to warm to room temperature under nitrogen. 4-[2-*tert*-butoxycarbonyl-3-(4-methoxy-benzylsulfanyl)-4-phenyl-butyl]-piperidine-1-carboxylic acid *tert*-butyl ester (0.65 g, 1.14 mmol) was added and the mixture was refluxed for 16 h. The mixture was allowed to cool to room temperature and concentrated under reduced pressure. The crude product was purified by

reverse-phase column chromatography (MeOH/H₂O, 1:1) to give the title compound as the TFA salt (0.27 g, 58 %).

¹H NMR (300 MHz) (DMSO) δ 1.22 (m), 1.49 (m), 1.67 (br), 2.21 (d), 2.98 (m), 7.25 (m, 5H), 8.27 (br), 8.57 (br), 12.59 (br).

5 MS (+) 294.3 (M-TFA).

Example 5

2-(2-Amino-pyridin-4-ylmethyl)-3-mercapto-propionic acid

10 (a) N-(4-Methyl-pyridin-2-yl)-acetamide

2-Amino-4-methylpyridine (99.0 g, 91.5 mmol) in acetic anhydride (250 mL) was warmed to 70°C for two h. The mixture was cooled to room temperature and diethyl ether (100 mL) added. The product crystallized as white needle crystals. Filtering and drying *in vacuo* afforded N-(4-methyl-pyridin-2-yl)-acetamide (130 g, 95 %).

15

(b) 2-Acetylamino-isonicotinic acid

A mixture of N-(4-methyl-pyridin-2-yl)-acetamide (40.0 g, 0.26 mol) and water (400 mL) was heated at 90°C until the solution was homogeneous. KMnO₄ (100 g, 0.62 mol) was added carefully in small portions with vigorous mechanical stirring over 2 h. The reaction mixture was kept at 90-95°C for further 3 h before filtering through Celite while still hot. The filtrate was concentrated to about 100 mL and concentrated HCl was added to adjust the pH to about 4. The reaction flask was cooled in an ice bath and the white solid filtered off. The crystals were washed with cold water and chloroform and dried *in vacuo* giving 2-acetylamino-isonicotinic acid (12.0 g, 25 %).

25

(c) 2-Amino-isonicotinic acid ethyl ester

2-Acetylamino-isonicotinic acid (10.8 g, 60.0 mmol) was suspended in ethanol (150 mL) and BF₃ OEt₂ (22 mL, 138 mmol) was added. The mixture was refluxed overnight, and after cooling to room temperature 10 % NaHCO₃ (250 mL) was added. The product was extracted with chloroform and the combined organic extracts were washed with water and dried. Filtering and concentration afforded 2-amino-isonicotinic acid ethyl ester (7.46 g, 79 %) as pale yellow crystals.

30

(d) 2-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-isonicotinic acid ethyl ester

To a solution of 2-amino-isonicotinic acid ethyl ester (5.00 g, 30 mmol) in *t*-BuOH (45 mL) and acetone (15 mL) was added DMAP (50 mg, 0.41 mmol) and di-*t*-butyl
5 dicarbonate (16.4 g, 75.0 mmol). The reaction was stirred at room temperature overnight and hexane (60 mL) was added. The reaction mixture was cooled in a refrigerator for 3 h and filtered to give 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-isonicotinic acid ethyl ester (8.71 g, 79 %).

10 (e) (4-Hydroxymethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester

A solution of 2-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-isonicotinic acid ethyl ester (35.0 g, 95.5 mmol) in THF (350 mL) was treated with LiAlH₄ (7.25 g, 191 mmol) and refluxed for 1 h under nitrogen. The reaction mixture was poured carefully onto crushed ice and the product extracted several times with CHCl₃ and CHCl₃ : MeOH (9:1). The combined
15 organic extracts were dried, filtered and concentrated under reduced pressure to give (4-hydroxymethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (18.5 g, 86 %) as a pale yellow solid.

(f) (4-Bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester

20 (4-Hydroxymethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (8.00 g, 35.6 mmol) was dissolved in CH₂Cl₂ (150 mL) and treated with PPh₃ (11.2 g, 42.8 mmol) under nitrogen. The reaction flask was cooled in an ice bath and CBr₄ (14.2 g, 42.8 mmol) was added in small portions. The ice bath was removed after 30 min and the reaction mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced
25 pressure and acetonitrile (50 mL) was added. The reaction flask was placed in a refrigerator for 3 h and the precipitate filtered and washed with cold acetonitrile. The white solid was dried *in vacuo* giving (4-bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (8.38 g, 82 %).

30 (g) 2-(2-*tert*-Butoxycarbonylamino-pyridin-4-ylmethyl)-malonic acid diethyl ester

To a solution of NaH (80%, 0.17 g, 4.00 mmol) in THF (5 mL) at 0°C under argon was added diethyl malonate (0.64 g, 4.00 mmol). After the mixture was stirred for 15 min the

mixture was added to a refluxed mixture of (4-bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (1.00 g, 3.48 mmol) in THF (10 mL), and the mixture was refluxed for 2 h. The mixture was concentrated under reduced pressure and the residue was partitioned between water and chloroform. The organic layer was washed with water and brine and dried. After filtration and evaporation of the solvent, the crude product was purified by flash chromatography (MeOH/ CH₂Cl₂, 1:100) to give 2-(2-*tert*-butoxycarbonylamino-pyridin-4-ylmethyl)-malonic acid diethyl ester (0.80 g, 55 %).

(h) 2-(2-*tert*-Butoxycarbonylamino-pyridin-4-ylmethyl)-malonic acid monoethyl ester

A solution of KOH (0.19 g, 3.43 mmol) in ethanol (5 mL) was added to a solution of 2-(2-*tert*-butoxycarbonylamino-pyridin-4-ylmethyl)-malonic acid diethyl ester (1.20 g, 3.27 mmol) in ethanol (5 mL) and methylene chloride (5 mL) at 0°C. The mixture was stirred for 18 h at room temperature. The mixture was concentrated under reduced pressure and water was added to the residue. The aqueous layer was washed with diethyl ether, acidified to pH 4 by 1M HCl, and extracted with methylene chloride. The organic layer was washed with water, brine and dried. After filtration and evaporation *in vacuo*, the crude product was purified by flash chromatography (CH₃OH/CH₂Cl₂, 1:20) to yield 2-(2-*tert*-butoxycarbonylamino-pyridin-4-ylmethyl)-malonic acid monoethyl ester (0.90 g, 81 %).

(i) 2-(2-*tert*-Butoxycarbonylamino-pyridin-4-ylmethyl)-acrylic acid ethyl ester

A solution of diethylamine (0.26 g, 2.67 mmol) in methylene chloride (4 mL) was added to a mixture of 2-(2-*tert*-butoxycarbonylamino-pyridin-4-ylmethyl)-malonic acid monoethyl ester (0.90 g, 2.66 mmol) and 37 % aq. solution of formaldehyde (0.24 g, 3.00 mmol) at 0°C. The mixture was stirred for 5 h at room temperature and the mixture was poured onto ice-water and extracted with methylene chloride. The organic layer was washed with 5 % NaHCO₃ and dried. The crude product was purified by flash chromatography (1 % methanol in CH₂Cl₂) to yield 2-(2-*tert*-butoxycarbonylamino-pyridin-4-ylmethyl)-acrylic acid ethyl ester (0.58 g, 71 %).

(j) 2-Acetylsulfanylmethyl-3-(2-*tert*-butoxycarbonylamino-pyridin-4-yl)-propionic acid ethyl ester

A solution of 2-(2-*tert*-butoxycarbonylamino-pyridin-4-ylmethyl)-acrylic acid ethyl ester (0.48 g, 1.57 mmol) and triethylamine (0.17 g, 1.64 mmol) was added to thioacetic acid (3 mL) at 0°C under nitrogen. The mixture was stirred at room temperature for 4 h. The mixture was poured onto ice-water and extracted with CH₂Cl₂. The organic phase was washed with saturated NaHCO₃ (aq) and dried. The crude product was purified by flash chromatography (2.5 % MeOH in CH₂Cl₂) to give 2-acetylsulfanylmethyl-3-(2-*tert*-butoxycarbonylamino-pyridin-4-yl)-propionic acid ethyl ester (0.60 g, 100 %).

(k) 2-Acetylsulfanylmethyl-3-(2-amino-pyridin-4-yl)-propionic acid ethyl ester

TFA (0.5 mL) was added to a solution of 2-acetylsulfanylmethyl-3-(2-*tert*-butoxycarbonylamino-pyridin-4-yl)-propionic acid ethyl ester (50 mg, 0.13 mmol) in methylene chloride under argon. The solution was stirred for 60 min and concentrated under reduced pressure to give crude 2-acetylsulfanylmethyl-3-(2-amino-pyridin-4-yl)-propionic acid ethyl ester (52 mg, 100 %).

¹H NMR (500 MHz, CD₃OD₃): δ 1.15 (t, 3H), 2.32 (s, 3H), 2.73-2.83 (m, 2H), 2.86-2.93 (m, 1H), 3.01-3.07 (dd, 1H), 3.12-3.18 (dd, 1H), 4.03-4.12 (m, 2H), 6.39 (s, 1H), 6.43 (d, 1H), 7.77 (d, 1H).

(l) 2-(2-Amino-pyridin-4-ylmethyl)-3-mercapto-propionic acid

2-Acetylsulfanylmethyl-3-(2-amino-pyridin-4-yl)-propionic acid ethyl ester (52 mg, 0.13 mmol) was dissolved in conc. HCl (2 mL) under argon. The solution was heated to reflux for 1 h. Concentration under reduced pressure gave the title compound as the hydrochloride salt (32 mg, 100 %).

¹H NMR (500 MHz, CD₃OD): δ 2.70 (bs, 2H), 2.85-3.0 (m, 3H), 6.76 (bs, 1H), 6.81 (bs, 1H), 7.67 (bs, 1H).

MS (+) 213 (M+1).

Example 6

3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-propionic acid

(a) 6-Amino-nicotinic acid ethyl ester

2-Amino-5-pyridinecarboxylic acid (25.0 g, 181 mmol) was suspended in ethanol (190 mL) and SOCl_2 (15 mL, 206 mmol) was added. The mixture was refluxed for 10 hs and more SOCl_2 (16 mL) was added. After 3 days with reflux (and more SOCl_2 (10 mL) added
5 each day), the reaction mixture was cooled to room temperature and diethyl ether was added. After 24 h at -20°C the mixture was filtered. The crude salt was dissolved in methanol (214 mL) and a solution of NaOH (40.0 g, 23.5 mmol) in methanol (90 mL) was added. The reaction mixture was stirred for 1 h and THF (270 mL) was added. The reaction mixture was filtered through a plug of silica (THF/MeOH) and concentrated under
10 reduced pressure to give 6-amino-nicotinic acid ethyl ester (36.2 g, 97 %).

(b) 6-*tert*-Butoxycarbonylamino-nicotinic acid ethyl ester

To a solution of 6-amino-nicotinic acid ethyl ester (36.0 g, 217.0 mmol) in *t*-BuOH (308 mL) and acetone (103 mL) was added DMAP (0.53 g, 4.34 mmol) and di-*t*-butyl
15 dicarbonate (72.0 g, 330 mmol). The reaction was stirred at room temperature for 10 h followed by addition of more di-*t*-butyl dicarbonate (2.60 g). After 10 h stirring at room temperature hexane (470 mL) was added. The reaction mixture was cooled to -20°C for 2 h and filtered. The filtrate was washed with hexane/dichloromethane (3:1) and dried *in vacuo* to give 6-*tert*-butoxycarbonylamino-nicotinic acid ethyl ester (40.5 g, 70 %).

(c) (5-Hydroxymethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester

To a stirred solution of 6-*tert*-butoxycarbonylamino-nicotinic acid ethyl ester (3.50 g, 13.1 mmol) in THF (20 mL) under nitrogen was added LiAlH_4 (0.91 g, 24.0 mmol) in THF (20 mL) over a period of 2 h. The reaction mixture was stirred for 6 h, then NH_4Cl (sat.) was
25 added (carefully) until neutral solution. The mixture was filtered and concentrated under reduced pressure to give (5-hydroxymethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (2.00 g, 68 %).

(d) (5-Bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester

30 Triphenylphosphine (8.70 g, 33.1 mmol) and carbontetrabromide (17.0 g, 51.2 mmol) were added to a suspension of (5-hydroxymethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (7.00 g, 31.2 mmol) in CH_2Cl_2 (200 mL) at room temperature. Stirring was continued for 5

h followed by evaporation of the solvent. Acetonitrile (200 mL) was added and the mixture was cooled to -20°C for 2 h. The mixture was then filtered and the crystalline residue washed with cold acetonitrile (2 x 10 mL), to give (5-bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (5.96 g, 67%).

5

(e) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-malonic acid diethyl ester

To a suspension of NaH (0.49 g, 16.3 mmol, 80%) in THF (15 mL) at 0°C was added diethyl malonate (2.61 g, 16.3 mmol). The mixture was stirred for 15 min and was then added dropwise to a refluxed mixture of (5-bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (3.90 g, 13.6 mmol) in THF (25 mL), and the resulting solution was refluxed for 15 min. After evaporation of the solvent, the crude product was purified by flash chromatography (methanol/ CH_2Cl_2 , 1:100 \rightarrow 2.5:100) to give 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-malonic acid diethyl ester (2.18 g, 44 %).

15 (f) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-malonic acid monoethyl ester

A solution of KOH (0.37 g, 6.54 mmol) in ethanol (5 mL) was added to a solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-malonic acid diethyl ester (2.18 g, 5.95 mmol) in ethanol (25 mL) and methylene chloride (10 mL) at 0°C . The mixture was stirred for 18 h at room temperature. The mixture was concentrated under reduced pressure and the residue dissolved in water. The aqueous layer was washed with ether, acidified to pH 4 by 1M HCl and extracted with methylene chloride. The organic layer was washed with water, brine and dried. After filtration and concentration under reduced pressure, the crude product was purified by flash chromatography (methanol/ CH_2Cl_2 , 1:20) to yield 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.00 g, 50 %).

25

(g) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-acrylic acid ethyl ester

Diethylamine (0.29 g, 3.00 mmol), water (2 mL) and methylene chloride (2 mL) was added to a mixture of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.00 g, 2.96 mmol) and 37 % aq. solution of formaldehyde (0.25 g, 3.05 mmol) at 0°C . The mixture was stirred for 16 h at room temperature and then poured onto ice-water and extracted with methylene chloride. The organic layer was washed with 5 %

30

NaHCO₃ and dried. Filtration and concentration under reduced pressure gave 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-acrylic acid ethyl ester (0.75 g, 83 %).

(h) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-propionic acid ethyl ester

2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-acrylic acid ethyl ester (0.49 g, 1.60 mmol) and triethylamine (0.17 g, 1.64 mmol) were added to thioacetic acid (3 mL) at 0°C. The mixture was stirred at room temperature for 6 h. The mixture was poured onto ice-water and extracted with CH₂Cl₂. The organic phase was washed with saturated NaHCO₃ and dried. The crude product was purified by flash chromatography (MeOH/CH₂Cl₂, 2.5:100) to give 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-propionic acid ethyl ester (0.36 g, 61 %).

(i) 2-Acetylsulfanylmethyl-3-(6-amino-pyridin-3-yl)-propionic acid ethyl ester

TFA (0.5 mL) was added to a solution of 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-propionic acid ethyl ester (100 mg, 0.26 mmol) in methylene chloride (2 mL) under argon. The solution was stirred for 60 min and concentrated under reduced pressure to give crude 2-acetylsulfanylmethyl-3-(6-amino-pyridin-3-yl)-propionic acid ethyl ester (104 mg, 100 %).

¹H NMR (500 MHz, CD₃OD): δ 1.21 (t, 3H), 2.33 (s, 3H), 2.78-2.97 (m, 3H), 3.05-3.13 (m, 1H), 3.14-3.21 (m, 1H), 4.08-4.15 (m, 2H), 6.99 (d, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

(j) 3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-propionic acid

2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-propionic acid ethyl ester (38 mg, 0.096 mmol) was dissolved in conc. HCl (2.0 mL) under argon. The solution was stirred at room temperature for 1 h and then heated to reflux for 1 h. Concentration under reduced pressure gave the title compound (25.7 mg, 100 %) as the hydrochloride salt.

¹H NMR (500 MHz, CD₃OD): δ 2.74-2.78 (m, 2H), 2.84-2.94 (m, 3H), 7.02 (d, 1H), 7.72 (s, 1H), 7.89 (d, 1H).

MS (+) 213 (M+1).

Example 73-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-2-methyl-propionic acid

(a) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-2-methyl-malonic acid *tert*-butyl ester ethyl ester

A solution of *tert*-butyl ethyl methylmalonate (457 mg, 2.26 mmol) in DMF (4 mL) was added dropwise to a suspension of NaH (90 mg, 2.26 mmol, 60 % in oil) in DMF (4 mL). The reaction mixture was stirred for 20 min. A solution of (5-bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (500 mg, 1.74 mmol) in DMF (2.5 mL) was added and the reaction was stirred for 70 min. EtOAc was added and the mixture was washed with water and brine, dried and concentrated under reduced pressure. Chromathography (Heptane/EtOAc, 3:1 → 1:3) gave 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-2-methyl-malonic acid *tert*-butyl ester ethyl ester (437 mg, 61 % yield).

(b) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-2-methyl-malonic acid mono-*tert*-butyl ester

1M NaOH (2 mL) was added to a solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-2-methyl-malonic acid *tert*-butyl ester ethyl ester (0.42g, 1.03 mmol) in THF/EtOH (4 mL, 1:1) . The reaction mixture was stirred at 50°C for 16 h. CH₂Cl₂ was added and the mixture was washed with 0.5 M HCl and brine and dried. Concentration under reduced pressure gave 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-2-methyl-malonic acid mono-*tert*-butyl ester (348 mg, 89 %).

(c) 3-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-2-hydroxymethyl-2-methyl-propionic acid *tert*-butyl ester

Methyl chloroformate (75 µL, 0.92 mmol) was added dropwise to a solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-2-methyl-malonic acid mono-*tert*-butyl ester (348 mg, 0.915 mmol) and Et₃N (123 µL, 0.92 mmol) in THF (6 mL). The reaction mixture was stirred for 20 min., filtered and added dropwise to a suspension of NaBH₄ (39 mg, 1.04 mmol) in THF (6 mL) at 0°C. The reaction was stirred for 16 h at room temperature. 0.2 M HCl was added followed by EtOAc. The organic phase was washed with brine and dried. Concentration under reduced pressure followed by chromathography

(toluene/EtOAc, 3:1 \rightarrow 1:3) gave 3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-hydroxymethyl-2-methyl-propionic acid *tert*-butyl ester (190 mg, 57 %).

(d) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-methyl-propionic acid *tert*-butyl ester

Diethyl azodicarboxylate (160 μ L, 1.01 mmol) was added dropwise to a solution of 3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-hydroxymethyl-2-methyl-propionic acid *tert*-butyl ester (180 mg, 0.49 mmol) and triphenylphosphine (266 mg, 1.01 mmol) in THF (6 mL) and the reaction was stirred for 5 min. Thiolacetic acid (96 μ L, 1.34 mmol) was added and the reaction was stirred for 16 h. Concentration under reduced pressure followed by chromatography (toluene/EtOAc, 10:1 \rightarrow 1:1) gave 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-methyl-propionic acid *tert*-butyl ester (137 mg, 65 %).

(e) 3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-2-methyl-propionic acid

2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-methyl-propionic acid *tert*-butyl ester (4 mg, 9.4 μ mol) was dissolved in conc. HCl under argon. The solution was heated to reflux for 1 h. Concentration under reduced pressure yielded the title compound as the hydrochloride salt (2.5 mg, 100 %).

^1H NMR (500 MHz, CD_3OD): δ 1.20 (s, 3H), 2.62 (d, 1H), 2.76-2.83 (m, 2H), 2.95 (d, 1H), 6.94 (d, 1H), 7.64 (d, 1H), 7.80 (dd, 1H).

MS (+) 227 (M+1).

Example 8

2-(6-Amino-pyridin-3-ylmethyl)-2-mercaptomethyl-butyric acid

(a) [5-(5-Ethyl-2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylmethyl)-pyridin-2-yl]-carbamic acid *tert*-butyl ester

(5-Bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (1.0 g, 3.48 mmol) was added to a solution of 2,2-dimethyl-5-ethyl-1,3-dioxane-4,6-dione (600 mg, 3.48 mmol) and triethylamine (0.51 mL, 3.66 mmol) in dimethyl sulfoxide (40 mL) under nitrogen. The reaction mixture was stirred over night and water (100 mL) was added. Filtration of the

precipitate gave [5-(5-ethyl-2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylmethyl)-pyridin-2-yl]-carbamic acid *tert*-butyl ester (1.15 g, 87 %).

(b) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-2-ethyl-malonic acid monoethyl ester

A solution of sodium metal (140 mg, 6.08 mmol) in ethanol (20 mL) was added to a solution of [5-(5-ethyl-2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylmethyl)-pyridin-2-yl]-carbamic acid *tert*-butyl ester (1.15 g, 3.04 mmol) in ethanol (10 mL). The reaction was stirred for 90 min. and methylene chloride was then added. The mixture was washed with 0.5 M HCl, dried and concentrated under reduced pressure to give 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-2-ethyl-malonic acid monoethyl ester (1.05 g, 95%).

(c) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-2-hydroxymethyl-butyric acid ethyl ester

Methyl chloroformate (150 μ L, 1.95 mmol) was added dropwise to a solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-2-ethyl-malonic acid monoethyl ester (700 mg, 1.91 mmol) and Et₃N (275 μ L, 1.97 mmol) in THF (15 mL) at -20°C under nitrogen. The reaction mixture was stirred for 50 min., filtered and added dropwise to a suspension of NaBH₄ (80 mg, 2.1 mmol) in THF (15 mL) at -20°C. The reaction was stirred for 16 h at room temperature. 0.2 M HCl was added followed by methylene chloride. The organic phase was washed with brine and dried. Concentration under reduced pressure followed by chromatography (toluene/EtOAc, 3:1 \rightarrow 1:3) gave 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-2-hydroxymethyl-butyric acid ethyl ester (300 mg, 45 %).

(d) 2-Acetylsulfanylmethyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester

Diisopropyl azodicarboxylate (296 μ L, 1.53 mmol) was added dropwise to a solution of triphenylphosphine (402 mg, 1.53 mmol) in THF (4 mL) at 0°C under argon and the reaction was stirred for 30 min. A solution of thiolacetic acid (109 μ L, 1.53 mmol) and 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-2-hydroxymethyl-butyric acid ethyl ester (0.27 g, 0.77 mmol) in THF (2 mL) was added dropwise during 10 min. The reaction was stirred for 60 min. at 0°C and then for 16 h at room temperature. Concentration under

reduced pressure followed by chromatography (heptane/EtOAc, 10:1 → 1:1) gave 2-acetylsulfanylmethyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester (193 mg, 61 %).

5 (e) 2-(6-Amino-pyridin-3-ylmethyl)-2-mercaptomethyl-butyrac acid

2-Acetylsulfanylmethyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester (12.3 mg, 30 μ mol) was dissolved in conc. HCl (2 mL) under argon. The solution was heated to reflux for 24 h. Concentration under reduced pressure gave the title compound as the hydrochloride salt (8.3 mg, 100 %).

10 ^1H NMR (500 MHz, CD_3OD): δ 0.91 (t, 3H), 1.71 (m, 2H), 2.68 (m, 2H), 2.92 (m, 2H), 6.96 (d, 1H), 7.65 (bs, 1H), 7.82 (dd, 1H).

MS (-) 239 (M-1).

Example 9

15 3-(6-Amino-5-methyl-pyridin-3-yl)-2-mercaptomethyl-2-methyl-propionic acid

(a) 2-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-3-Methyl-5-(2,2,5-trimethyl-4,6-dioxo-[1,3]dioxan-5-ylmethyl)-pyridin

2-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-5-bromomethyl-3-methyl-pyridin (1.6 g, 4.0 mmol) was added to a solution of 2,2,5-trimethyl-1,3-dioxane-4,6-dione (630 mg, 4.0 mmol) and triethylamine (0.58 mL, 4.2 mmol) in dimethyl sulfoxide (40 mL). The reaction mixture was stirred overnight and water (100 mL) was added. The mixture was extracted with EtOAc, the combined organic phases washed with water and brine and dried.

Concentration under reduced pressure gave crude 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-3-methyl-5-(2,2,5-trimethyl-4,6-dioxo-[1,3]dioxan-5-ylmethyl)-pyridin (2.06 g)

(b) 2-(6-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-2-methyl-malonic acid monoethyl ester

A solution of sodium metal (184 mg, 8.0 mmol) in ethanol (20 mL) was added to a solution of crude 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-3-methyl-5-(2,2,5-trimethyl-4,6-dioxo-[1,3]dioxan-5-ylmethyl)-pyridin (2.06 g, ~4.0 mmol) in ethanol (20 mL) under argon. The reaction was stirred for 60 min. and methylene chloride was then added. The

mixture was washed with 0.5 M HCl and brine, dried and concentrated under reduced pressure to give crude 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-2-methyl-malonic acid monoethyl ester (1.9 g)

5 (c) 3-(6-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-2-hydroxymethyl-2-methyl-propionic acid ethyl ester

Methyl chloroformate (338 μ L, 4.4 mmol) was added dropwise to a solution of crude 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-2-methyl-malonic acid monoethyl ester (1.9 g) and Et₃N (641 μ L, 4.6 mmol) in THF (30 mL) at -20°C. The
10 reaction mixture was stirred for 50 min., filtered and added dropwise to a suspension of NaBH₄ (182 mg, 4.8 mmol) in THF (30 mL) at -20°C. The reaction was stirred for 16 h at room temperature. 0.5 M HCl was added followed by methylene chloride. The organic phase was washed with brine and dried. Concentration under reduced pressure followed by chromatography (toluene/EtOAc, 10:1 \rightarrow 1:3) gave 3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)-
15 amino]-5-methyl-pyridin-3-yl)-2-hydroxymethyl-2-methyl-propionic acid ethyl ester (885 mg, 49 %).

(d) 2-Acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-2-methyl-propionic acid ethyl ester

20 Diisopropyl azodicarboxylate (755 μ L, 3.91 mmol) was added dropwise to a solution of triphenylphosphine (1.026 g, 3.91 mmol) in THF (10 mL) at 0°C and the reaction was stirred for 30 min. A solution of thiolacetic acid (279 μ L, 3.91 mmol) and 3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-2-hydroxymethyl-2-methyl-propionic acid ethyl ester (885 mg, 1.96 mmol) in THF (5 mL) was added dropwise during
25 10 min. The reaction was stirred for 60 min. at 0°C and then for 16 h at room temperature. Concentration under reduced pressure followed by chromatography (heptane/EtOAc, 10:1 \rightarrow 1:3) gave impure 2-acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-2-methyl-propionic acid ethyl ester (1.46 g)

(e) 2-Acetylsulfanylmethyl-3-(6-amino-5-methyl-pyridin-3-yl)-2-methyl-propionic acid ethyl ester

Crude 2-acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-2-methyl-propionic acid ethyl ester (1.46g) was dissolved in TFA (5 mL) and stirred for 60 min. Concentration under reduced pressure followed by chromatography (toluene/EtOAc, 1:1 → 1:10 → 0:1) gave slightly impure 2-acetylsulfanylmethyl-3-(6-amino-5-methyl-pyridin-3-yl)-2-methyl-propionic acid ethyl ester (696 mg, 84%)

(f) 3-(6-Amino-5-methyl-pyridin-3-yl)-2-mercaptomethyl-2-methyl-propionic acid

2-Acetylsulfanylmethyl-3-(6-amino-5-methyl-pyridin-3-yl)-2-methyl-propionic acid ethyl ester (17 mg, 40 μmol) was dissolved in conc. HCl (2 mL) under argon. The solution was heated to reflux for 150 min. Concentration under reduced pressure gave the title compound as the hydrochloride salt (10.7 mg, 96 %).

¹H NMR (500 MHz, CD₃OD): δ 1.20 (s, 3H), 2.23 (s, 3H), 2.61 (d, 1H), 2.79 (2d, 2H), 2.94 (d, 1H), 7.55 (m, 1H), 7.69 (m, 1H).

MS (+) 241 (M+1).

Example 10

3-Mercapto-2-[(piperidine-4-carbonyl)-amino]-propionic acid

CH₂Cl₂ (70 mL) was added to 4-methoxytrityl chloride resin (7 g, L=0.91 mmol/g, 6.37 mmol) under argon and the resin was allowed to swell for 10 min and 2-amino-3-mercapto-propionic acid ethyl ester HCl-salt (5.9 g, 32 mmol) was added. TFA (70 mL) was then added in small portions over 10 min. The slurry was shaken at room temperature for 1 h and concentrated under reduced pressure. When almost dry, toluene (150 mL) was added and the mixture was again concentrated under reduced pressure. This procedure was repeated twice. The now yellow resin was washed with DMF (3x60 mL), CH₂Cl₂ (2x60 mL), TEA:CH₂Cl₂ (1:1, 2x60 mL), CH₂Cl₂ (2x60 mL), MeOH (2x60 mL) and dried under vacuum overnight.

To calculate the loading of 2-amino-3-mercapto-propionic acid ethyl ester on the resin, 50 mg of the product was treated with 10% TFA in CH₂Cl₂ for 1 minute, and this procedure was repeated 4 times. The mixture was concentrated under reduced pressure to give 2-

Amino-3-mercapto-propionic acid ethyl ester (9.8 mg), indicating a loading of about 0.6 mmol/g.

A solution of piperidine-1,4-dicarboxylic acid mono-*tert*-butyl ester (28 mg, 0.12 mmol) in DMF (1 mL) was added to the resin (100 mg, L=0.6 mmol/g, 0.06 mmol) in a plastic syringe, followed by PyBOP (62 mg, 0.12 mmol) in DMF (0.5 mL) and DIPEA (41 μ L, 0.24 mmol). The reaction was left at room temperature for 2 h with occasional stirring and the procedure was repeated once more. The resin was then washed with DMF (2x2 mL), CH₂Cl₂ (2x2 mL), MeOH (2x2 mL), CH₂Cl₂ (2x2 mL) and THF (2x2 mL).

THF (800 μ L) was added to the syringe and the resin was allowed to swell for 10 min. Then water (250 μ L) and 10 M NaOH (50 μ L) were added. The reaction was left at room temperature for 16 h with occasional stirring. The resin was then washed with THF:water (1:1, 2x2 mL), THF (2x2 mL), CH₂Cl₂ (2x2 mL), MeOH (2x2 mL) and CH₂Cl₂ (2x2 mL).

10 % TFA in CH₂Cl₂ (1 mL) was added to the syringe and after 5 min the solution was collected in a tared vial. This procedure was repeated one more time and the combined organic phases were concentrated under reduced pressure to yield the title compound as the TFA salt (15.3 mg, 74 %).

¹H NMR (500 MHz, CD₃OD): δ 1.85-2.10 (m, 4H), 2.65-2.72 (m, 1H), 2.85-2.92 (m, 1H), 2.95-3.08 (m, 3H), 3.40-3.47 (m, 2H), 4.55-4.60 (m, 1H).

Example 11

2-[(Azetidine-2-carbonyl)-amino]-3-mercapto-propionic acid

The title compound was prepared from azetidine-1,2-dicarboxylic acid 1-*tert*-butyl ester by the method described in Example 14. Yield: 13.8 mg (72 %).

¹H NMR (500 MHz, CD₃OD): δ 2.54-2.63 (m, 1H), 2.82-3.05 (m, 3H), 3.93-4.15 (m, 2H), 4.66-4.71 (m, 1H), 5.05-5.10 (m, 1H).

Example 12

3-Mercapto-2-[(piperidine-3-carbonyl)-amino]-propionic acid

The title compound was prepared from piperidine-1,3-dicarboxylic acid 1-*tert*-butyl ester by the method described in Example 14. Yield: 15.1 mg (73 %).

¹H NMR (500 MHz, CD₃OD): δ 1.73-2.10 (m, 4H), 2.84-2.92 (m, 2H), 2.95-3.14 (m, 2H), 3.15-3.29 (m, 3H), 4.56-4.62 (m, 1H).

Example 13

5 2-[(Azetidine-3-carbonyl)-amino]-3-mercapto-propionic acid

The title compound was prepared from azetidine-1,3-dicarboxylic acid mono-*tert*-butyl ester by the method described in Example 14. Yield: 13.5 mg (71 %).

¹H NMR (500 MHz, CD₃OD): δ 2.86-3.02 (m, 2H), 3.72-3.80 (m, 1H), 4.20-4.24 (d, 4H), 4.62-4.67 (m, 1H).

10

Example 14

3-(6-Amino-5-methyl-pyridin-3-yl)-2-mercaptopomethyl-propionic acid

(a) 5-Bromo-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-3-methyl-pyridin

15 2-Amino-5-bromo-3-methylpyridine (15.0 g, 80.2 mmol) in *tert*-butanol was treated with di-*tert*-butyl dicarbonate (43.6 g, 200 mmol) and DMAP (0.60 g, 4.91 mmol). The reaction mixture was left at ambient temperature overnight and was then concentrated under reduced pressure. Hexane was added and the product precipitated as a solid. Filtering afforded 5-bromo-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-3-methyl-pyridin (22.0 g, 71 %).

20

(b) 2-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-5-(*tert*-butyl-dimethyl-silanyloxymethyl)-3-methylpyridin

A solution of 5-bromo-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-3-methyl-pyridin (26.0 g, 67.1 mmol), *tert*-butyl-dimethyl-tributylstannanylmethoxy-silane (47.6 g, 109 mmol), and
25 bis(triphenylphosphine)palladium(II) dichloride (0.90 g, 1.42 mmol) in 1,2-dichloroethane (80 mL) was stirred at 90°C for two days. The mixture was cooled to 0°C and diethyl ether (200 mL) was added followed by saturated aqueous potassium fluoride (40 mL). The mixture was stirred vigorously for 30 min and filtered. The organic phase was washed
30 (hexane/EtOAc, 100:0 → 95:5) gave 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-(*tert*-butyl-dimethyl-silanyloxymethyl)-3-methylpyridin (18.0 g, 59 %).

(c) 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-hydroxymethyl-3-methylpyridin

Tetrabutylammonium fluoride (25.1 g, 79.6 mmol) was added to a solution of 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-(*tert*-butyl-dimethyl-silanyloxymethyl)-3-methylpyridin (18.0 g, 39.8 mmol) in THF (150 mL). The reaction mixture was stirred overnight at room temperature. Concentration under reduced pressure followed by flash chromatography (hexane/EtOAc, 50:50) gave 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-hydroxymethyl-3-methylpyridin (8.0 g, 59 %).

(d) 5-Bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-3-methylpyridin

Triphenylphosphine (7.43 g, 28.3 mmol) and CBr₄ (9.49 g, 28.6 mmol) was added to a solution of 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-hydroxymethyl-3-methylpyridin (8.00 g, 23.6 mmol) in dichloromethane (220 mL) at 0°C. The reaction mixture was stirred for 3 h and was then concentrated under reduced pressure. Flash chromatography (hexane/EtOAc, 80:20) gave 5-bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-3-methylpyridin (8.0 g, 77 %).

(e) 2-(6-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester

To a suspension of NaH (0.24 g, 6.0 mmol, 60%) in DMF (5 mL) was added diethyl malonate (0.91 mL, 6.0 mmol) and the mixture was stirred for 15 min. A solution 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-bromomethyl-3-methyl-pyridin (2.0 g, 5.0 mmol) in DMF (5 mL) was added and the resulting solution stirred for 120 min at 60°C. Ethyl acetate was added and the mixture was washed with water and brine and dried. After evaporation of the solvent, the crude product was purified by flash chromatography (CH₃OH/CH₂Cl₂, 1:100 → 1:20) to give 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (1.2 g, 50 %).

(f) 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester

A solution of KOH (154 mg, 2.75 mmol) in ethanol (2 mL) was added to a solution 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (1.2 g, 2.50 mmol) in ethanol (10 mL) and methylene chloride (4 mL) at 0°C. The

mixture was stirred for 18 h at room temperature. The mixture was concentrated under reduced pressure and the residue dissolved in water. Ethyl acetate was added and the organic layer was washed with 0.5 M HCl, water, brine and dried. After filtration and concentration under reduced pressure gave crude 2-(6-[*N,N*-bis(*tert*-butoxy-

5 carbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.0 g, 88%).

(g) 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester

Diethylamine (0.26 g, 2.67 mmol) was added a mixture of 2-(6-[*N,N*-bis(*tert*-

10 butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.0 g, 2.2 mmol) and 37 % aq. solution of formaldehyde (0.24 g, 3.00 mmol) in methylene chloride (2 mL) at 0 °C. The mixture was stirred for 16 h at room temperature and ethyl acetate was added. The organic layer was washed with water and 5 % NaHCO₃ and dried. Concentration under reduced pressure followed by flash chromatography (toluene/ethyl

15 acetate, 3:1 → 1:2) gave 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester (0.68 g, 73 %).

(h) 2-Acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-propionic acid ethyl ester

Triethylamine (0.234 mL, 1.68 mmol) was added to a solution of 2-(6-[*N,N*-bis(*tert*-

20 butoxycarbonyl)amino]-5-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester (0.68 g, 1.61 mmol) in thioacetic acid (3 mL) at 0°C. The mixture was stirred at room temperature for 16 h. Ethyl acetate was added and the organic phase was washed with water, saturated NaHCO₃ and brine and dried. The crude product was purified by flash chromatography

25 (toluene/ethyl acetate, 3:1 → 1:2) to give pure 2-acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-propionic acid ethyl ester (489 mg, 61%) and slightly impure 2-acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-propionic acid ethyl ester (0.34 g, 43%).

(i) 3-(6-Amino-5-methyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid

2-Acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-

30 propionic acid ethyl ester (17 mg, 0.034 mmol) was dissolved in conc. HCl (3.0 mL). The

solution was heated to reflux for 1 h. Concentration under reduced pressure gave the title compound (8.9 mg, 100 %) as the hydrochloride salt.

¹H NMR (500 MHz, CD₃OD): δ 2.26 (s, 3H), 2.72-2.75 (m, 2H), 2.83-2.91 (m, 3H), 7.60 (s, 1H), 7.77 (s, 1H).

5 MS (+) 227 (M+1).

Example 15

3-(6-Amino-4-methyl-pyridin-3-yl)-2-mercaptopomethyl-propionic acid

10 (a) 2-Amino-5-bromo-4-methylpyridine

2-Amino-4-methylpyridine (110 g, 1.02 mol) in hydrobromic acid (1 L, 48%) was stirred at 70°C and a solution of hydrogen peroxide (300 mL, 15 %) was added dropwise over a one h at such a rate that the temperature of the reaction mixture remained at 70 - 80°C. The mixture was stirred for 90 min at 70°C and poured onto crushed ice. The pH was adjusted
15 to 4-5 with sodium carbonate and the precipitated solid (containing mostly dibrominated products) was filtered off and discarded. The pH was subsequently raised to 9 and the precipitated product collected by filtration. Recrystallization from toluene gave 2-Amino-5-bromo-4-methylpyridine (76.3 g, 40 %).

20 (b) 2-[N,N-bis(tert-Butoxycarbonyl)amino]-5-bromo-4-methylpyridin

2-Amino-5-bromo-4-methylpyridine (5.70 g, 30.5 mmol) in chloroform was treated with di-tert-butyl dicarbonate (20.0 g, 91.60 mmol) and DMAP (0.60 g, 4.91 mmol). The reaction mixture was left at ambient temperature overnight and was then concentrated under reduced pressure. Flash chromatography (hexane/EtOAc, 95:5) gave 2-[N,N-bis(tert-
25 butoxycarbonyl)amino]-5-bromo-4-methylpyridin (8.02 g, 68 %).

(c) 2-[N,N-bis(tert-Butoxycarbonyl)amino]-5-(tert-butyl-dimethyl-silanyloxymethyl)-4-methylpyridin

A solution of 2-[N,N-bis(tert-butoxycarbonyl)amino]-5-bromo-4-methylpyridin (15.0 g, 38.70 mmol), tert-butyl-dimethyl-tributylstannanylmethoxy-silane (25.4 g, 58.3 mmol),
30 and bis(triphenylphosphine)palladium(II) dichloride (0.90 g, 1.42 mmol) in 1,2-dichloroethane (50 mL) was stirred at 90°C for two days. The mixture was cooled to 0°C and

diethyl ether (200 mL) was added followed by saturated aqueous potassium fluoride (40 mL). The mixture was stirred vigorously for 30 min and filtered. The organic phase was washed with water, dried and concentrated under reduced pressure. Flash chromatography (hexane/EtOAc, 95:5) gave 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-(*tert*-butyl-dimethyl-silanyloxymethyl)-4-methylpyridin (10.0 g, 57 %).

(d) 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-hydroxymethyl-4-methylpyridin

Tetrabutylammonium fluoride (13.9 g, 44.1 mmol) was added to a solution of 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-(*tert*-butyl-dimethyl-silanyloxymethyl)-4-methylpyridin (10.0 g, 24.3 mmol) in THF (100 mL). The reaction mixture was stirred for 3 h at room temperature. Concentration under reduced pressure followed by flash chromatography (hexane/EtOAc, 50:50) gave 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-hydroxymethyl-4-methylpyridin (5.0 g, 67 %).

(e) 5-Bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methylpyridin

Triphenylphosphine (4.69 g, 17.9 mmol) and CBr₄ (4.89 g, 14.8 mmol) was added to a solution of 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-hydroxymethyl-4-methylpyridin (5.00 g, 22.0 mmol) in dichloromethane (130 mL) at 0°C. The reaction mixture was stirred for 3 h and was then diluted with dichloromethane. The organic phase was washed with water, dried and concentrated under reduced pressure. Flash chromatography (hexane/EtOAc, 80:20) gave 5-bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methylpyridin (5.35 g, 90 %).

(f) 2-(6-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester

To a suspension of NaH (0.24 g, 6.0 mmol, 60%) in DMF (5 mL) was added diethyl malonate (0.91 mL, 6.0 mmol) and the mixture was stirred for 15 min. A solution 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-bromomethyl-4-methyl-pyridin (2.0 g, 5.0 mmol) in DMF (5 mL) was added and the resulting solution stirred for 120 min at 60 °C. Ethyl acetate was added and the mixture was washed with water and brine and dried. After evaporation of the solvent, the crude product was purified by flash chromatography (CH₃OH/CH₂Cl₂, 1:100 → 1:20) to give a pure fraction 2-(6-[*N,N*-bis(*tert*-butoxy-

carbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (1.15 g, 48 %) and an impure fraction 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (1.1 g).

5 (g) 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester

A solution of KOH (141 mg, 2.52 mmol) in ethanol (2 mL) was added to a solution 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (1.1 g, 2.29 mmol) in ethanol (10 mL) and methylene chloride (4 mL) at 0°C. The mixture was stirred for 18 h at room temperature. The mixture was concentrated under reduced pressure and the residue dissolved in water. Ethyl acetate was added and the organic layer was washed with 0.5 M HCl, water, brine and dried. After filtration and concentration under reduced pressure gave crude 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)-amino]-4-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.0 g, 97 %).

15

(h) 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester

Diethylamine (0.26 g, 2.67 mmol) was added a mixture of 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.0 g, 2.2 mmol) and 37 % aq. solution of formaldehyde (0.24 g, 3.00 mmol) in methylene chloride (2 mL) at 0°C. The mixture was stirred for 16 h at room temperature and ethyl acetate was added. The organic layer was washed with water and 5 % NaHCO₃ and dried. Concentration under reduced pressure followed by flash chromatography (toluene/ethyl acetate, 3:1 → 1:1) gave 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester (0.81 g, 88 %).

25

(i) 2-Acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-yl)-propionic acid ethyl ester

Triethylamine (0.279 mL, 2.0 mmol) was added to a solution of 2-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester (0.8 g, 1.9 mmol) in thioacetic acid (3 mL) at 0°C. The mixture was stirred at room temperature for 16 h. Ethyl acetate was added and the organic phase was washed with water, saturated

30

NaHCO₃ and brine and dried. The crude product was purified by flash chromatography (toluene/ethyl acetate, 3:1 → 1:2) to give pure 2-acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-methyl-pyridin-3-yl)-propionic acid ethyl ester (200 mg, 21 %) and slightly impure 2-acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-yl)-propionic acid ethyl ester (0.68 g).

(j) 3-(6-Amino-4-methyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid

2-Acetylsulfanylmethyl-3-(6-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-4-methyl-pyridin-3-yl)-propionic acid ethyl ester (36 mg, 0.072 mmol) was dissolved in conc. HCl (3.0 mL). The solution was heated to reflux for 1 h. Concentration under reduced pressure gave the title compound (18.7 mg, 98 %) as the hydrochloride salt.

¹H NMR (500 MHz, CD₃OD): δ 2.42 (s, 3H), 2.72-2.95 (m, 5H), 6.81 (s, 1H), 7.58 (s, 1H). MS (+) 227 (M+1).

Example 16

2-Mercaptomethyl-3-piperidin-4-yl-butyric acid

(a) 4-formyl-piperidine-1-carboxylic acid *tert*-butyl ester

Periodinane (26.9 g, 63.5 mmol) was added to a solution of 1-*tert*-butoxycarbonyl-piperidine-4-methanol (10.5 g, 48.8 mmol) in methylene chloride (200 mL) and the mixture was stirred for 90 min. Diethyl ether was added and precipitates were removed by extraction with 10 % Na₂S₂O₃/saturated NaHCO₃ (1:1, 300 mL). The organic layer was washed with 0.5 M NaOH and brine, dried and concentrated under reduced pressure. Flash chromatography (hexane/EtOAc, 8:2) gave 4-formyl-piperidine-1-carboxylic acid *tert*-butyl ester (8.5 g, 81 %).

(b) 2-(1-*tert*-Butoxycarbonyl-piperidin-4-ylmethylene)-malonic acid diethyl ester

To a solution of diethyl malonate (710 μL, 4.7 mmol) and 4-formyl-piperidine-1-carboxylic acid *tert*-butyl ester (1.0 g, 4.7 mmol) in methylene chloride (5 mL) was added piperidine (46 μL, 0.47 mmol) and acetic acid (27 μL, 0.47 mmol). The reaction mixture was stirred for 72 h at room temperature and then for 16 h at 45°C. EtOAc was added and the mixture was washed with water and brine, dried and concentrated under reduced

pressure. The crude was purified by flash chromatography (heptane/EtOAc, 3:1 → 1:3) to give 2-(1-*tert*-butoxycarbonyl-piperidin-4-ylmethylene)-malonic acid diethyl ester (0.69 g, 40 %).

5 (c) 2-[1-(1-*tert*-Butoxycarbonyl-piperidin-4-yl)-ethyl]-malonic acid diethyl ester

MeLi (5.34 mL, 8.54 mmol, 1.6 M in diethyl ether) was added dropwise to a slurry of CuI (0.74 g, 3.88 mmol) in THF (5 mL) at -78°C under argon and the mixture was stirred for 30 min. A solution of 2-(1-*tert*-butoxycarbonyl-piperidin-4-ylmethylene)-malonic acid diethyl ester (0.69 g, 1.94 mmol) in THF (5 mL) was added dropwise and the reaction mixture was
10 stirred for 120 min at -78°C and was then allowed to warm to room temperature during 60 min. Concentrated aqueous NH₄OH was added and the mixture was then extracted with EtOAc, washed with concentrated aqueous NH₄OH and brine, dried and concentrated under reduced pressure. The crude was purified by flash chromatography (heptane/EtOAc, 3:1 → 1:6) to give 2-[1-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-ethyl]-malonic acid diethyl
15 ester (0.39 g, 54 %).

(d) 2-[1-(1-*tert*-Butoxycarbonyl-piperidin-4-yl)-ethyl]-malonic acid monoethyl ester

A solution of KOH (84 mg, 1.16 mmol) in EtOH (2 mL) was added dropwise to a solution of 2-[1-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-ethyl]-malonic acid diethyl ester (0.39 g,
20 1.01 mmol) in methylene chloride (4 mL) and EtOH (10 mL) at 0°C. The resulting mixture was stirred at room temperature over night. EtOAc was added and the mixture was washed with 0.5 M HCl and brine, dried and concentrated under reduced pressure to give 416 mg of crude 2-[1-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-ethyl]-malonic acid monoethyl ester.

25 (e) 4-(2-Ethoxycarbonyl-1-methyl-allyl)-piperidine-1-carboxylic acid *tert*-butyl ester

Formaldehyde (132 mg, 1.65 mmol, 37 % in water) was added to a solution of crude 2-[1-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-ethyl]-malonic acid monoethyl ester (416 mg) in methylene chloride (2 mL) at 0°C. Diethylamine (153 µL, 1.47 mmol) was added dropwise and the mixture was stirred at room temperature over night. EtOAc was added and the
30 mixture was washed with water and saturated NaHCO₃, dried and concentrated under reduced pressure. The crude was purified by flash chromatography (toluene/EtOAc, 3:1) to

give 4-(2-ethoxycarbonyl-1-methyl-allyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.18 g, 49 % over two steps).

(f) 4-(3-Acetylsulfanyl-2-ethoxycarbonyl-1-methyl-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester

TEA (86 μ L, 0.617 mmol) was added to a solution of 4-(2-ethoxycarbonyl-1-methyl-allyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.18 g, 0.59 mmol) in thioacetic acid (2 mL) at 0°C. After stirring for 6 h more thioacetic acid (2 mL) was added and the mixture was stirred at 45°C over night. EtOAc was added and the mixture was washed with water, saturated NaHCO₃ and brine, dried and concentrated under reduced pressure. The crude was purified by flash chromatography (toluene/EtOAc, 5:1 \rightarrow 1:1) to slightly unpure 4-(3-acetylsulfanyl-2-ethoxycarbonyl-1-methyl-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.17 g, 75 %).

(g) 2-Acetylsulfanylmethyl-3-piperidin-4-yl-butyric acid ethyl ester

TFA (2 mL) was added to a solution of 4-(3-acetylsulfanyl-2-ethoxycarbonyl-1-methyl-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.17 g, 0.439 mmol) in methylene chloride (10 mL). The reaction was stirred for 90 min and concentrated under reduced pressure. The crude product was purified using HPLC (10 \rightarrow 50 % acetonitrile in water, 0.1 % TFA) to give 2-acetylsulfanylmethyl-3-piperidin-4-yl-butyric acid ethyl ester (101 mg, 54 %) as the TFA salt.

(h) 2-Mercaptomethyl-3-piperidin-4-yl-butyric acid

Conc. hydrochloric acid (4 mL) was added to 2-acetylsulfanylmethyl-3-piperidin-4-yl-butyric acid ethyl ester TFA salt (0.101 g, 0.252 mmol) under argon. The reaction was heated to reflux for 5 h and then concentrated under reduced pressure to give a diastereomeric mixture of the title compound (73.7 mg) as the hydrochloride salt.

¹H NMR (500 MHz, CD₃OD) for the major diastereomer: δ 1.10 (d, 3H), 1.36-1.58 (m, 2H), 1.71-1.78 (m, 2H), 1.93-1.99 (m, 1H), 2.05-2.11 (m, 1H), 2.60-2.66 (m, 2H), 2.80-2.86 (m, 1H), 2.94-3.02 (m, 2H), 3.38-3.45 (M, 2H).

MS (+) 218 (M+1).

Example 173-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-butyric acid(a) (5-formyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester

5 (5-hydroxymethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (7.00 g, 31.2 mmol) was dissolved in dry DMSO (50 mL) and the reaction flask immersed in a waterbath at 15°C. TEA (13.1 mL, 94.0 mmol) was added, followed by sulfur trioxide pyridine complex (15.0 g, 94.0 mmol) in portions. The reaction mixture was stirred for further 45 min and poured onto crushed ice. The product was extracted with diethyl ether and the combined organic
10 extracts were washed with brine, dried and concentrated under reduced pressure. Recrystallisation from hexane/CH₂Cl₂ afforded (5-formyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (5.40 g, 78 %) as white crystals.

(b) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)methylene)-malonic acid diethyl ester

15 To a solution of diethyl malonate (710 µL, 4.7 mmol) and (5-formyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (1.04 g, 4.7 mmol) in methylene chloride/DMF (1:1, 5 mL) was added piperidine (46 µL, 0.47 mmol) and acetic acid (27 µL, 0.47 mmol). The reaction mixture was stirred for 72 h at room temperature and then for 16 h at 45°C. Heptane was added slowly to give 2-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)methylene)-malonic acid
20 diethyl ester (0.69 g, 40 %) as grey crystals.

(c) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-ethyl]-malonic acid diethyl ester

MeLi (6.5 mL, 10.4 mmol, 1.6 M in diethyl ether) was added dropwise to a slurry of CuI (0.9 g, 4.73 mmol) in THF (28 mL) at -78°C under argon. The reaction mixture was stirred
25 for 30 min. A solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)methylene)-malonic acid diethyl ester (0.84 g, 2.3 mmol) in THF (7 mL) was added dropwise and the reaction was stirred for 180 min at -78°C. Saturated aqueous NH₄OH was added dropwise and the mixture was extracted with EtOAc. The organic phase was washed with saturated aqueous NH₄OH and NaCl, dried and concentrated under reduced pressure. Flash chromatography
30 (toluene/EtOAc, 3:1 → 1:6) gave 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-ethyl]-malonic acid diethyl ester (0.723 g, 82.4 %) as a white solid.

(d) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-ethyl]-malonic acid monoethyl ester

A solution of KOH (113.6 mg, 2.04 mmol) in EtOH (2 mL) was added dropwise to a solution of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-ethyl]-malonic acid diethyl ester (0.7 g, 1.84 mmol) in methylene chloride (4 mL) and EtOH (10 mL) at 0°C under argon and the reaction mixture was stirred over night. 1M KOH (100 mL) was added and the mixture was washed with methylene chloride. The aqueous phase was acidified to pH 2 using 2 M HCl and extracted with EtOAc. The organic phase was dried and concentrated under reduced pressure to give the crude 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-ethyl]-malonic acid monoethyl ester (423 mg, 65 %).

(e) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-ethyl]-acrylic acid ethyl ester

Diethylamine (0.153 mL, 1.473 mmol) was added to a solution of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-ethyl]-malonic acid monoethyl ester (423 mg, 1.2 mmol) and formaldehyde (132 mg, 1.626 mmol, 36 % in water) in methylene chloride (2 mL) at 0°C under argon. The mixture was stirred at room temperature over night. EtOAc was added and the solution was washed with water, NaHCO₃ and brine, dried and concentrated under reduced pressure. Flash chromatography (toluene/EtOAc, 3:1) gave 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-ethyl]-acrylic acid ethyl ester (158 mg, 41 %).

(f) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-butyric acid ethyl ester

TEA (0.076 mL, 0.542 mmol) was added to a solution of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-ethyl]-acrylic acid ethyl ester (158 mg, 0.493 mmol) in thioacetic acid (2 mL) at 0°C under argon. The mixture was stirred at 45°C over night. EtOAc was added and the solution was washed with NaHCO₃ and brine, dried and concentrated under reduced pressure. Flash chromatography (toluene/EtOAc, 5:1 → 1:1) gave slightly unpure 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-butyric acid ethyl ester (178 mg, 91 %).

(g) 2-Acetylsulfanylmethyl-3-(6-amino-pyridin-3-yl)-butyric acid ethyl ester

TFA (2 mL) was added to a solution of 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-butyric acid ethyl ester (178 mg, 0.449 mmol) in methylene chloride

(2 mL). The mixture was stirred for 60 min and concentrated under reduced pressure. Flash chromatography (toluene/ EtOAc, 1:6) gave unpure 2-acetylsulfanylmethyl-3-(6-amino-pyridin-3-yl)-butyric acid ethyl ester (176 mg, 95 %). Further purification by HPLC (10 → 70 % acetonitrile in water, 0.1 % TFA) gave 2-acetylsulfanylmethyl-3-(6-amino-pyridin-3-yl)-butyric acid ethyl ester (104 mg, 56 %) as the TFA salt.

(h) 3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-butyric acid

Conc. hydrochloric acid (4 mL) was added to 2-acetylsulfanylmethyl-3-(6-amino-pyridin-3-yl)-butyric acid ethyl ester (104 mg, 0.253 mmol) under argon. The reaction was heated to reflux for 5 h and then concentrated under reduced pressure to give a diastereomeric mixture of the title compound (61 mg, 92 %) as the hydrochloride salt.

¹H NMR (500 MHz, D₂O) for the major diastereomer: δ 1.26 (d, 3H), 2.49-2.53 (m, 2H), 2.64-2.77 (m, 1H), 2.95-3.02 (m, 1H), 7.02 (d, 1H), 7.69 (d, 1H), 7.88 (m, 1H).

MS (+) 227 (M+1).

Example 18

3-(6-Amino-2-methyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid

(a) (5-Bromo-6-methyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester

5-Bromo-6-methyl-pyridin-2-ylamine (25.0 g, 133.7 mmol) in THF/*tert*-butanol (1:10, 550 mL) was treated with di-*tert*-butyl dicarbonate (39.3 g, 180.0 mmol) and DMAP (2.40 g, 19.6 mmol). The reaction mixture was stirred for 4 h at 40°C and concentrated under reduced pressure. Flash chromatography (methylene chloride) gave (5-bromo-6-methyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (17.0 g, 44 %).

(b) [5-(*tert*-Butyl-dimethyl-silanyloxymethyl)-6-methyl-pyridin-2-yl]-carbamic acid *tert*-butyl ester

A solution of (5-bromo-6-methyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (27.5 g, 95.8 mmol), *tert*-butyl-dimethyl-tributylstannanylmethoxy-silane (43.5 g, 100.2 mmol), and bis(triphenylphosphine)palladium(II) dichloride (1.00 g, 1.40 mmol) in 1,2-dichloroethane (350 mL) was stirred at reflux for 48 h. Additional bis(triphenylphosphine)palladium(II) dichloride (1.00 g, 1.40 mmol) was added every 12 h. The mixture was cooled to 0°C and

diethyl ether (300 mL) was added followed by saturated aqueous potassium fluoride (100 mL). The mixture was stirred vigorously for 60 min and filtered. The organic phase was washed with water, dried and concentrated under reduced pressure. Flash chromatography (MeOH/CH₂Cl₂, 1:99) gave [5-(*tert*-butyl-dimethyl-silanyloxymethyl)-6-methyl-pyridin-2-yl]-carbamic acid *tert*-butyl ester (15 g, 47 %).

(c) (5-Hydroxymethyl-6-methyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester

Tetrabutylammonium fluoride (19.6 g, 62.4 mmol) was added to a solution of [5-(*tert*-butyl-dimethyl-silanyloxymethyl)-6-methyl-pyridin-2-yl]-carbamic acid *tert*-butyl ester (10.5 g, 31.23 mmol) in THF (100 mL) and stirred at room temperature overnight. Water was added and the product extracted with chloroform. The organic phase was dried and concentrated under reduced pressure. Flash chromatography (MeOH/CH₂Cl₂, 2.5:77.5) gave (5-hydroxymethyl-6-methyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (6.0 g, 81 %).

(d) 5-Bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin

Triphenylphosphine (9.83 g, 37.5 mmol) and CBr₄ (17.7 g, 53.5 mmol) was added to a solution of (5-hydroxymethyl-6-methyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (8.50 g, 35.7 mmol) in dichloromethane (30 mL) at 0°C. The reaction mixture was stirred for 3 h at room temperature and was then diluted with dichloromethane. The organic phase was washed with water, dried and concentrated under reduced pressure. Flash chromatography (CH₂Cl₂) gave 5-bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin (4.05 g, 38 %).

(e) 2-(6-*tert*-Butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester

A solution of diethyl malonate (1.21 mL, 7.97 mmol) in DMF (2 mL) was added dropwise to a suspension of NaH (348 mg, 7.97 mmol, 55 % in mineral oil) in DMF (5 mL) at 0 °C under argon. The reaction mixture was stirred for 45 min and a solution of (5-bromo-6-methyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (2.0 g, 6.64 mmol) in DMF (5 mL) was added dropwise. The mixture was stirred over night (0°C → 20°C). EtOAc was added and the solution was washed with water and brine, dried and concentrated under

reduced pressure. Flash chromatography (heptane/EtOAc, 4:1) gave 2-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (1.87 g, 74 %).

(f) 2-(6-*tert*-Butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester

5 A solution of KOH (300 mg, 5.35 mmol) in EtOH (4 mL) was added to a solution of 2-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (1.85 g, 4.86 mmol) in EtOH/methylene chloride (2:1, 21 mL) at 0°C. The mixture was stirred for 40 h at room temperature and EtOAc was added. The mixture was washed with 0.5 M
10 HCl and brine, dried and concentrated under reduced pressure to give crude 2-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.45 g).

(g) 2-(6-*tert*-Butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester

15 Diethylamine (359 mg, 4.90 mmol) was added dropwise to a solution of 2-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.44 g, 4.09 mmol) and formaldehyde (464 mg, 5.72 mmol, 37 % in water) in methylene chloride (35 mL) at 0°C under argon. The mixture was stirred at room temperature over night. Methylene chloride was added and the solution was washed with Na₂CO₃ and brine, dried
20 and concentrated under reduced pressure to give 2-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester (1.03 g, 79 %).

(h) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-yl)-propionic acid ethyl ester

25 TEA (0.556 mL, 3.99 mmol) was added to a solution of 2-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester (1.23 g, 3.84 mmol) in thioacetic acid (10 mL) at 0 °C under argon. The mixture was stirred at room temperature for 64 h. EtOAc was added and the solution was washed with Na₂CO₃ and brine, dried and concentrated under reduced pressure. Flash chromatography (toluene/EtOAc, 5:1 → 1:1) gave 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-yl)-propionic
30 acid ethyl ester (1.33 g, 87 %).

(i) 3-(6-Amino-2-methyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid

Conc. hydrochloric acid (2 mL) was added to 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-2-methyl-pyridin-3-yl)-propionic acid ethyl ester (77 mg, 0.19 mmol) under argon. The reaction was heated to reflux for 110 min and was then concentrated under reduced pressure to give the title compound (39 mg, 76 %) as the hydrochloride salt.

¹H NMR (500 MHz, D₂O): δ 2.49 (s, 3H), 2.73-2.92 (m, 5H), 6.81 (d, 1H), 7.77 (d, 1H).

MS (+) 227 (M+1).

10 Example 192-Acetylsulfanylmethyl-3-(2-amino-pyrimidin-5-yl)-propionic acid ethyl ester(a) 2-[N,N-bis(*tert*-Butoxycarbonyl)amino]-5-bromopyrimidin

2-Amino-5-bromopyrimidine (9.00 g, 51.7 mmol) in THF/*tert*-butanol (1:1, 100 mL) was treated with di-*tert*-butyl dicarbonate (34.0 g, 156.0 mmol) and DMAP (3.00 g, 24.5 mmol). The reaction mixture was left at ambient temperature overnight and concentrated under reduced pressure. The residue was partitioned between dichloromethane and water and pH was adjusted to 4 with 1 M HCl. The solution was extracted with dichloromethane, dried and concentrated under reduced pressure. The crude product was suspended in hexane and filtered to yield 2-[N,N-bis(*tert*-butoxycarbonyl)amino]-5-bromopyrimidin (15.0 g, 77 %).

(b) 2-[N,N-bis(*tert*-Butoxycarbonyl)amino]-5-(*tert*-butyl-dimethyl-silanyloxymethyl)-pyrimidin

25 A solution of 2-[N,N-bis(*tert*-butoxycarbonyl)amino]-5-bromopyrimidin (16.0 g, 45.0 mmol), *tert*-butyl-dimethyl-tributylstannanylmethoxy-silane (20.5 g, 47.1 mmol), and bis(triphenylphosphine)palladium(II) dichloride (1.00 g, 1.40 mmol) in 1,2-dichloroethane (50 mL) was stirred at reflux overnight. Additional bis(triphenylphosphine)palladium(II) dichloride (1.00 g, 1.40 mmol) was added and the solution was refluxed for 8 h. The mixture was cooled to 0°C and diethyl ether (200 mL) was added followed by saturated aqueous potassium fluoride (50 mL). The mixture was stirred vigorously for 60 min and filtered. The organic phase was washed with water, dried and concentrated under reduced

pressure. Flash chromatography (MeOH/CH₂Cl₂, 1:99) gave 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-(*tert*-butyl-dimethyl-silanyloxymethyl)-pyrimidin (10.2 g, 55 %).

5 (c) 2-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-5-hydroxymethyl-pyrimidin

Tetrabutylammonium fluoride (15.3 g, 48.6 mmol) was added to a solution of 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-(*tert*-butyl-dimethyl-silanyloxymethyl)-pyrimidin (10.0 g, 24.3 mmol) in THF (100 mL) and stirred at room temperature overnight. Water was added and the product extracted with chloroform. The organic phase was dried and
10 concentrated under reduced pressure. Flash chromatography (MeOH/CH₂Cl₂, 2.5:77.5) gave 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-hydroxymethyl-pyrimidin (4.20 g, 53 %).

(d) 5-Bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin

Triphenylphosphine (2.71 g, 10.73 mmol) and CBr₄ (4.89 g, 14.8 mmol) was added to a
15 solution of 2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-5-hydroxymethyl-pyrimidin (3.20 g, 9.83 mmol) in dichloromethane (30 mL) at 0°C. The reaction mixture was stirred for 1 h and was then diluted with dichloromethane. The organic phase was washed with water, dried and concentrated under reduced pressure. Flash chromatography (CH₂Cl₂) gave 5-bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin (2.55 g, 67 %).

20

(e) 2-(2-[*N,N*-bis(*tert*-Butoxycarbonyl)amino]-pyrimidin-5-ylmethyl)-malonic acid diethyl ester

A solution of diethyl malonate (0.704 mL, 4.64 mmol) in DMF (2 mL) was added dropwise to a suspension of NaH (200 mg, 4.64 mmol, 55 % in mineral oil) in DMF (4
25 mL) at 0 °C under argon. The reaction mixture was stirred for 30 min and a solution of 5-bromomethyl-2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin (1.5 g, 3.86 mmol) in DMF (4 mL) was added dropwise. The mixture was stirred at room temperature for 3 h. EtOAc was added and the solution was washed with water and brine, dried and concentrated under reduced pressure. Flash chromatography (heptane/EtOAc, 3:2) gave 2-
30 (2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-ylmethyl)-malonic acid diethyl ester (0.87 g, 40 %).

(f) 2-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-ylmethyl)-malonic acid monoethyl ester

A solution of KOH (106 mg, 1.88 mmol) in EtOH (2 mL) was added to a solution of 2-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-ylmethyl)-malonic acid diethyl ester (0.80 g, 1.71 mmol) in EtOH/methylene chloride (2:1, 12 mL) at 0°C. The mixture was stirred for 16 h at room temperature and EtOAc was added. The mixture was washed with 0.5 M HCl and brine, dried and concentrated under reduced pressure to give 2-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-ylmethyl)-malonic acid monoethyl ester (0.67 g, 89 %).

(g) 2-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-ylmethyl)-acrylic acid ethyl ester

Diethylamine (0.124 mL, 1.69 mmol) was added dropwise to a solution of 2-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-ylmethyl)-malonic acid monoethyl ester (0.62 g, 1.41 mmol) and formaldehyde (160 mg, 2.0 mmol, 37 % in water) in methylene chloride (15 mL) at 0 °C under argon. The mixture was stirred at room temperature over night. EtOAc was added and the solution was washed with water, NaHCO₃ and brine, dried and concentrated under reduced pressure to give crude 2-(2-[*N,N*-bis(*tert*-butoxycarbonyl)-amino]-pyrimidin-5-ylmethyl)-acrylic acid ethyl ester (0.54 g, 94 %).

(h) 2-Acetylsulfanylmethyl-3-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-yl)-propionic acid ethyl ester

TEA (0.189 mL, 1.35 mmol) was added to a solution of 2-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-ylmethyl)-acrylic acid ethyl ester (0.53 g, 1.30 mmol) in thioacetic acid (13 mL) at 0°C under argon. The mixture was stirred at room temperature for 40 h. EtOAc was added and the solution was washed with Na₂CO₃ and brine, dried and concentrated under reduced pressure. Flash chromatography (heptane/EtOAc, 5:1 → 1:1) gave 2-acetylsulfanylmethyl-3-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-yl)-propionic acid ethyl ester (0.56 g, 89 %).

(i) 2-Acetylsulfanylmethyl-3-(2-amino-pyrimidin-5-yl)-propionic acid ethyl ester

TFA (1.5 mL) was added to a solution of 2-acetylsulfanylmethyl-3-(2-[*N,N*-bis(*tert*-butoxycarbonyl)amino]-pyrimidin-5-yl)-propionic acid ethyl ester (225 mg, 0.46 mmol) in methylene chloride (1.5 mL). The reaction was stirred for 120 min and concentrated under reduced pressure to give the title compound (172 mg, 94 %) as the TFA salt.

¹H NMR (500 MHz, CD₃OD): δ 1.22 (t, 3H), 2.35 (s, 3H), 2.80-3.00 (m, 3H), 3.00-3.22 (m, 2H), 4.13 (q, 2H), 8.43 (s, 2H).

MS (+) 284 (M+1).

10 Example 202-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-butyric acid(a) 3-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-2-(diethoxy-phosphoryl)-propionic acid ethyl ester

15 To a suspension of NaH (1.17 g, 60% in mineral oil, 29.3 mmol) in DMF (70 mL) was added triethyl phosphonoacetate (6.01 g, 26.82 mmol) at 0°C. The reaction mixture was allowed to stir at 0 °C for 0.5 h. To the reaction was added (5-bromomethyl-pyridin-2-yl)-carbamic acid *tert*-butyl ester (7.0 g, 24.38 mmol) at 0°C and the reaction mixture was stirred at room temperature for 16 h. The reaction was quenched with the slow addition of saturated aqueous ammonium chloride (70 mL). The mixture was extracted with EtOAc, washed with brine and dried. The crude product was purified by column chromatography (CH₂Cl₂/EtOAc, 1:0 → 1:1 → 0:1) to give 3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-(diethoxy-phosphoryl)-propionic acid ethyl ester (5.1 g, 50%).

25 (b) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-but-2-enoic acid ethyl ester

To a suspension of NaH (278.8 mg, 60% in mineral oil, 6.97 mmol) in THF (25 mL) at 0°C was added a solution of 3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-(diethoxy-phosphoryl)-propionic acid ethyl ester (2.5 g, 5.81 mmol) in THF (30 mL). The reaction mixture was allowed to stir at 0°C for 1 h. To the reaction was added acetaldehyde (512 mg, 11.6 mmol) dropwise at 0°C. The reaction mixture was allowed to warm to room temperature and then stir for 16 h. Acetaldehyde (2.0 g) was added to the reaction vessel

and the reaction mixture was allowed to stir at room temperature for an additional 16 h. The reaction was quenched with the slow addition of saturated aqueous ammonium chloride (30 mL). The mixture was extracted with EtOAc, washed with brine and dried to afford the crude product. The crude product was purified by column chromatography (EtOAc/hexane, 1:8) to give ethyl 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-but-2-enoic acid ethyl ester as a mixture of isomers (1.1 g, 60%).

(c) 3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester

- To thiolacetic acid (15 mL) were added Et₃N (1.5 g, 14.8 mmol) and ethyl 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-but-2-enoic acid ethyl ester (920 mg, 2.9 mmol) at room temperature. The reaction mixture was stirred at 40 – 45°C for 7 days (additional thiolacetic acid (1.5 mL) was added to the reaction mixture every two days). The reaction mixture was cooled to room temperature and then diluted with EtOAc (50 mL). The organic layer was separated, washed with sat. NaHCO₃, brine and dried. The combined organic layers were concentrated under reduced pressure. The crude was purified subsequently by three chromatography columns (CH₂Cl₂, EtOAc/hexane, 1:5 and acetone/hexane, 1:8) to afford 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester as a diastereometric mixture (780 mg, 68%).
- The diastereomeric mixture was separated using preparative chiral chromatography according to the procedure described below to give the four isomers 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/A, 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/B, 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/C and 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/D.

3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester /D

- 3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/D was separated from a mixture of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/A, 3-acetylsulfanyl-2-(6-*tert*-

butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/B, 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/C and 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/D on a chiralcel OJ column eluting with isohexane:acetonitrile: isopropyl alcohol:diethyl amine
5 (99; 0.5; 0.5; 0.1). The enantiomeric excess was > 99% as measured by HPLC using a chiralpak OJ column eluting with isohexane: ethanol: diethyl amine (99; 1; 0.5).

3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/A

10 3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/A was separated from a mixture of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/A, 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/B and 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester /C on a chiralcel OJ
15 column eluting with isohexane: 1-propanol: diethyl amine (98; 2; 0.1). The enantiomeric excess was > 99% as measured by HPLC using a chiralpak OJ column eluting with isohexane: ethanol: diethyl amine (99; 1; 0.5).

3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/B

20 3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/B was separated from a mixture of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/B and 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/C on a chiralcel AS column
25 eluting with hexane: ethanol: diethyl amine (99: 1: 0.5). The enantiomeric excess was > 99% as measured by HPLC using a chiralpak AS column eluting with isohexane: ethanol: diethyl amine (99; 1; 0.5).

3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/C

30 3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/C was separated from a mixture of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-

pyridin-3-ylmethyl)-butyric acid ethyl ester/B and 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/C on a chiralcel AS column eluting with hexane: ethanol: diethyl amine (99: 1: 0.5). The enantiomeric excess was 87 % as measured by HPLC using a chirapak AS column eluting with isohexane:
5 ethanol:diethyl amine (99; 1; 0.5).

(d) 2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-butyric acid /A

A solution of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/A (45 mg; 0.11 mmol) in concentrated HCl (2 mL) was refluxed under
10 argon for 1 hour. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford 28.4 mg of the title compound as the hydrochloride salt.

¹H NMR (400 MHz, D₂O): δ 7.89 (d, 1H), 7.71 (s, 1H), 7.03 (d, 1H), 3.23-3.33 (m, 1H), 3.1-3.2 (m, 1H), 2.75-2.9 (m, 2H), 1.47 (d, 3H).

15 MS(+) 227 (M+1).

(e) 2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-butyric acid /B

A solution of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/B (55 mg; 0.14 mmol) in concentrated HCl (2 mL) was refluxed under
20 argon for 1 hour. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford 39.4 mg of the title compound as the hydrochloride salt.

¹H NMR (400 MHz, D₂O): δ 7.89 (d, 1H), 7.71 (s, 1H), 7.03 (d, 1H), 3.23-3.33 (m, 1H), 3.1-3.2 (m, 1H), 2.75-2.9 (m, 2H), 1.47 (d, 3H).

25 MS(+) 227 (M+1).

(f) 2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-butyric acid/C

A solution of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/C (9 mg; 0.02 mmol) in concentrated HCL (0.5 mL) was refluxed under
30 argon for 1 hour. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford 6.4 mg of the title compound as the hydrochloride salt.

¹H NMR (400 MHz, D₂O): δ 7.82-7.9 (m, 1H), 7.67 (br s, 1H), 7.0 (d, 1H), 3.16-3.28 (m, 1H), 2.96-3.04 (m, 1H), 2.76-2.86 (m, 2H), 1.47 (d, 3H).
MS(+) 227 (M+1).

5 (g) 2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-butyric acid/D

A solution of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-butyric acid ethyl ester/C (9 mg; 0.02 mmol) in concentrated HCL (0.5 mL) was refluxed under argon for 1 hour. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford 6.8 mg of the title compound as the
10 hydrochloride salt.

¹H NMR (400 MHz, D₂O): δ 7.82-7.9 (m, 1H), 7.67 (br s, 1H), 7.0 (d, 1H), 3.16-3.28 (m, 1H), 2.96-3.04 (m, 1H), 2.76-2.86 (m, 2H), 1.47 (d, 3H).
MS(+) 227 (M+1).

15 Example 21

6-Amino-pyridin-3-ylmethyl)-3-mercapto-pentanoic acid

(a) 2-(6-*tert*-Butoxycarbonylamino-pyridin-3-ylmethyl)-pent-2-enoic acid ethyl ester

To a solution of NaH (290.5 mg, 60% in mineral oil, 7.5 mmol) in THF (25 mL) at 0°C
20 was added a solution of 3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-(diethoxy-phosphoryl)-propionic acid ethyl ester (2.5 g, 5.81 mmol) in THF (30 mL). The reaction mixture was allowed to stir at 0°C for 1 h. To the reaction was added propionaldehyde (725 mg, 12.5 mmol) dropwise at 0°C. The reaction mixture was allowed to stir at room temperature for 16 h. Propionaldehyde (2.5 g) was added and the mixture was stirred at
25 room temperature for an additional 16 h. The reaction was quenched with the slow addition of saturated aqueous NH₄Cl (30 mL). The mixture was extracted with EtOAc, washed with brine and dried. The crude product was purified by column chromatography (EtOAc/hexane, 1:8) to give 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-pent-2-enoic acid ethyl ester as a mixture of isomers (1.2 g, 60%).

(b) 3-Acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester

To thiolacetic acid (15 mL) were added Et₃N (1.8 g, 17 mmol) and 2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pent-2-enoic acid ethyl ester (1.1 g, 3.3 mmol) at room temperature. The reaction mixture was stirred at 65°C for 8 days (additional thioacetic acid (1.5 mL) was added to the reaction mixture every 2 days). The reaction mixture was cooled to room temperature and then diluted with EtOAc. The organic layer was separated, washed with saturated NaHCO₃, brine and dried. The combined organic layers were concentrated under reduced pressure. The residue was purified subsequently by two chromatography columns (CH₂Cl₂ and EtOAc/hexane, 1:5) to afford 350 mg of a mixture of desired products and unreacted starting material. The crude product was further purified by HPLC (EtOH/Hexane, 1:9) and then column chromatography (acetone/hexane, 1:8) to give the title compound as a diastereometric mixture (180 mg, 18%). The diastereomeric mixture of 3-acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester was separated using preparative chiral chromatography according to the procedure described below to give the four isomers 3-acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester/A, 3-acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester/B, 3-acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester/C and 3-acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester/D. The diastereomeric mixture was separated on two chiralcel OJ columns, which were connected to each other, eluting with isohexane: isopropyl alcohol: methanol (97:1: 2). The enantiomeric excess was measured by analytical HPLC using two chiralcel OJ columns, which were connected to each other, eluting with with isohexane: isopropyl alcohol: methanol (97:1: 2). For 3-acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester A through C the enantiomeric excess was found to be > 99%, whereas it was found to be 97% for 3-acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester D.

(c) 6-Amino-pyridin-3-ylmethyl)-3-mercapto-pentanoic acid/A

A solution of 3-acetylsulfanyl-2-(6-tert-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester/A (50.4 mg; 0.12 mmol) in concentrated HCl (2 mL) was

refluxed under argon for 1.5 hours. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford 33.9 mg of the title compound as the hydrochloride salt.

¹H NMR (500 MHz, D₂O): δ 7.87 (dd, 1H), 7.67 (d, 1H), 7.0 (d, 1H), 3.02-3.16 (m, 2H), 2.79-2.87 (m, 2H), 1.79-1.88 (m, 1H), 1.53-1.64 (m, 1H), 1.07 (t, 3H).

MS(+) 241 (M+1).

(d) 2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-pentanoic acid/B

A solution of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester/B (51.6 mg; 0.13 mmol) in concentrated HCl (2 mL) was refluxed under argon for 1.5 hours. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford 34.7 mg of the title compound as the hydrochloride salt.

¹H NMR (500 MHz, D₂O): δ 7.87 (dd, 1H), 7.67 (d, 1H), 7.0 (d, 1H), 3.02-3.16 (m, 2H), 2.79-2.87 (m, 2H), 1.79-1.88 (m, 1H), 1.53-1.64 (m, 1H), 1.07 (t, 3H).

MS(+) 241 (M+1).

(e) 2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-pentanoic acid/C

A solution of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester/C (4.3 mg; 0.01 mmol) in concentrated HCl (2 mL) was refluxed under argon for 1.5 hours. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford 2.9 mg of the title compound as the hydrochloride salt.

¹H NMR (500 MHz, D₂O): δ 7.86 (dd, 1H), 7.66 (br s, 1H), 7.0 (d, 1H), 2.94-3.04 (m, 2H), 2.74-2.9 (m, 2H), 1.88-1.97 (m, 1H), 1.55-1.66 (m, 1H), 1.05 (t, 3H).

MS(+) 241 (M+1).

(f) 2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-pentanoic acid/D

A solution of 3-acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-pentanoic acid ethyl ester/D (19.2 mg; 0.05 mmol) in concentrated HCl (2 mL) was refluxed under argon for 1.5 hours. The reaction mixture was allowed to cool to room

temperature and concentrated under reduced pressure to afford 12.9 mg of the title compound as the hydrochloride salt.

¹H NMR (500 MHz, D₂O): δ 7.86 (dd, 1H), 7.66 (br s, 1H), 7.0 (d, 1H), 2.94-3.04 (m, 2H), 2.74-2.9 (m, 2H), 1.88-1.97 (m, 1H), 1.55-1.66 (m, 1H), 1.05 (t, 3H).

5 MS(+) 241 (M+1).

Example 22

3-(6-Amino-5-chloro-pyridin-3-yl)-2-mercaptopomethyl-propionic acid

10 (a) 6-Amino-5-chloro-nicotinic acid ethyl ester

N-Chlorosuccinimide (21.7 g, 0.162 mol) was added to a suspension of 6-amino-nicotinic acid ethyl ester (18.0 g, 0.108 mol) in acetonitrile (270 ml) and the mixture was refluxed for 2 h. The reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved in dichloromethane, washed with water and dried. Flash chromatography (2.5 % MeOH in CH₂Cl₂) gave pure 6-amino-5-chloro-nicotinic acid ethyl ester
15 (17.23 g, 79 %).

(b) 6-bis(tert-butoxycarbonyl)-amino-5-chloro-nicotinic acid ethyl ester

DMAP (0.11 g, 0.9 mmol) and (Boc)₂O (21.54 g, 99 mmol) was added to a solution of 6-amino-5-chloro-nicotinic acid ethyl ester (9.0 g, 45 mmol) in dichloromethane (250 ml).
20 The reaction mixture was stirred for 24 h. DMAP (0.02 equiv.) and (Boc)₂O (3 x 0.5 equiv.) was added during the reaction time. The reaction mixture was washed with water and dried. The crude product was washed with hexane to give pure 6-bis(tert-butoxycarbonyl)-amino-5-chloro-nicotinic acid ethyl ester (11.87 g, 66 %).

25

(c) (3-chloro-5-hydroxymethyl-pyridin-2-yl)-carbamic acid tert-butyl ester

LiAlH₄ (2.4 g, 63.2 mmol) was added in portions over a period of 3.5 h to solution of 6-bis(tert-butoxycarbonyl)-amino-5-chloro-nicotinic acid ethyl ester (11.5 g, 28.6 mmol) in THF (70 ml) at 0°C. The reaction mixture was stirred in room temperature over night, then
30 NH₄Cl (sat.) was added carefully followed by water. The solution was filtered, dried and concentrated under reduced pressure to yield crude (3-chloro-5-hydroxymethyl-pyridin-2-yl)-carbamic acid tert-butyl ester (5.86 g, 79 %).

(d) (5-bromomethyl-3-chloro-pyridin-2-yl)-carbamic acid *tert*-butyl ester

Triphenylphosphine (2.61 g, 9.7 mmol) followed by carbontetrabromide (4.58 g, 13.8 mmol) was added to a suspension of (3-chloro-5-hydroxymethyl-pyridin-2-yl)carbamic acid *tert*-butyl ester (2.38 g, 9.2 mmol) in CH₂Cl₂ (60 ml) at 0°C. The mixture was stirred at room temperature for 5 h and concentrated under reduced pressure. Acetonitrile (40 ml) was added and the mixture was kept to -20°C overnight. The mixture was then filtered and the crystalline residue washed with cold acetonitrile. The filtrate was concentrated under reduced pressure and another crop of bromide was obtained as described above. (5-bromomethyl-3-chloro-pyridin-2-yl)-carbamic acid *tert*-butyl ester (1.86 g, 63 %) was obtained as white crystals.

(e) 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-malonic acid diethyl ester

Diethyl malonate (1.87 ml, 12.31 mmol) was added to a suspension of NaH (0.54 g, 12.31 mmol, 55 %) in dry DMF (15 ml) at -8°C. This mixture was stirred for 15 min. before it was added dropwise to a solution of (5-bromomethyl-3-chloro-pyridin-2-yl)-carbamic acid *tert*-butyl ester (3.30 g, 10.26 mmol) in dry DMF (50 ml) at 0°C. The resulting solution was stirred for 40 minutes at 0°C, then NH₄Cl (5 ml, sat.) was added carefully. Stirring at room temperature overnight and concentration under reduced pressure gave a residue, which was dissolved in water/CH₂Cl₂. The aqueous layer was extracted with CH₂Cl₂ and the combined organic extracts were dried, filtered and concentrated under reduced pressure. Flash chromatography (1 % MeOH in CH₂Cl₂) gave 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-malonic acid diethyl ester (2.45, 60 %) as a sticky clear oil.

(f) 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-malonic acid monoethyl ester

A solution of KOH (0.44 g, 6.72 mmol, 85 %) in ethanol (5 ml) was added to a solution of 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-malonic acid diethyl ester (2.45 g, 6.11 mmol) in ethanol (25 ml) and methylene chloride (10 ml) at 0°C. The mixture was stirred for 18 h at room temperature. The solvent was evaporated *in vacuo* and the

residue dissolved in water. The aqueous layer was washed with ether, acidified to pH 4 by 1 M HCl and extracted with methylene chloride and ethyl acetate. The combined organic layers were washed with water and brine and dried. Filtration and concentration under reduced pressure gave the crude product which was purified by flash chromatography (10 % MeOH in CH₂Cl₂) giving 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.41 g, 62 %) as a yellow-white glassy foam.

(g) 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-acrylic acid ethyl ester
Diethylamine (3.67 ml, 3.67 mmol) was added dropwise followed by water (2.5 ml) and CH₂Cl₂ (2.5 ml) to a mixture of 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-malonic acid monoethyl ester (1.40 g, 3.64 mmol) and 37 % aq. solution of formaldehyde (0.29 ml, 3.75 mmol) in CH₂Cl₂ (2 ml) at 0°C. The mixture was stirred for 20 h at room temperature and then poured onto ice-water and extracted with methylene chloride. The organic layer was washed with 5% NaHCO₃, dried and concentrated under reduced pressure. Flash chromatography (1-2.5% methanol in CH₂Cl₂) yielded 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-acrylic acid ethyl ester 0.81 g (65 %).

(h) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-propionic acid ethyl ester

Thioacetic acid (4 ml) was added to a suspension of 2-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-acrylic acid ethyl ester (0.732 g, 2.16 mmol) and triethylamine (0.31 ml, 2.23 mmol) at 0°C. The mixture was stirred at room temperature under argon overnight, poured onto ice-water and extracted with CH₂Cl₂. The organic phase was washed with saturated NaHCO₃ until gas evolution ceased and then dried. The crude product was purified twice with flash chromatography (CH₂Cl₂, 1-2.5 % MeOH in CH₂Cl₂ and Hexane/EtOAc, 5:2 → 1:1) to give pure 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-propionic acid ethyl ester (0.79 g, 87 %).

(i) 3-(6-Amino-5-chloro-pyridin-3-yl)-2-mercaptomethyl-propionic acid

A solution of 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-yl)-propionic acid ethyl ester (55mg, 0.132 mmol) in concentrated HCl (4 mL) was

refluxed for 90 min. The reaction was cooled and concentrated under reduced pressure to give the title compound as the HCl salt (36mg, 96.4 %)

¹H NMR (400 MHz, D₂O): δ 2.70-2.97 (m, 5H), 7.73 (s, 1H), 8.09 (s, 1H)

MS (+) 248 (M+1)

5

Example 23

3-(6-Amino-5-hydroxymethyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid

(a) 6-bis(*tert*-Butoxycarbonyl)amino-5-vinyl-nicotinic acid ethyl ester

10 A mixture of 5-bromo-6-bis(*tert*-butoxycarbonyl)amino-nicotinic acid ethyl ester (4.50 g, 10.1 mmol), vinyltributyltin (3.52 g, 11.1 mmol) and tetrakis(palladium triphenylphosphine) (0.50 g, 0.40 mmol) in THF (15 ml) was stirred at reflux for 24 h. Tetrakis(palladium triphenylphosphine) (0.50 g) was added and after 24 h at reflux the reaction mixture was cooled and diluted with dichloromethane (100 ml). Saturated aqueous KF (25 ml) was added and the solution stirred for 1 h. Water was added and the product extracted with
15 dichloromethane, the organic phase was dried and concentrated under reduced pressure. Flash chromatography (1% MeOH in dichloromethane) gave 6-bis(*tert*-butoxycarbonyl)-amino-5-vinyl-nicotinic acid ethyl ester 3.20 g, (81%).

(b) (5-hydroxymethyl-3-vinyl-pyridin-2-yl)carbamic acid *tert*-butyl ester

20 DIBAL (25 ml, 1M in hexane) was added dropwise to a solution of 6-bis(*tert*-butoxycarbonyl)amino-5-vinyl-nicotinic acid ethyl ester (2.00 g, 5.1 mmol) in THF (40 ml) at 0°C. The mixture was stirred at room temperature for 1 h. NH₄Cl (sat.) was added carefully followed by water, and the mixture was concentrated under reduced pressure. The residue
25 was suspended in 5% MeOH in dichloromethane and filtered through silicagel. The filtrate was dried and concentrated under reduced pressure to give (5-hydroxymethyl-3-vinyl-pyridin-2-yl)carbamic acid *tert*-butyl ester (1.00 g, 78 %).

(c) (5-bromomethyl-3-vinyl-pyridin-2-yl)carbamic acid *tert*-butyl ester

30 To a stirred suspension of (5-hydroxymethyl-3-vinyl-pyridin-2-yl)carbamic acid *tert*-butyl ester (10.0 g, 40.0 mmol) in CH₂Cl₂ (150 ml) and THF (60 ml) was added triphenyl-

phosphine (11.5 g, 44.0 mmol) followed by carbontetrabromide (19.9 g, 60.0 mmol) at 0°C. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure. Acetonitrile (100 ml) was added and the mixture was kept at -20°C overnight. The mixture was then filtered and the crystalline residue washed with cold acetonitrile. The product was purified by flash-chromatography (1 % MeOH in dichloromethane) to give (5-bromomethyl-3-chloro-pyridin-2-yl)-carbamic acid *tert*-butyl ester (4.5 g, 36 %).

(d) 2-(6-*tert*-Butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)-malonic acid diethyl ester

Diethyl malonate (2.30 g, 14.3 mmol) was added to a suspension of NaH (0.61 g, 14.3 mmol, 55 %) in dry DMF (75 ml) at 0°C. The mixture was stirred for 15 min and then added dropwise to a solution of (5-bromomethyl-3-chloro-pyridin-2-yl)-carbamic acid *tert*-butyl ester (4.50 g, 14.3 mmol) in dry DMF (100 ml) at 0°C. The resulting solution was stirred for 40 min at 0°C, then NH₄Cl (30 ml, sat.) was added carefully. Concentration under reduced pressure gave a residue, which was dissolved in water/CH₂Cl₂. The aqueous layer was extracted with CH₂Cl₂ and the combined extracts were dried, filtered and concentrated under reduced pressure. Flash chromatography (1 % MeOH in CH₂Cl₂) gave 2-(6-*tert*-Butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (4.30 g, 77 %).

(e) 2-(6-*tert*-Butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester

A solution of KOH (0.71 g, 12.6 mmol, 85 %) in ethanol (10 ml) was added to a solution of 2-(6-*tert*-butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)-malonic acid diethyl ester (4.30 g, 11.0 mmol) in ethanol (25 ml) and dichloromethane (10 ml) at 0°C. The mixture was stirred for 6 h at room temperature. The solvent was evaporated *in vacuo* and the residue dissolved in water. The aqueous layer was washed with ether, acidified to pH 4 by 1 M HCl and extracted with dichloromethane. The organic layer was washed with water and brine and dried. Filtration and concentration under reduced pressure followed by flash chromatography (10 % MeOH in CH₂Cl₂) gave 2-(6-*tert*-butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester (3.05 g, 76 %).

(f) 2-(6-*tert*-Butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)- acrylic acid ethyl ester

Diethylamine (0.85 ml, 8.80 mmol) was added dropwise to a mixture of 2-(6-*tert*-butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)-malonic acid monoethyl ester (3.05 g, 8.37 mmol) and 37 % aq. solution of formaldehyde (0.71 g, 8.80 mmol) in CH₂Cl₂ (2 ml) at 0°C. The mixture was stirred for 3 h at room temperature and then poured onto ice-water and extracted with dichloromethane. The organic layer was washed with 5% NaHCO₃ and dried. Flash chromatography (1 % methanol in CH₂Cl₂) yielded 2-(6-*tert*-butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)- acrylic acid ethyl ester (1.70 g, 61 %).

(g) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-5-vinyl-pyridin-3-yl)-propionic acid ethyl ester

Thioacetic acid (4 ml) was added to a suspension of 2-(6-*tert*-butoxycarbonylamino-5-vinyl-pyridin-3-ylmethyl)-acrylic acid ethyl ester (0.73 g, 2.16 mmol) in triethylamine (0.31 ml, 2.23 mmol) at 0°C. The mixture was stirred at room temperature under argon overnight, poured onto ice-water and extracted with CH₂Cl₂. The organic phase was washed with saturated NaHCO₃ until gas evolution ceased and then dried. Flash chromatography (1 % MeOH in CH₂Cl₂) gave 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-5-chloro-pyridin-3-ylmethyl)-propionic acid ethyl ester (0.51 g, 70 %).

(h) 3-(6-*tert*-butoxycarbonylamino-5-hydroxymethyl-pyridin-3-yl)-mercaptomethyl-propionic acid ethyl ester

Ozone was bubbled through a solution of 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-5-vinyl-pyridin-3-yl)-propionic acid ethyl ester (0.65 g, 1.60 mmol) in ethanol (25 ml) at -78°C. O₂ was then bubbled through the mixture for 5 min followed by N₂ bubbling for 15 min. A mixture of NaBH₄ (0.30 g, 8.00 mmol) in water was carefully added to the mixture at -78°C, and the reaction mixture allowed to reach 0°C. Stirring was continued for 3 h. Acetone (10 ml) was added and the reaction mixture evaporated to 1/3 of the initial volume. 50 % NaCl (aq) was added and the mixture was extracted with dichloro-methane, dried and concentrated under reduced pressure to give crude 3-(6-*tert*-

butoxy-carbonylamino-5-hydroxymethyl-pyridin-3-yl)-mercaptomethyl-propionic acid ethyl ester (0.38 g, 63 %).

(i) 2-Acetylsulfanylmethyl-3-(6-tert-butoxycarbonylamino-5-hydroxymethyl-pyridin-3-yl)-propionic acid ethyl ester

A mixture of crude 3-(6-tert-butoxycarbonylamino-5-hydroxymethyl-pyridin-3-yl)-mercaptomethyl-propionic acid ethyl ester (0.38 g, 1.0 mmol) and KHCO_3 (0.11 g, 1.1 mmol) in acetic acid anhydride (1 mL) was stirred at room temperature for 5 h. NH_4Cl (sat.) and water was then added. The mixture was extracted with dichloromethane, dried and concentrated under reduced pressure. Flash chromatography (CH_2Cl_2 , 2.5 % MeOH in CH_2Cl_2) gave 2-acetylsulfanylmethyl-3-(6-tert-butoxycarbonylamino-5-hydroxymethyl-pyridin-3-yl)-propionic acid ethyl ester (0.23 g, 60 %).

(j) 3-(6-Amino-5-hydroxymethyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid

A solution of 3-(6-tert-butoxycarbonylamino-5-hydroxymethyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid ethyl ester (50 mg, 135 μmol) in concentrated HCl (2 mL) was refluxed for 60 min. The reaction was cooled and concentrated under reduced pressure to give the title compound as the HCl salt (37mg, 98.3 %).

^1H NMR (400 MHz, D_2O): δ 2.70-2.95 (m, 5H), 4.65 (s, 2H), 7.68 (s, 1H), 7.88 (s, 1H)

MS (+) 244 (M+1)

Example 24

2-Mercaptomethyl-3-pyrrolidin-3-yl-propionic acid

(a) (1-Benzyl-pyrrolidin-3-yl)-methanol

Red-Al (160 mL of a 3.5 M solution in toluene, 560 mmol) was added to a solution of 1-benzyl-5-oxo-pyrrolidine-3-carboxylic acid (20 g, 91 mmol) in dry THF (650 mL) under argon. The reaction mixture was refluxed for 2.5 h and then poured onto a mixture of crushed ice and NaOH (20 %). The phases were separated, the aqueous phase was extracted with toluene and the combined organic phases were dried and concentrated under reduced pressure to give 17.9 g of the crude product as a yellow oil.

(b) 3-Hydroxymethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester

10% Pd-C (6.1 g) and ammonium formate (10g, 158 mmol) were added to a solution of (1-Benzyl-pyrrolidin-3-yl)-methanol (6.1 g, 32 mmol) in methanol (220 mL) under argon.

After reflux for 15 minutes the reaction mixture was filtered while warm through a pad of
5 celite, the celite was further washed with methanol, and the combined organic phases were

concentrated. The residue was dissolved in THF (35 mL) and water (35 mL), the solution
was cooled to 0°C and K₂CO₃ (22 g, 159 mmol) and di- *tert*- butyl dicarbonate (6.95 g, 32
mmol) were added. The reaction mixture was stirred at room temperature overnight. The
THF was removed under reduced pressure, water added and the aqueous phase was

10 extracted with EtOAc. The combined organic phases were dried and concentrated under
reduced pressure to give 4.64 g of the crude product. Flash chromatography
(Heptane/EtOAc: 1/0 → 68/32) of the crude product afforded 3-hydroxymethyl-
pyrrolidine-1-carboxylic acid *tert*-butyl ester (3.82 g, 60%) as a colorless oil.

15 (c) 3-Trifluoromethanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester

Methanesulfonyl chloride (0.4 mL, 5.17 mmol) was added dropwise to a solution of 3-
hydroxymethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester (1 g, 4.97 mmol) and triethyl
amine (1.04 mL, 7.46 mmol) in CH₂Cl₂ (15 mL) at 0°C. The reaction mixture was stirred at
room temperature overnight. After filtration CH₂Cl₂ was added, and the organic phase was
20 washed with 1 M HCl, dried and concentrated under reduced pressure to yield 3-
trifluoromethanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester (1.4 g,
97%).

(d) 3-Bromomethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester

25 A mixture of 3-trifluoromethanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid *tert*-
butyl ester (3.85 g, 13.8 mmol) and LiBr (3.61 g, 42 mmol) in dry acetone (30 mL) was
refluxed overnight. The reaction mixture was allowed to cool to room temperature, filtered
and concentrated. The residue was dissolved in CH₂Cl₂ and washed with water, dried and
concentrated under reduced pressure to give 6 g of the crude product. Purification by flash
30 chromatography (Heptane/EtOAc: 1/0 → 68/32) afforded 3-bromomethyl-pyrrolidine-1-
carboxylic acid *tert*-butyl ester (2.84 g, 78%) as a colourless oil.

(e) 2-(1-*tert*-Butoxycarbonyl-pyrrolidin-3-ylmethyl)-malonic acid diethyl ester

Diethyl malonate (1.93 mL, 12.7 mmol) was added dropwise to a solution of NaH (60%; 0.51 g, 12.8 mmol) in dry THF (15 mL) at 0°C. The mixture was stirred at room temperature for 1 h after which it was added to a refluxed mixture of 3-bromomethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester (2.8 g, 10.6 mmol) in dry THF (30 mL). The reaction mixture was further refluxed for 19 h, and then concentrated to almost dryness. Water (1 L) was added, and the product was extracted with CH₂Cl₂. The combined organic phases were dried and concentrated under reduced pressure to yield 3.3 g of the crude product. Purification by flash chromatography (CH₂Cl₂/EtOAc: 1/0 → 68/32) afforded 2-(1-*tert*-butoxycarbonyl-pyrrolidin-3-ylmethyl)-malonic acid diethyl ester (1.64 g, 45%).

(f) 2-(1-*tert*-Butoxycarbonyl-pyrrolidin-3-ylmethyl)-malonic acid monoethyl ester

A solution of KOH (0.26 g; 4.6 mmol) in ethanol (7 mL) was added to a solution of 2-(1-*tert*-butoxycarbonyl-pyrrolidin-3-ylmethyl)-malonic acid diethyl ester (1.52 g; 4.4 mmol) in ethanol (7 mL) at 0°C. The reaction mixture was stirred at room temperature overnight, concentrated under reduced pressure and the residue was dissolved in water (500 mL). The aqueous layer was washed with diethyl ether, acidified to pH 3 by 0.5 M HCl, and extracted with diethyl ether. The organic phase was dried and concentrated under reduced pressure to yield 2-(1-*tert*-butoxycarbonyl-pyrrolidin-3-ylmethyl)-malonic acid monoethyl ester (1.13 g, 81%).

(g) 3-(2-Ethoxycarbonyl-allyl)-pyrrolidine-1-carboxylic acid *tert*-butyl ester

Diethyl amine (0.34 mL; 3.3 mmol) was added to a mixture of 2-(1-*tert*-butoxycarbonyl-pyrrolidin-3-ylmethyl)-malonic acid monoethyl ester (0.69 g, 2.19 mmol) in 36% aqueous solution of formaldehyde (0.27 mL, 3.5 mmol), CH₂Cl₂ (1.6 mL) and water (1.6 mL) at 0°C. The reaction mixture was stirred at room temperature overnight, poured onto ice-water (500 mL) and extracted with CH₂Cl₂. The combined organic phases were washed with 5% NaHCO₃, dried and concentrated under reduced pressure to yield 3-(2-ethoxycarbonyl-allyl)-pyrrolidine-1-carboxylic acid *tert*-butyl ester (0.55 g, 87%) as a colourless oil.

(h) 3-(3-Acetylsulfanyl-2-ethoxycarbonyl-propyl)-pyrrolidine-1-carboxylic acid *tert*-butyl ester

Thioacetic acid (5 mL), which had been cooled to 0°C, was added to a mixture of 3-(2-ethoxycarbonyl-allyl)-pyrrolidine-1-carboxylic acid *tert*-butyl ester (0.72 g; 2.54 mmol) and triethyl amine (0.37 mL; 2.67 mmol) at 0°C. The reaction mixture was stirred at 0°C for 30 minutes, at room temperature for 23 hours and then poured onto ice-water (400 mL). The aqueous layer was extracted with CH₂Cl₂. The combined organic phases were washed with saturated NaHCO₃, dried and concentrated under reduced pressure. The crude product was purified by flash chromatography (CH₂Cl₂/EtOAc: 1/0 → 68/32) to yield 3-(3-acetylsulfanyl-2-ethoxycarbonyl-propyl)-pyrrolidine-1-carboxylic acid *tert*-butyl ester (0.72 g, 79%) as an oil.

(i) 2-Mercaptomethyl-3-pyrrolidin-3-yl-propionic acid

A solution of 3-(3-acetylsulfanyl-2-ethoxycarbonyl-propyl)-pyrrolidine-1-carboxylic acid *tert*-butyl ester (0.52 g; 1.45 mmol) in concentrated HCl (15 mL) was refluxed under argon for 1 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford a diastomeric mixture of the title compound as the hydrochloride salt (0.33 g; 100%).

¹H NMR (500 MHz, D₂O): δ 1.60-1.92 (m, 3H), 2.19-2.32 (m, 1H), 2.32-2.42 (m, 1H), 2.66-2.83 (m, 3H), 2.84-2.96 (m, 1H), 3.23-3.32 (m, 1H), 3.40-3.58 (m, 2H).

MS (+) 190 (M+1).

Example 25

3-(*Cis*-4-amino-cyclopent-2-enyl)-2-mercaptomethyl-propionic acid

25

(a) *Cis*-methanesulfonic acid 4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl ester

Methanesulfonyl chloride (0.76 mL, 9.8 mmol) was added to a solution of *cis*-(4-hydroxymethyl-cyclopent-2-enyl)-carbamic acid *tert*-butyl ester (2 g, 9.4 mmol) and triethyl amine (1.96 mL, 14.1 mmol) in CH₂Cl₂ (30 mL) at 0°C. The reaction mixture was stirred at room temperature overnight. After filtration CH₂Cl₂ was added, and the organic phase was washed with 1 M HCl, dried and concentrated under reduced pressure to yield

of *cis*-methanesulfonic acid 4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl ester (2.64 g, 96%).

(b) *Cis*-(4-bromomethyl-cyclopent-2-enyl)-carbamic acid *tert*-butyl ester

5 A mixture of *cis*-methanesulfonic acid 4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl ester (2.51 g, 8.6 mmol) and LiBr (2.24 g, 25.8 mmol) in dry acetone (20 mL) was refluxed overnight. The reaction mixture was allowed to cool to room temperature, filtered and concentrated. The residue was dissolved in CH₂Cl₂ and washed with water, dried and concentrated under reduced pressure to give of *cis*-(4-bromomethyl-cyclopent-2-enyl)-carbamic acid *tert*-butyl ester (2.23 g, 94%).

(c) 2-(*Cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl)-malonic acid diethyl ester
Diethyl malonate (1.29 mL, 8.5 mmol) was added to a mixture of NaH (60%, 0.34 g; 8.5 mmol) in DMF (10 mL). After stirring at room temperature for 15 min a solution of *cis*-(4-bromomethyl-cyclopent-2-enyl)-carbamic acid *tert*-butyl ester (1.95 g, 7.1 mmol) in DMF (12 mL) was added, and the reaction mixture was stirred at 60°C for 19 h. EtOAc was added and the organic phase was extracted with water and brine, dried and concentrated under reduced pressure to give 2.44 g of the crude product. Purification by flash chromatography (CH₂Cl₂/EtOAc: 1/0 → 68/32) afforded of 2-(*cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl)-malonic acid diethyl ester (1.47 g, 58%).

(d) 2-(*Cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl)-malonic acid monoethyl ester

A solution of KOH (0.19 g; 3.4 mmol) in ethanol (6 mL) was added to a solution of 2-(*Cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl)-malonic acid diethyl ester (1.15 g; 3.2 mmol) in ethanol (6 mL) at 0°C. The reaction mixture was stirred at room temperature overnight, concentrated and ice-water (400 mL) was added. The aqueous phase was washed with diethyl ether (the emulsion formed during the extraction was treated with brine in order to get good phase separation), acidified to pH 3 with 0.5 M HCl, and extracted with diethyl ether. The organic phase was dried and concentrated under reduced pressure to afford 2-(*cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl)-malonic acid monoethyl ester (0.86 g, 81%) as white crystals.

(e) 2-(Cis-4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl)-acrylic acid ethyl ester
Diethyl amine (0.31 mL; 3.0 mmol) was added to a mixture of 2-(*cis*-4-*tert*-butoxy-
carbonylamino-cyclopent-2-enylmethyl)-malonic acid monoethyl ester (0.66 g, 2.0 mmol)
in 36% aqueous solution of formaldehyde (0.25 mL, 3.2 mmol), CH₂Cl₂ (1.6 mL) and
water (1.6 mL) at 0°C. The reaction mixture was stirred at room temperature overnight,
poured onto ice-water (400 mL) and extracted with CH₂Cl₂. During the extraction, phase
separation was improved by the addition of brine. The combined organic phases were
washed with 5% NaHCO₃, dried and concentrated under reduced pressure to yield 2-(*cis*-4-
tert-butoxycarbonylamino-cyclopent-2-enylmethyl)-acrylic acid ethyl ester (0.56 g, 94%)
as an oil.

(f) 2-Acetylsulfanylmethyl-3-(*cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enyl)-propionic acid ethyl ester

15 Thioacetic acid (4 mL), which had been cooled to 0°C, was added to a mixture of 2-(*cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enylmethyl)-acrylic acid ethyl ester (0.56 g, 1.9 mmol) and triethyl amine (0.28 mL, 2.0 mmol) at 0°C. The reaction mixture was stirred at 0°C for 30 min, at room temperature for 19 h and then poured onto ice-water (400 mL). The aqueous layer was extracted with CH₂Cl₂. The organic phase was washed with

20 saturated NaHCO₃, dried and concentrated under reduced pressure to give 1.7 g of the crude product. Purification by flash chromatography (CH₂Cl₂/EtOAc: 1/0 → 68/32) afforded 2-acetylsulfanylmethyl-3-(*cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enyl)-propionic acid ethyl ester (0.46 g, 65%).

25 (g) 3-(*Cis*-4-amino-cyclopent-2-enyl)-2-mercaptomethyl-propionic acid
A solution of 2-acetylsulfanylmethyl-3-(*cis*-4-*tert*-butoxycarbonylamino-cyclopent-2-enyl)-propionic acid ethyl ester (86 mg, 0.23 mmol) in concentrated HCl (5 mL) was refluxed under argon for 1 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford a diastomeric mixture of
30 the title compound as the hydrochloride salt (65 mg).

¹H NMR (400 MHz, D₂O): δ 1.35-1.47 (m, 2H), 1.60-1.72 (m, 1H), 1.74-1.92 (m, 2H), 1.92-2.04 (m, 1H), 2.67-2.92 (m, 10H), 4.34-4.43 (m, 2H), 5.79-5.85 (br s, 2H), 6.12 (d, 1H), 6.18 (d, 1H).

5 Example 26

2-Mercaptomethyl-3-piperazin-1-yl-propionic acid

(a) 4-(2-Ethoxycarbonyl-allyl)-piperazine-1-carboxylic acid *tert*-butyl ester

To a solution of 2-bromomethyl-acrylic acid ethyl ester (1.93 g, 10 mmol) in N,N-dimethylformamide (25 mL) was added piperazine-1-carboxylic acid *tert*-butyl ester (1.86 g, 10 mmol) and then, dropwise, ethyl-diisopropyl-amine (1.71 mL, 10 mmol). After stirring for 16 h at room temperature the solvent was removed under reduced pressure and water (50 mL) and dichloromethane (50 mL) were added. After stirring for 2 min the layers were separated, the organic was washed with water and brine, and dried over magnesium sulphate. The solvent was removed under reduced pressure to give crude 4-(2-ethoxycarbonyl-allyl)-piperazine-1-carboxylic acid *tert*-butyl ester (2.456 g, 82%).

(b) 4-(3-Acetylsulfanyl-2-ethoxycarbonyl-propyl)-piperazine-1-carboxylic acid *tert*-butyl ester

To crude 4-(2-ethoxycarbonyl-allyl)-piperazine-1-carboxylic acid *tert*-butyl ester (2.45 g, 8.2 mmol) was added thiolacetic acid (7.5 mL) under argon. The mixture was cooled to 0°C and triethylamine (1.14 mL, 8.2 mmol) was added dropwise. The mixture was then stirred at room temperature for 2 d and thiolacetic acid (2.5 mL) was added. Stirring was continued for 1 d, then aqueous saturated sodium hydrogencarbonate solution was added carefully until neutral reaction and the mixture was extracted three times with dichloromethane. The combined organic layers were washed twice with aqueous saturated sodium hydrogencarbonate solution and once with brine. After drying over magnesium sulphate the solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel, 1.7% methanol in dichloromethane) to give 4-(3-acetylsulfanyl-2-ethoxycarbonyl-propyl)-piperazine-1-carboxylic acid *tert*-butyl ester (0.29 g, 9.4%).

(c) 2-Mercaptomethyl-3-piperazin-1-yl-propionic acid

To 4-(3-acetylsulfanyl-2-ethoxycarbonyl-propyl)-piperazine-1-carboxylic acid *tert*-butyl ester (0.095 g, 0.25 mmol) argon saturated hydrochloric acid (3 mL, 37%) was added and the mixture was heated under argon to reflux for 2.5 h. The solution was concentrated under reduced pressure to give the title compound as the dihydrochloride salt (0.071 g, quantitativ).

¹H NMR (300 MHz, D₂O): δ 3.86 – 3.49 (m, 10 H), 3.36 – 3.28 (m, 1 H), 3.01 – 2.88 (m, 2 H).

MS 205 (M+H).

Example 273-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-pentanoic acid(a) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-propyl]-malonic acid diethyl ester

To a stirred suspension of copper iodide (5.71 g, 30 mmol) in diethyl ether (120 mL) under argon was added ethylmagnesium bromide (3 M solution in diethyl ether, 20 mL, 20 mmol) within 10 min at 0°C. After 5 min stirring the mixture was cooled to -78°C and a solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethylene)-malonic acid diethyl ester (5.47 g, 15.0 mmol) in tetrahydrofurane (60 mL) was added dropwise within 0.5 h. During this period tetrahydrofurane (40 mL) was added. The mixture was allowed to stir at -40°C for 2.5 h. Then a solution of ammonium chloride (5%) in aqueous ammonia solution (5%) was added with vigorous stirring, allowing access of air, and the mixture was warmed up to room temperature. The mixture was extracted twice with ethyl acetate. The combined organic layers were washed successively with aqueous ammonia solution (5%) and brine, and dried over magnesium sulphate. The solvent was removed under reduced pressure and the residue was recrystallised from a mixture of diisopropyl ether and tetrahydrofurane (5:1, vol./vol.) to give 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-propyl]-malonic acid diethyl ester (3.23 g, 55%).

b) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-propyl]-malonic acid monoethyl ester

2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-propyl]-malonic acid diethyl ester (3.23 g, 8.19 mmol) was dissolved in a mixture of dichloromethane (12 mL) and ethanol (24 mL,

99.5%). To this solution was added dropwise a solution of potassium hydroxide (0.528 g, 87%, 8.20 mmol) in ethanol (16 mL, 99.5%) at 0°C over 0.5 h. Stirring was continued for 16 h while the mixture was allowed to warm up to room temperature. After concentration under reduced pressure to 5 – 10 mL, water (50 mL) was added and the resulting emulsion was stirred for 0.5 h, and then filtered. The filtrate was washed twice with a mixture of ethyl acetate and diethyl ether (2:1, vol/vol). The aqueous layer was acidified by addition of a solution of citric acid in water (10%) to reach a pH of 4 to 5, and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulphate, and the solvent was removed under reduced pressure to yield 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-propyl]-malonic acid monoethyl ester (2.47 g, 82%)

(c) 2-[1-(6-*tert*-Butoxycarbonyl-pyridin-3-yl)-propyl]-acrylic acid ethyl ester

To a solution of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-propyl]-malonic acid monoethyl ester (2.45 g, 6.69 mmol) in dichloromethane (11 mL) were added an aqueous solution of formaldehyde (0.49 mL, 37%) and diethylamine (0.62 mL, 6.4 mmol) at 0°C. After stirring the mixture vigorously for 16 h water (40 mL) and ethyl acetate (40 mL) were added. After additional 2 min stirring at room temperature the layers were separated and the aqueous was extracted twice with ethyl acetate. The combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate and brine. After drying over sodium sulphate the solvent was removed under reduced pressure to afford 2-[1-(6-*tert*-Butoxycarbonyl-pyridin-3-yl)-propyl]-acrylic acid ethyl ester (1.21 g, 54%).

(d) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-pentanoic acid ethyl ester

2-[1-(6-*tert*-Butoxycarbonyl-pyridin-3-yl)-propyl]-acrylic acid ethyl ester (1.20 g, 3.59 mmol) was dissolved in thiolacetic acid (4 mL) under argon and triethylamine (0.56 mL, 4.0 mmol) was added. The mixture was heated to 60°C. After 22 h thiolacetic acid (2 mL) was added. After additional 14 h the mixture was cooled to room temperature and a saturated solution of sodium hydrogenacarbonate was added slowly to obtain a neutral solution. This was extracted three times with ethyl acetate. The combined organic layers were washed with aqueous saturated sodium hydrogencarbonate solution and brine, and

dried over magnesium sulphate. After concentration under reduced pressure the residue was purified by column chromatography (silica gel, 1.7% methanol in dichloromethane) to yield 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-pentanoic acid ethyl ester (1.22 g, 83%).

5

The mixture of diastereomers was separated in preparative scale by chiral chromatography using a Chiralpak AD column (250*4.6 mm) as stationary phase and hexane (mixture of isomers)/ethanol mixture (85:15), containing diethylamine (0.05%) at a flow rate of 1 mL/min with a sample concentration of 5 mg/mL.

10

The enantiomeric excess was determined analytically by chiral HPLC on the same column with hexane/ethanol mixture (85:15) as eluent.

2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-pentanoic acid ethyl ester/A:

15

Retention time 10.72 min, ee = 99%.

2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-pentanoic acid ethyl ester/B

Retention time 14.41 min, ee = 98%

20

2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-pentanoic acid ethyl ester/C

Retention time 23.01 min, ee = 98%

25

2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-pentanoic acid ethyl ester/D

Retention time 29.83 min, ee = 97%

(e) 3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-pentanoic acid

30

Hydrochloric acid (38%, 4 mL) was added to 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-pentanoic acid ethyl ester (0.041 g, 0.1 mmol) under argon and the mixture was heated to reflux for 4 h. Concentration under reduced pressure

11.

11.

5

5

5

10

10

15

15

15

20

20

20

25

25

25

30

Example 283-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-4-methyl-pentanoic acid(a) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-2-methyl-propyl]-malonic acid diethyl ester

To a stirred solution of copper cyanide (3.58 g, 40 mmol) in tetrahydrofuran (50 mL) at -15°C a solution of isopropylmagnesium bromide (40 mL, 2 M, 80 mmol) in tetrahydrofuran was added under argon over 15 min. After additional 15 min stirring a solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethylene)-malonic acid diethyl ester (3.78 g, 10.4 mmol) in tetrahydrofuran (50 mL) was added dropwise over 15 min. After stirring for 16 h the mixture was allowed to warm up to room temperature. Then a solution of ammonium chloride (5%) in aqueous ammonia solution (5%) was added with vigorous stirring, allowing access of air. The mixture was extracted twice with ethyl acetate. The combined organic layers were washed successively with aqueous ammonia solution (5%) and brine, and dried over magnesium sulphate. The solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel, 1.7% methanol in dichloromethane) to give crude 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-methyl-propyl]-malonic acid diethyl ester (2.85 g, 25%).

(b) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-2-methyl-propyl]-malonic acid monoethyl ester

To a solution of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-methyl-propyl]-malonic acid diethyl ester (1.569 g, 3.84 mmol) in a mixture of dichloromethane (6 mL) and ethanol (12 mL, 95%) at 0°C a solution of potassium hydroxide (0.272 g, 85%, 4.2 mmol) in ethanol (6 mL, 95%) was added dropwise over 40 min. After additional 1 h stirring the mixture was allowed to warm up to room temperature and stirring was continued for 18 h. Then water (30 mL) and dichloromethane (30 mL) were added, and after 3 min stirring the layers were separated. The organic was extracted once with water and the combined aqueous were washed once with ether. Then an aqueous solution of citric acid (10%) was added to adjust the pH to 4, and the solution was extracted three times with ethyl acetate. The combined organic layers were washed with brine and dried over magnesium sulphate.

After evaporation of the solvent crude 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-methyl-propyl]-malonic acid monoethyl ester (0.94 g, 64%) was obtained.

(c) 2-[1-(6-*tert*-Butoxycarbonyl-pyridin-3-yl)-2-methyl-propyl]-acrylic acid ethyl ester

- 5 To a solution of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-methyl-propyl]-malonic acid monoethyl ester (0.94 g, 2.47 mmol) in dichloromethane (4 mL) were added an aqueous solution of formaldehyde (0.18 mL, 37%) and diethylamine (0.23 mL, 2.32 mmol) at 0°C. After stirring the mixture vigorously for 16 h water (30 mL) and ethyl acetate (30 mL) were added. After additional 2 min stirring at room temperature the layers were
- 10 separated and the aqueous was extracted twice with ethyl acetate. The combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate and brine. After drying over sodium sulphate the solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel, 1.7% methanol in dichloromethane) to give 2-[1-(6-*tert*-butoxycarbonyl-pyridin-3-yl)-2-methyl-propyl]-
- 15 acrylic acid ethyl ester (0.24 g, 28%).

(d) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-4-methyl-pentanoic acid ethyl ester

- 2-[1-(6-*tert*-Butoxycarbonyl-pyridin-3-yl)-2-methyl-propyl]-acrylic acid ethyl ester (0.431 g, 1.24 mmol) was dissolved in thiolacetic acid (4 mL) under argon and triethylamine (0.21 mL, 1.5 mmol) was added. The mixture was heated to 60°C. After 24 h thiolacetic acid (2 mL) was added. After additional 20 h the mixture was cooled to room temperature and a saturated solution of sodium hydrogenacarbonate was added slowly to obtain a neutral solution. This was extracted three times with ethyl acetate. The combined organic layers
- 25 were washed with aqueous saturated sodium hydrogencarbonate solution and brine, and dried over magnesium sulphate. After concentration under reduced pressure the residue was purified by column chromatography (silica gel, 1.7% methanol in dichloromethane) to yield 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-4-methyl-pentanoic acid ethyl ester (0.284 g, 54%) as a mixture of diastereomers (6:1).

(e) 3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-4-methyl-pentanoic acid

Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-4-methyl-pentanoic acid ethyl ester (0.085 g, 0.20 mmol) was dissolved in argon saturated hydrochloric acid (5 mL, 37%) and heated to reflux under argon for 5.5 h. Concentration under reduced pressure and drying at 45°C/0.3 mbar gave the title compound as the hydrochloride salt (0.058 g, 99%) as a mixture of diastereomers (6:1).

¹H NMR (300 MHz, D₂O): δ 7.81 (m, 1 H), 7.62 (m, 1 H), 6.98 (m, 1 H), 3.18 – 3.06 (m, 1 H), 2.93 – 2.40 (m, 3 H), 2.23 – 1.93 (m, 1 H), 0.93 – 0.74 (m, 6 H).

MS 255 (M+H)

Example 29

3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-3-phenyl-propionic acid

(a) 2-[(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-malonic acid diethyl ester

To a vigorously stirred suspension of copper(I)cyanide (1.71 g, 19.06 mmol) in dry THF (18 mL) was added a solution of phenylmagnesium bromide (12.7 mL 3 M in ether, 38.11 mmol) at 0°C under argon. The mixture was allowed to warm to room temperature, giving a dark brown solution. After 150 minutes a solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethylene)-malonic acid diethyl ester (1.74 g, 4.76 mmol) in dry THF (19 mL) was added at 0°C. The mixture was left stirring for 3 days then aqueous ammonium chloride was added. The aqueous layer was separated and extracted with ethyl acetate. The combined organic layers were washed with brine and dried. Removal of the solvent *in vacuo* gave a residue, which was suspended in hexane. Filtration of the crystals gave 2-[(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-malonic acid diethyl ester (1.85 g, 88%).

(b) 2-[(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-malonic acid monoethyl ester

A solution of KOH (0.266 g, 4.11 mmol) in ethanol (14 mL) was added to a solution of 2-[(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-malonic acid diethyl ester (1.82 g, 4.11 mmol) in ethanol (12 mL) and methylene chloride (13 mL) at 0°C. The

mixture was stirred overnight at room temperature. More KOH (80 mg dissolved in 3 mL ethanol) was added at 0°C. The reaction mixture was stirred for additional 18 h. The mixture was concentrated under reduced pressure and ethyl acetate, and 0.5 M HCl were added to the residue. The organic layer was washed with brine and dried. After filtration and evaporation *in vacuo*, the residue was suspended in hexane. Filtration of the crystals gave 2-[(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-malonic acid monoethyl ester (1.7 g, 98%).

(c) 2-[(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-acrylic acid ethyl ester

Diethylamine (0.52 mL, 5.04 mmol) was added to a mixture of 2-[(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-malonic acid monoethyl ester (1.7 g, 4.1 mmol) and 37 % aq. solution of formaldehyde (0.42 mL, 5.6 mmol) in methylene chloride (6.5 mL) at 0°C. The mixture was stirred overnight at room temperature and then diluted with ethyl acetate. The organic layer was washed with aqueous saturated sodium bicarbonate and brine and dried. After filtration and evaporation *in vacuo* the crude product was purified by flash chromatography (CH₂Cl₂) to yield 2-[(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-acrylic acid ethyl ester (0.36 g, 23%).

(d) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-3-phenyl-propionic acid ethyl ester

Triethylamine (0.105 g, 1.04 mmol) was added to a solution of 2-[(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-phenyl-methyl]-acrylic acid ethyl ester (0.36 g, 0.94 mmol) in thioacetic acid (4 mL) at 0°C under argon. The mixture was heated at 45°C for 24 h. Ethyl acetate was added and the organic phase was washed with aqueous saturated sodium bicarbonate and brine and dried. After filtration and evaporation *in vacuo* the crude product was purified by flash chromatography (toluene/ethyl acetate, 1:0 → 5:1) to give 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-3-phenyl-propionic acid ethyl ester (0.314 g, 73%).

3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-3-phenyl-propionic acid

2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-3-phenyl-propionic acid ethyl ester (58 mg, 0.125 mmol) was dissolved in conc. HCl (3.0 mL). The solution was heated to reflux for 130 min under argon. Concentration under reduced pressure gave the title compound as the hydrochloride salt (41 mg, 100 %).

¹H NMR (500 MHz, D₂O): δ 8.03-7.83 (m, 2H), 7.5-7.3 (m, 5H), 7.05-6.95 (m, 1H), 4.27-4.15 (m, 1H), 3.6-3.45 (m, 1H), 2.84-2.58 (m, 2H).

MS (+) 289 (M+1).

Example 30

3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-4-phenyl-butyric acid

(a) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-malonic acid diethyl ester

To a vigorously stirred suspension of copper(I)cyanide (0.66 g, 7.32 mmol) in dry THF (5 mL) was added a solution of benzylmagnesium bromide (5 mL 2.93 M in ether, 14.64 mmol) at 0°C under argon. The mixture was allowed to warm to room temperature, giving a dark brown solution. After 60 minutes a solution of 2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethylene)-malonic acid diethyl ester (0.67 g, 1.83 mmol) in dry THF (4 mL) was added at 0°C. The mixture was stirred overnight at room temperature then aqueous ammonium chloride was added. The aqueous layer was separated and extracted with ethyl acetate. The combined organic layers were washed with brine and dried. Removal of the solvent *in vacuo* gave a residue which was purified by flash chromatography (CH₂Cl₂/ethyl acetate, 1:0 → 100:15) to give 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-malonic acid diethyl ester (0.44 g, 53%).

(b) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-malonic acid
monoethyl ester

A solution of KOH (0.067 g, 1.03 mmol) in ethanol (3 mL) was added to a solution of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-malonic acid diethyl ester (0.44 g, 0.96 mmol) in ethanol (3 mL) and methylene chloride (2 mL) at 0°C. The mixture

was stirred for 48 h at room temperature. The mixture was concentrated under reduced pressure and ethyl acetate and 0.5 M HCl were added to the residue. The organic layer was washed with brine and dried. Filtration and evaporation *in vacuo* gave 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-malonic acid monoethyl ester (0.37, 90%).

(c) 2-[1-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-acrylic acid ethyl ester

Diethylamine (0.27 mL, 2.59 mmol) was added to a mixture of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-malonic acid monoethyl ester (0.37 g, 0.86 mmol) and 37 % aq. solution of formaldehyde (0.22 mL, 2.9 mmol) in methylene chloride (3.5 mL) at 0°C. The mixture was stirred overnight at room temperature. More formaldehyde (0.24 mL) and diethylamine (0.24 mL) was added. Stirring at room temperature was continued for 18 h and ethyl acetate and water was then added. The organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried and concentrated under reduced pressure to give 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-acrylic acid ethyl ester (0.34 g, 99%).

(d) 2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-4-phenyl-butyric acid ethyl ester

Triethylamine (0.096 g, 0.95 mmol) was added to a solution of 2-[1-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-phenyl-ethyl]-acrylic acid ethyl ester (0.34 g, 0.86 mmol) in thioacetic acid (3.5 mL) at 0°C under argon. The mixture was heated at 45°C for 24 h. Ethyl acetate was added and the organic phase was washed with aqueous saturated sodium bicarbonate and brine and dried. After filtration and evaporation *in vacuo* the crude product was purified by flash chromatography (CH₂Cl₂/ethyl acetate, 1:0 → 100:5) to give 2-acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-4-phenyl-butyric acid ethyl ester (0.264 g, 65%).

(e) 3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-4-phenyl-butyric acid

2-Acetylsulfanylmethyl-3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-4-phenyl-butyric acid ethyl ester (0.14 g, 0.3 mmol) was dissolved in conc. HCl (5.0 mL). The solution was

heated to reflux for 4.5 h under argon. Concentration under reduced pressure gave the title compound as the hydrochloride salt (100 mg, 98 %).

¹H NMR (500 MHz, D₂O): δ 7.90-7.83 (m, 1H), 7.43 (d, 1H), 7.34-7.18 (m, 3H), 7.17-7.06 (m, 2H), 7.01-6.9 (m, 1H), 3.4-2.5 (m, 6H).

5 MS (+) 303 (M+1).

Example 31

2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-5-phenyl-pentanoic acid

10 (a) Ethyl (E,Z)-2-({6-[(*tert*-butoxycarbonyl)amino]-3-pyridinyl}methyl)-5-phenyl-2-
pentenoate

To a suspension of NaH (310 mg, 7.12 mmol, 55% in mineral oil) in THF (25 mL) at 0°C under argon was added a solution of (ethyl 3-{6-[(*tert*-butoxycarbonyl)amino]-3-pyridinyl}-2-(diethoxyphosphoryl)propanoate (2.55 g, 5.95 mmol) in THF (25 mL). After 1 h, a solution of 3-phenylpropanal (1.59 g, 11.9 mmol) was added dropwise. The reaction was stirred for 17 h at room temperature, then quenched with NH₄Cl (50 mL, sat, aq). The mixture was extracted with ethyl acetate, the organic layer was washed with brine, dried (Na₂SO₄), filtered and concentrated under reduced pressure. Column chromatography (CH₂Cl₂/EtOAc 20:1 → 10:1) gave ethyl (*E,Z*)-2-({6-[(*tert*-butoxycarbonyl)amino]-3-pyridinyl}methyl)-5-phenyl-2-pentenoate (2.49 g, 100%).

(b) Ethyl 3-(acetylsulfanyl)-2-({6-[(*tert*-butoxycarbonyl)amino]-3-pyridinyl}methyl)-5-phenylpentanoate

Triethylamine (1.22 mL, 0.617 mmol) was added to a solution of ethyl (*E,Z*)-2-({6-[(*tert*-
butoxycarbonyl)amino]-3-pyridinyl}methyl)-5-phenyl-2-pentenoate (400 mg, 0.597 mmol)
in thioacetic acid (10 mL) at 40°C. After stirring for 90 h., the mixture was concentrated
under reduced pressure. Column chromatography (CH₂Cl₂/EtOAc 20:1 → 10:1), then
(toluene/EtOAc, 10:1) and then (heptane/EtOAc 2:1) gave ethyl 3-(acetylsulfanyl)-2-({6-
[(*tert*-butoxycarbonyl)amino]-3-pyridinyl}methyl)-5-phenylpentanoate (126 mg, 27%) as a
diastereomeric mixture 1:1.

(c) 2-(6-Amino-pyridin-3-ylmethyl)-3-mercapto-5-phenyl-pentanoic acid

Ethyl 3-(acetylsulfanyl)-2-({6-[(*tert*-butoxycarbonyl)amino]-3-pyridinyl}methyl)-5-phenylpentanoate (9 mg, 18.5 μ mol) was dissolved in conc. HCl (1 mL) under argon. The solution was heated to reflux for 4.5 h. Concentration under reduced pressure yielded the title compound as the hydrochloride salt (6.4 mg, 98 %) as a diastereomeric mixture 1:1. ¹H NMR (400 MHz, D₂O): δ 1.78-2.20 (m, 2H), 2.70-3.04 (m, 6H), 6.88, 6.92 (2d, 1H), 7.22-7.39 (m, 5H), 7.52, 7.54 (2d, 1H), 7.69, 7.75 (2d, 1H). MS (+) 317 (M+1).

Example 32

3-[3-(6-Amino-pyridin-3-yl)-2-ethoxycarbonyl-propyldisulfanyl]-2-(6-amino-pyridin-3-ylmethyl)-propionic acid ethyl ester

(a) 3-[3-(6-*tert*-Butoxycarbonylamino-pyridin-3-yl)-2-ethoxycarbonyl-propyldisulfanyl]-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-propionic acid ethyl ester

3-Acetylsulfanyl-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-propionic acid ethyl ester (150 mg, 0.392 mmol) was dissolved in ethanol (15 mL) saturated with NH₃ (g). After stirring for 160 min., the mixture was concentrated under reduced pressure. The residue was dissolved in EtOH (10 mL) whereafter a solution of I₂ in EtOH (0.5 M, 0.784 mL) was added. The reaction was stirred for 30 min. at room temperature, then diluted with CH₂Cl₂, washed with saturated aqueous Na₂S₂O₅ and saturated aqueous NaHCO₃, dried, filtered and concentrated under reduced pressure to give 3-[3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-ethoxycarbonyl-propyldisulfanyl]-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-propionic acid ethyl ester (130 mg, 98%).

(b) 3-[3-(6-Amino-pyridin-3-yl)-2-ethoxycarbonyl-propyldisulfanyl]-2-(6-amino-pyridin-3-ylmethyl)-propionic acid ethyl ester

Ethylacetate saturated with HCl (g) (15 mL) was added to a solution of 3-[3-(6-*tert*-butoxycarbonylamino-pyridin-3-yl)-2-ethoxycarbonyl-propyldisulfanyl]-2-(6-*tert*-butoxycarbonylamino-pyridin-3-ylmethyl)-propionic acid ethyl ester (130 mg, 0.191 mmol) in ethylacetate (7 mL) at 0°C. The reaction was allowed to attain room temperature and was stirred for 19 h, then evaporated under reduced pressure. The residue was

dissolved in water, saturated aqueous Na_2CO_3 was added and the aqueous phase was extracted with CH_2Cl_2 . The organic layer was dried and concentrated under reduced pressure to give the title compound (90 mg, 98%).

^1H NMR (400 MHz, CDCl_3): δ 1.19 (t, 3H), 1.20 (t, 3H), 2.68-2.86 (m, 6H), 2.90-3.01 (m, 4H), 4.07-4.14 (m, 4H), 6.45 (d, 2H), 7.28 (m, 2H), 7.87 (s, 2H).

MS (+) 479 (M+1).

Example 33

3-(6-Amino-pyridin-3-yl)-2-mercaptomethyl-hexanoic acid

(a) N-(5-Butyryl-pyridin-2-yl)-2,2-dimethyl-propionamide

A solution of N-(5-bromopyridin-2-yl)-2,2-dimethyl-propionamide (3.582 g, 13.9 mmol) in diethyl ether (36 mL) was cooled to -78°C under argon and n-butyllithium (1.6 M, 19 mL, 30.4 mmol) was added dropwise within 20 min. 5 min after complete addition the mixture was allowed to warm up to 0°C . N-Methoxy-N-methyl butyramide (3.65 g, 27.8 mmol) was added within less than 5 min and stirring was continued for 45 min. The clear solution was acidified with 2 N hydrochloric acid to pH 2. After vigorous stirring for 15 min the mixture was neutralised with sodium hydrogen carbonate and the layers were separated. The aqueous layer was extracted three times with diethyl ether. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The resulting oil was dried in oil pump vacuum to remove the excess reagent. After flash chromatography (dichloromethane / methanol 60:1) crude N-(5-butyryl-pyridin-2-yl)-2,2-dimethyl-propionamide (2.47 g, 71%) was obtained as a light orange oil which was not purified further.

(b) N-[5-(1-Hydroxy-butyl)-pyridin-2-yl]-2,2-dimethyl-propionamide

To a solution of N-(5-butyryl-pyridin-2-yl)-2,2-dimethyl-propionamide (2.47 g, 9.95 mmol) in ethanol (20 mL) sodium borohydride (185 mg, 5.0 mmol) was added. After 40 min stirring at room temperature the mixture was acidified with 1 N hydrochloric acid to pH 2 and stirred for 10 min. After neutralisation with sodium hydrogencarbonate the mixture was extracted three times with dichloromethane. The combined organic extracts were washed twice with sodium hydrogen carbonate solution and once with brine. After

drying and concentration under reduced pressure the residue was purified by flash chromatography (dichloromethane/methanol 30:1) to give N-[5-(1-hydroxy-butyl)-pyridin-2-yl]-2,2-dimethyl-propionamide (1.025 g, 41%).

5 (c) 2-{1-[6-(2,2-Dimethyl-propionylamino)-pyridin-3-yl]-butyl}-malonic acid monoethyl ester

To a solution of N-[5-(1-hydroxy-butyl)-pyridin-2-yl]-2,2-dimethyl-propionamide (1.025 g, 4.09 mmol) in trichloromethane (12 mL), thionylchloride (6 mL) was added and the mixture was heated to 55°C for 1 h. Then the solution was concentrated under reduced
10 pressure to leave crude N-[5-(1-chloro-butyl)-pyridin-2-yl]-2,2-dimethyl-propionamide hydrochloride as a colourless solid.

To a solution of diethyl malonate (1.31 g, 8.2 mmol) in dimethylformamide (20 mL) sodium hydride (60% dispersion in mineral oil, 350 mg, 8.7 mmol) was added and the mixture was stirred at room temperature for 15 min. After cooling to 0°C the solution of
15 the intermediate N-[5-(1-chloro-butyl)-pyridin-2-yl]-2,2-dimethyl-propionamide hydrochloride in dimethylformamide (5 mL) was added. After 1 h stirring the solvent was concentrated under reduced pressure and ethyl acetate (25 mL) was added followed by ammonium chloride solution (half-saturated) for neutralisation. The layers were separated, the aqueous was extracted with ethyl acetate and the combined organic layers were washed
20 three times with water and brine, and dried. After concentrated under reduced pressure the residue was filtered through silica gel with dichloromethane/methanol mixture (30:1) as solvent.

This crude 2-{1-[6-(2,2-dimethyl-propionylamino)-pyridin-3-yl]-butyl}-malonic acid diethyl ester was dissolved in a mixture of dichloromethane (2.5 mL) and ethanol (5 mL) at
25 0°C and a solution of potassium hydroxide (87%, 111 mg, 5.4 mmol) in ethanol (4 mL) was added. The mixture was allowed to warm up slowly to room temperature and stirring was continued for 24 h. Then dichloromethane (20 mL), water (20 mL) and brine (3 mL) was added. The mixture was stirred vigorously for 2 min. Then the layers were separated, the aqueous was washed with dichloromethane. The combined aqueous layers were
30 acidified (pH 5) with citric acid, and extracted three times with dichloromethane. The combined organic layers were washed with brine and dried. Concentration under reduced

pressure gave crude 2-{1-[6-(2,2-dimethyl-propionylamino)-pyridin-3-yl]-butyl}-malonic acid monoethyl ester (258 mg, 41%).

(d) 2-{1-[6-(2,2-Dimethyl-propionylamino)-pyridin-3-yl]-butyl}-acrylic acid ethyl ester

5 To a solution of 2-{1-[6-(2,2-dimethyl-propionylamino)-pyridin-3-yl]-butyl}-malonic acid monoethyl ester (712 mg, 1.95 mmol) in THF (6.5 mL) at 0°C formaldehyde (37% in water, 0.3 mL) was added within 5 min. Stirring was continued for 10 min, then piperidine (0.26 mL, 2.63 mmol) was added dropwise within 10 min. The mixture was allowed to warm up overnight to room temperature. After 14 h the mixture was concentrated under
10 reduced pressure to one third of its volume, then ether and water were added (15 mL each). After 2 min vigorous stirring the layers were separated, the aqueous was extracted with ether and the combined organic layers were washed with water, 4 % citric acid, water and brine. Drying and concentration under reduced pressure gave 2-{1-[6-(2,2-dimethyl-propionylamino)-pyridin-3-yl]-butyl}-acrylic acid ethyl ester (550 mg, 85%) as a
15 colourless solid.

(e) 2-Acetylsulfanylmethyl-3-[6-(2,2-dimethyl-propionylamino)-pyridin-3-yl]-hexanoic acid ethyl ester

2-{1-[6-(2,2-Dimethyl-propionylamino)-pyridin-3-yl]-butyl}-acrylic acid ethyl ester (550
20 mg, 1.65 mmol) was dissolved under argon in thiolacetic acid (4 mL), and triethylamine (0.24 mL, 1.7 mmol) was added dropwise. After stirring for 16 h at 50°C thiolacetic acid (2 mL) was added and stirring was continued for 14 h. The solution was cooled to room temperature and neutralised by addition of sodium hydrogen carbonate solution. The mixture was extracted three times with ethyl acetate, the combined extracts were washed
25 with sodium hydrogen carbonate solution and brine. After drying and concentration under reduced pressure the residue was purified by flash chromatography (dichloromethane/methanol, 60:1) to give 2-acetylsulfanylmethyl-3-[6-(2,2-dimethyl-propionylamino)-pyridin-3-yl]-hexanoic acid ethyl ester (619 mg, 92%) as a viscous oil.

30 (f) 3-(6-Amino-pyridin-3-yl)-2-mercaptopomethyl-hexanoic acid

2-Acetylsulfanylmethyl-3-[6-(2,2-dimethyl-propionylamino)-pyridin-3-yl]-hexanoic acid ethyl ester (40.4 mg, 99 μ mol) was dissolved under argon in aqueous hydrochloric acid

(37%, 4.2 mL) and heated under reflux for 2 h. Concentration under reduced pressure (0.3 torr, 40°C) gave the title compound as the hydrochloride salt (28 mg, 97%).

¹H NMR (300 MHz, D₂O): δ 7.86 (d, 1H), 7.65 (d, 1H), 7.02 (t, 1H), 2.98-2.42 (m, 4 H), 1.85-1.54 (m, 2 H), 1.19-1.00 (m, 2 H), 0.87-0.77 (m, 3H).

5 MS (+) 255 (M+1).

Example 34

3-(2-Amino-thiazol-5-yl)-2-mercaptopomethyl-propionic acid

10 (a) 2-(2-Amino-thiazol-5-ylmethylene)-malonic acid diethyl ester

To a solution of 2-amino-thiazole-5-carbaldehyde (47%; 6 g; 23 mmol) in CH₂Cl₂ (30 mL) and DMF (30 mL), was added 4A molecular sieves, diethyl malonate (3.5 mL; 23 mmol), piperidine (1.1 mL; 11.5 mmol) and acetic acid (0.7 mL; 11.5 mmol). The reaction mixture was stirred at room temperature for 96 hours. Then EtOAc was added, and the reaction mixture was filtered through celite in order to remove the precipitate formed. EtOAc (500 mL) was added to the filtrate, and the organic phase was washed with NaHCO₃ and brine. The organic phase was dried and concentrated to yield 4.9 g of the crude product. Addition of petroleum ether to a solution of the crude product in ethanol followed by filtration afforded 2-(2-amino-thiazol-5-ylmethylene)-malonic acid diethyl ester (1.13 g, 18%).

20

(b) 2-(2-Amino-thiazol-5-ylmethyl)-malonic acid diethyl ester

NaCNBH₃ (1.88 g; 29.9 mmol) was added to a stirred solution of 2-(2-amino-thiazol-5-ylmethylene)-malonic acid diethyl ester (1.13 g; 4.2 mmol) in ethanol at 0°C. The pH of the solution was monitored by addition of a small amount of Bromocresol Green to the solution. Concentrated HCl was added dropwise until the solution turned yellow. The ice bath was removed, and the reaction mixture was stirred at room temperature for 5 hours. Water was added and the product was extracted with CH₂Cl₂. The combined organic phases were dried and concentrated to yield 2-(2-amino-thiazol-5-ylmethyl)-malonic acid diethyl ester (1 g, 87.8%).

30

(c) 2-(2-*tert*-Butoxycarbonylamino-thiazol-5-ylmethyl)-malonic acid diethyl ester

BOC₂O (0.6 g; 27.5 mmol) was added to a solution of triethyl amine (0.4 mL; 30.1 mmol), 4-(dimethylamino)pyridine (0.34 g; 27.8 mmol) and 2-(2-amino-thiazol-5-ylmethyl)-malonic acid diethyl ester (0.75 g; 27.5 mmol) in CH₂Cl₂ (5 mL) at 0°C. The reaction mixture was stirred at room temperature overnight. Additional BOC₂O (0.15 g; 0.7 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 1 hour. CH₂Cl₂ was added, and the organic phase was extracted with 0.3 M KHSO₄ and brine). The organic phase was dried and concentrated to yield 0.78 g of the crude product. NMR indicated that approximately 40% of 2-(2-amino-thiazol-5-ylmethyl)-malonic acid diethyl ester remained. BOC₂O (0.6 g; 27.5 mmol) was added to a solution of the crude product (0.78 g), triethyl amine (0.4 mL; 30.1 mmol), 4-(dimethylamino)pyridine (0.34 g; 27.8 mmol) in CH₂Cl₂ (5 mL) at 0°C. The reaction mixture was stirred at room temperature overnight and the work up procedure was repeated. The crude product (1 g) was purified by flash chromatography (Heptane/EtOAc; 1:1) and HPLC to afford 2-(2-*tert*-butoxycarbonylamino-thiazol-5-ylmethyl)-malonic acid diethyl ester (184 mg, 17.9%).

(d) 2-(2-*tert*- Butoxycarbonylamino-thiazol-5-ylmethyl)-malonic acid monoethyl ester

2-(2-*tert*-Butoxycarbonylamino-thiazol-5-ylmethyl)-malonic acid diethyl ester (158 mg; 0.43 mmol) was dissolved in ethanol (1 mL) and THF (0.5 mL), and a solution of KOH (24 mg; 0.43 mmol) in ethanol (0.14 mL) was added at 0°C. The reaction mixture was stirred at room temperature for 96 hours, and then poured onto ice-water. The aqueous phase was extracted with diethyl ether, acidified to pH 3 by addition of 0.5 M HCl, and extracted with diethyl ether. The combined organic phases were dried and concentrated to yield 2-(2-*tert*-butoxycarbonylamino-thiazol-5-ylmethyl)-malonic acid monoethyl ester (97 mg, 66.4%).

(e) 2-(2-*tert*-Butoxycarbonylamino-thiazol-5-ylmethyl)-acrylic acid ethyl ester

To a mixture of 2-(2-*tert*-butoxycarbonylamino-thiazol-5-ylmethyl)-malonic acid monoethyl ester (94 mg; 0.27 mmol), a 36% aqueous solution of formaldehyde (36 μ l; 1.2 mmol), CH₂Cl₂ (0.2 mL) and water (0.2 mL) was added at 0°C diethyl amine (30 μ l; 0.40 mmol). The reaction mixture was stirred at room temperature overnight, poured onto ice-water and extracted with CH₂Cl₂. The combined organic phases were washed with 5%

NaHCO₃, dried and concentrated to yield 2-(2-*tert*-butoxycarbonylamino-thiazol-5-ylmethyl)-acrylic acid ethyl ester (69 mg, 80.9%).

(f) 2-Acetylsulfanylmethyl-3-(2-*tert*-butoxycarbonylamino-thiazol-5-yl)-propionic acid ethyl ester

Triethyl amine (32 μ l; 0.23 mmol) was added to a solution of 2-(2-*tert*-butoxycarbonylamino-thiazol-5-ylmethyl)-acrylic acid ethyl ester (67 mg; 0.21 mmol) in thioacetic acid (0.4 mL) at 0°C. The reaction mixture was stirred at room temperature for 48 hours, and then poured onto ice-water. The aqueous layer was extracted with CH₂Cl₂. The combined organic phases were washed with saturated NaHCO₃, dried and concentrated to yield 190 mg of the crude product. The crude product was purified by flash chromatography (Heptane/EtOAc: 1:0 \rightarrow 68:32) to yield 2-acetylsulfanylmethyl-3-(2-*tert*-butoxycarbonylamino-thiazol-5-yl)-propionic acid ethyl ester (43 mg, 51.6%).

(g) 3-(2-Amino-thiazol-5-yl)-2-mercaptomethyl-propionic acid

A solution of 2-acetylsulfanylmethyl-3-(2-*tert*-butoxycarbonylamino-thiazol-5-yl)-propionic acid ethyl ester (43 mg; 0.11 mmol) in concentrated HCl (1.5 mL) was refluxed under argon for 1.5 hours. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure to yield 30 mg of the crude product. The crude product was purified by preparative HPLC to afford the title compound (8 mg; 21%) as the hydrochloride salt.

¹H NMR (500 MHz, D₂O): δ 2.75-3.1 (m, 5H), 7.0 (br s, 1H).

MS (+) 219 (M+1).

Abbreviations

Ac = acetate

aq = aqueous

AIBN = α,α' -azoisobutyronitrile

Bn = benzyl

Bu = butyl


Bz = benzoyl

DCC = dicyclohexylcarbodiimide

- DIAD = diisopropyl azodicarboxylate
DIPEA = diisopropylethylamine
DMAP = N,N-dimethyl amino pyridine
DME = 1,2-dimethoxyethane
5 DMF = dimethylformamide
DMSO = dimethylsulfoxide
EDC = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
ee = enantiomeric excess
Et = ethyl
10 EtOAc = ethyl acetate
EtOH = ethanol
h = hour
HOAc = acetic acid
HOBt = 1-hydroxybenzotriazol
15 HPLC = high performance liquid chromatography
KHMDs = potassium bis(trimethylsilyl)amide
LDA = lithium diisopropylamide
MCPBA = 3-chloroperbenzoic acid
Me = methyl
20 MeOH = methanol
min = minutes
PMB = 4-methoxybenzyl
Ph = phenyl
Pr = propyl
25 PyBOP = (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
TEA = triethylamine
TFA = trifluoroacetic acid
THF = tetrahydrofuran
Tos = toluene-4-sulfonyl

CLAIMS

1. A compound of general Formula I



5

or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,
wherein

R_1 represents,

- C_1 - C_6 alkyl, substituted with one or more basic groups such as amino, amidino and/or
 10 guanidino;
 cycloalkyl, substituted with one or more basic groups such as amino, amidino and/or
 guanidino;
 heterocyclyl, containing at least one nitrogen atom;
 heterocyclyl, containing at least one hetero atom selected from S or O,
 15 and substituted with one or more basic groups such as amino, amidino and/or
 guanidino;
 or aryl, substituted with one or more basic groups such as amino, amidino and/or
 guanidino,

R_2 represents H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl,

- 20 aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano,
 cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, Z_2N -
 CO-O-, ZO-CO-NZ- or Z_2N -CO-NZ- group,

R_3 represents $COOR_5$, $SO(OR_5)$, SO_3R_5 , $P=O(OR_5)_2$, $B(OR_5)_2$, $P=OR_5(OR_5)$, or tetrazole,
or any carboxylic acid isostere,

- 25 R_4 represents SH, S-CO- C_1 - C_6 alkyl or S-CO-aryl,

R_5 represents H, C_1 - C_6 alkyl or aryl,

R_6 represents H or C_1 - C_6 alkyl,

X represents O, S, SO, SO_2 , $C(Z)_2$, N(Z), NR_6SO_2 , SO_2NR_6 , NR_6CO or $CONR_6$,

Y represents $C(Z)_2$,

Z represents independently H, C₁-C₆ alkyl, aryl, cycloalkyl or heterocyclyl.

2. The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,

5 wherein

R₁ represents,

cycloalkyl, substituted with one or more basic groups such as amino, amidino and/or guanidino;

heterocyclyl, containing at least one nitrogen atom;

10 heterocyclyl, containing at least one hetero atom selected from S or O, and substituted with one or more basic groups such as amino, amidino and/or guanidino;

or aryl, substituted with one or more basic groups such as amino, amidino and/or guanidino;

R₂ represents H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl,

15 aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, Z₂N-CO-O-, ZO-CO-NZ- or Z₂N-CO-NZ- group,

R₃ represents COOR₅,

R₄ represents SH, S-CO-C₁-C₆ alkyl or S-CO-aryl,

20 R₅ represents H, C₁-C₆ alkyl or aryl,

R₆ represents H or C₁-C₆ alkyl,

X represents O, S, SO, SO₂, C(Z)₂, N(Z), NR₆SO₂, SO₂NR₆, or CONR₆,

Y represents C(Z)₂,

Z represents independently H, C₁-C₆ alkyl, aryl, cycloalkyl or heterocyclyl.

25 3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,

wherein

R₁ represents,

30 cycloalkyl, substituted with one or more basic groups such as amino, amidino and/or guanidino;

heterocyclyl, containing at least one nitrogen atom;

heterocyclyl, containing at least one hetero atom selected from S or O, and substituted with one or more basic groups such as amino, amidino and/or guanidino;

R₂ represents H, C₁-C₃ alkyl, amino, halogen, hydroxy,

R₃ represents COOR₅,

5 R₄ represents SH, S-CO-C₁-C₆ alkyl or S-CO-aryl,

R₅ represents H, C₁-C₆ alkyl or aryl,

X represents C(Z)₂,

Y represents C(Z)₂,

Z represents independently H or C₁-C₆ alkyl.

10

4. The compound according to any previous claim, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,

wherein

R₁ represents,

15 cycloalkyl, substituted with one or more basic groups such as amino, amidino and/or guanidino;

heterocyclyl, containing at least one nitrogen atom;

R₂ represents H, F, or C₁ alkyl,

R₃ represents COOR₅,

20 R₄ represents SH, S-CO-C₁-C₆ alkyl or S-CO-aryl,

R₅ represents H, C₁-C₆ alkyl or aryl,

X represents C(Z)₂,

Y represents C(Z)₂,

Z represents independently H or C₁-C₆ alkyl.

25

5. The compound according to any previous claim, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein

R₁ represents cyclopentyl, pyridyl, pyrimidinyl, piperidinyl or thiazolyl,

R₂ represents H, F, or C₁ alkyl,

30 R₃ represents COOR₅,

R₄ represents SH,

R₅ represents H,


(XIV)

wherein R_1 , R_2 , and R_3 are as defined in claim 1 and X is O, S, $C(Z)_2$, or $N(Z)$, with a compound of general Formula IX,



wherein R_5 is a suitable protecting group, such as Ac or Bz, in the presence of a suitable reagent, such as PPh_3 /DIAD, under standard conditions.

8. A process for the preparation of a compound according to any one of claims 1-5, wherein R_1 , R_2 , R_3 , R_4 , and Y are as defined in claim 1 and X is NR_6CO , or NR_6SO_2 comprising the step of:
- 10 reacting a compound of the general Formula XV,



wherein R_2 , R_3 , R_6 and Y are as defined in claim 1 and R_5 is a suitable protecting group, such as Ac, Bz, PMB or Bn, with a compound of the general Formula XVI,



15

wherein R_1 is as defined for in claim 1 and X is $COOH$ or SO_2Cl in the presence of suitable coupling reagents, such as PyBOP/DIPEA, DCC/HOBt, EDC/TEA/DMAP or pyridine, under standard conditions.

- 20 9. A pharmaceutical formulation containing a compound according to any one of claims 1 to 5 as active ingredient in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.

10. The use of a compound according to any one of claims 1 to 5 in therapy.

25

11. The use of a compound according to any one of claims 1 to 5 for the manufacture of a medicament for the inhibition of carboxypeptidase U.

12. A method for treatment or prophylaxis of conditions associated with inhibition of carboxypeptidase U, comprising administering to a mammal, including man, in need of such treatment an effective amount of a compound as defined in any of claims 1-5.

13. A pharmaceutical formulation for use in the treatment or prophylaxis of conditions associated with inhibition of carboxypeptidase U, comprising a compound as defined in any of claims 1-5 in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.

14. A pharmaceutical formulation, comprising:

- (i) a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, and
- (ii) one or more antithrombotic agent with a different mechanism of action, such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P_2T) antagonist,

in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

15. A kit of parts comprising:

- (i) a pharmaceutical formulation containing a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and
- (ii) a pharmaceutical formulation containing one or more antithrombotic agent with a different mechanism of action, such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P_2T) antagonist,

in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier;

which compound (i) and agent (ii) are each provided in a form that is suitable for administration in conjunction with the other.

16. A method for treatment of a patient suffering from, or susceptible to, a condition in which inhibition of carboxypeptidase U and a different antithrombotic mechanism are required or desired, which method comprises administering to the patient a therapeutically effective total amount of

(i) a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction with


(ii) one or more antithrombotic agent with a different mechanism of action, such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P_2T) antagonist,

in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

17. A method for treatment of a patient suffering from, or susceptible to, a condition in which inhibition of carboxypeptidase U and a different antithrombotic mechanism are required or desired, which method comprises administering to the patient a formulation as defined in claim 14.

ABSTRACT

The present invention relates to compounds of Formula I, and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts,



which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds: to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NEW COMPOUNDS

the specification of which is attached hereto unless the following box is checked:

☒ was filed on 3 May 2000 as United States Application Number or PCT International Application Number PCT/SE00/00834 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

			Priority Not Claimed
<u>9901573-7</u>	<u>Sweden</u>	<u>3 May 1999</u>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>
(Number)	(Country)	(Day(Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

<u> </u>	<u> </u>
(Application Number)	(Filing Date)
<u> </u>	<u> </u>
(Application Number)	(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application Number)

(Filing Date)

(Status -- patented, pending, abandoned)

(Application Number)

(Filing Date)

(Status -- patented, pending, abandoned)

(14) I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Dimitrios Drivas, Reg. No. 32,218; Cecilia O'Brien Lofters, Reg. No. 33,434; Warren S. Heit, Reg. No. 36,828; David Bender, Reg. No. 35,445; John M. Genova, Reg. No. 32,224; Richard J. Sterner, Reg. No. 35,372; Hans-Peter G. Hoffmann, Reg. No. 37,352; Leslie Morioka, Reg. No. 40,304; John Scheibeler, Reg. No. 35,346; Thelma A. Chen Cleland, Reg. No. 40,948; Jean E. Shimotake, Reg. No. 36,273; Jeff Oelke, Reg. No. 37,409; Chase Romick, Reg. No. 45,051; and Louis S. Silvestri, Reg. No. 45,108 of the firm of WHITE & CASE LLP, with offices at 1155 Avenue of the Americas, New York, New York 10036,

Address all telephone calls to: _____
at telephone number _____

Address all correspondence to WHITE & CASE, LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Full name of sole or first inventor
(given name, family name)

Marcel Linschoten

First inventor's signature



Date: 14 June 2000

Residence Address

Västra Frölunda, Sweden SEX

Citizenship Dutch


Post Office Address

AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

2-00
Full name of second joint inventor, if any
(given name, family name)

Magnus Polla

Second inventor's signature



Date

2000-06-14

Residence Address

Gothenburg, Sweden SEX

Citizenship

Swedish

Post Office Address

AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

3-00
Full name of third joint inventor, if any
(given name, family name)

Peder Svensson

Third inventor's signature



Date

2000-06-20

Residence Address

Gothenburg, Sweden SEX

Citizenship

Swedish

Post Office Address

AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden